Background  ||| S:24 E:43 ||| FW
Plasminogen  ||| S:43 E:55 ||| FW
activator  ||| S:55 E:65 ||| FW
inhibitor-1  ||| S:65 E:77 ||| FW
( ||| S:77 E:78 ||| -LRB-
PAI-1 ||| S:78 E:83 ||| NNP
)  ||| S:83 E:85 ||| -RRB-
is  ||| S:85 E:88 ||| VBZ
a  ||| S:88 E:90 ||| DT
serine  ||| S:90 E:105 ||| JJ
proteinase  ||| S:105 E:116 ||| JJ
inhibitor  ||| S:116 E:126 ||| NN
in  ||| S:126 E:129 ||| IN
the  ||| S:129 E:133 ||| DT
serpin  ||| S:133 E:140 ||| JJ
superfamily  ||| S:140 E:152 ||| NNS
[  ||| S:152 E:154 ||| -LRB-
1  ||| S:154 E:156 ||| CD
2  ||| S:156 E:158 ||| CD
3  ||| S:158 E:160 ||| CD
]  ||| S:160 E:162 ||| -RRB-
.  ||| S:162 E:172 ||| .
This  ||| S:172 E:177 ||| DT
50  ||| S:177 E:180 ||| CD
kDa  ||| S:180 E:184 ||| JJ
glycoprotein  ||| S:184 E:197 ||| NN
is  ||| S:197 E:200 ||| VBZ
apparently  ||| S:200 E:211 ||| RB
the  ||| S:211 E:215 ||| DT
most  ||| S:215 E:220 ||| RBS
important  ||| S:220 E:238 ||| JJ
physiological  ||| S:238 E:252 ||| JJ
inhibitor  ||| S:252 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
tissue-type  ||| S:265 E:277 ||| JJ
plasminogen  ||| S:277 E:297 ||| JJ
activator  ||| S:297 E:307 ||| NNS
( ||| S:307 E:308 ||| -LRB-
tPA ||| S:308 E:311 ||| NNP
)  ||| S:311 E:313 ||| -RRB-
and  ||| S:313 E:317 ||| CC
of  ||| S:317 E:320 ||| IN
urokinase  ||| S:320 E:330 ||| FW
plasminogen  ||| S:330 E:342 ||| FW
activator  ||| S:342 E:360 ||| FW
( ||| S:360 E:361 ||| -LRB-
uPA ||| S:361 E:364 ||| NNP
) ||| S:364 E:365 ||| -RRB-
.  ||| S:365 E:367 ||| .
[  ||| S:367 E:369 ||| -LRB-
4  ||| S:369 E:371 ||| LS
]  ||| S:371 E:373 ||| -RRB-
It  ||| S:373 E:376 ||| PRP
was  ||| S:376 E:380 ||| VBD
shown  ||| S:380 E:386 ||| VBN
to  ||| S:386 E:389 ||| TO
play  ||| S:389 E:394 ||| VB
a  ||| S:394 E:396 ||| DT
crucial  ||| S:396 E:404 ||| JJ
role  ||| S:404 E:409 ||| NN
in  ||| S:409 E:412 ||| IN
the  ||| S:412 E:424 ||| DT
regulation  ||| S:424 E:435 ||| NN
of  ||| S:435 E:438 ||| IN
vascular  ||| S:438 E:447 ||| JJ
thrombosis ||| S:447 E:457 ||| NN
,  ||| S:457 E:459 ||| ,
tumor  ||| S:459 E:465 ||| NN
invasion ||| S:465 E:473 ||| NN
,  ||| S:473 E:483 ||| ,
neovascularization ||| S:483 E:501 ||| NN
,  ||| S:501 E:503 ||| ,
inflammation  ||| S:503 E:516 ||| NN
and  ||| S:516 E:520 ||| CC
wound  ||| S:520 E:526 ||| VBD
healing.  ||| S:526 E:535 ||| CD
[  ||| S:535 E:537 ||| -LRB-
5  ||| S:537 E:539 ||| CD
6  ||| S:539 E:541 ||| CD
]  ||| S:541 E:551 ||| -RRB-
Increased  ||| S:551 E:561 ||| VBN
plasma  ||| S:561 E:568 ||| JJ
levels  ||| S:568 E:575 ||| NNS
of  ||| S:575 E:578 ||| IN
PAI-1  ||| S:578 E:584 ||| NNP
were  ||| S:584 E:589 ||| VBD
found  ||| S:589 E:595 ||| VBN
to  ||| S:595 E:598 ||| TO
be  ||| S:598 E:609 ||| VB
correlated  ||| S:609 E:620 ||| VBN
with  ||| S:620 E:625 ||| IN
an  ||| S:625 E:628 ||| DT
increased  ||| S:628 E:638 ||| JJ
risk  ||| S:638 E:643 ||| NN
for  ||| S:643 E:647 ||| IN
cardiovascular  ||| S:647 E:670 ||| JJ
diseases.  ||| S:670 E:680 ||| NNP
[  ||| S:680 E:682 ||| -LRB-
6  ||| S:682 E:684 ||| CD
7  ||| S:684 E:686 ||| CD
8  ||| S:686 E:688 ||| CD
]  ||| S:688 E:690 ||| -RRB-
The  ||| S:690 E:694 ||| DT
essential  ||| S:694 E:704 ||| JJ
function  ||| S:704 E:713 ||| NN
of  ||| S:713 E:716 ||| IN
PAI-1  ||| S:716 E:722 ||| CD
in  ||| S:722 E:725 ||| IN
the  ||| S:725 E:737 ||| DT
fibrinolytic  ||| S:737 E:750 ||| JJ
system  ||| S:750 E:757 ||| NN
has  ||| S:757 E:761 ||| VBZ
been  ||| S:761 E:766 ||| VBN
confirmed  ||| S:766 E:776 ||| VBN
by  ||| S:776 E:779 ||| IN
studies  ||| S:779 E:787 ||| NNS
with  ||| S:787 E:800 ||| IN
transgenic  ||| S:800 E:811 ||| CD
animals.  ||| S:811 E:820 ||| CD
[  ||| S:820 E:822 ||| -LRB-
7  ||| S:822 E:824 ||| CD
9  ||| S:824 E:826 ||| CD
]  ||| S:826 E:836 ||| -RRB-
PAI-1  ||| S:836 E:842 ||| CD
shares  ||| S:842 E:849 ||| NNS
a  ||| S:849 E:851 ||| DT
35 ||| S:851 E:853 ||| CD
%  ||| S:853 E:855 ||| NN
homology  ||| S:855 E:864 ||| NN
with  ||| S:864 E:869 ||| IN
40  ||| S:869 E:872 ||| CD
other  ||| S:872 E:878 ||| JJ
serpins.  ||| S:878 E:887 ||| NNP
[  ||| S:887 E:889 ||| -LRB-
10  ||| S:889 E:900 ||| CD
]  ||| S:900 E:902 ||| -RRB-
The  ||| S:902 E:906 ||| DT
X-ray  ||| S:906 E:912 ||| NN
structure  ||| S:912 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
active  ||| S:925 E:932 ||| JJ
PAI-1  ||| S:932 E:938 ||| NNP
[  ||| S:938 E:940 ||| -LRB-
11  ||| S:940 E:943 ||| CD
12  ||| S:943 E:946 ||| CD
]  ||| S:946 E:948 ||| -RRB-
consists  ||| S:948 E:957 ||| VBZ
of  ||| S:957 E:968 ||| IN
three  ||| S:968 E:974 ||| CD
sheets  ||| S:974 E:981 ||| NNS
( ||| S:981 E:982 ||| -LRB-
A-C ||| S:982 E:985 ||| NNP
) ||| S:985 E:986 ||| -RRB-
,  ||| S:986 E:988 ||| ,
nine  ||| S:988 E:993 ||| CD
helices  ||| S:993 E:1001 ||| NNS
( ||| S:1001 E:1002 ||| -LRB-
a-i ||| S:1002 E:1005 ||| NNP
)  ||| S:1005 E:1007 ||| -RRB-
and  ||| S:1007 E:1011 ||| CC
a  ||| S:1011 E:1013 ||| DT
reactive  ||| S:1013 E:1030 ||| JJ
center  ||| S:1030 E:1037 ||| NN
loop  ||| S:1037 E:1042 ||| NNS
( ||| S:1042 E:1043 ||| -LRB-
RCL ||| S:1043 E:1046 ||| NNP
) ||| S:1046 E:1047 ||| -RRB-
.  ||| S:1047 E:1049 ||| .
The  ||| S:1049 E:1053 ||| DT
RCL  ||| S:1053 E:1057 ||| NNP
contains  ||| S:1057 E:1066 ||| VBZ
the  ||| S:1066 E:1070 ||| DT
residues  ||| S:1070 E:1079 ||| JJ
Ser331  ||| S:1079 E:1086 ||| NN
to  ||| S:1086 E:1097 ||| TO
Arg356  ||| S:1097 E:1104 ||| CD
( ||| S:1104 E:1105 ||| -LRB-
P16-P10 ||| S:1105 E:1112 ||| NNP
' ||| S:1112 E:1113 ||| POS
) ||| S:1113 E:1114 ||| -RRB-
,  ||| S:1114 E:1116 ||| ,
and  ||| S:1116 E:1120 ||| CC
within  ||| S:1120 E:1127 ||| IN
it  ||| S:1127 E:1130 ||| PRP
there  ||| S:1130 E:1136 ||| EX
is  ||| S:1136 E:1139 ||| VBZ
a  ||| S:1139 E:1141 ||| DT
peptide  ||| S:1141 E:1149 ||| JJ
loop  ||| S:1149 E:1162 ||| NNS
( ||| S:1162 E:1163 ||| -LRB-
Glu  ||| S:1163 E:1167 ||| NNP
351  ||| S:1167 E:1171 ||| CD
to  ||| S:1171 E:1174 ||| TO
Pro  ||| S:1174 E:1178 ||| NNP
357 ||| S:1178 E:1181 ||| CD
,  ||| S:1181 E:1183 ||| ,
P5 ||| S:1183 E:1185 ||| NNP
' ||| S:1185 E:1186 ||| POS
-P11 ||| S:1186 E:1190 ||| NNP
' ||| S:1190 E:1191 ||| POS
) ||| S:1191 E:1192 ||| -RRB-
,  ||| S:1192 E:1194 ||| ,
which  ||| S:1194 E:1200 ||| WDT
is  ||| S:1200 E:1203 ||| VBZ
defined  ||| S:1203 E:1211 ||| VBN
as  ||| S:1211 E:1214 ||| IN
the  ||| S:1214 E:1226 ||| DT
distal  ||| S:1226 E:1233 ||| JJ
hinge  ||| S:1233 E:1239 ||| NNS
( ||| S:1239 E:1240 ||| -LRB-
Table  ||| S:1240 E:1246 ||| NNP
1 ||| S:1246 E:1247 ||| CD
) ||| S:1247 E:1248 ||| -RRB-
.  ||| S:1248 E:1250 ||| .
It  ||| S:1250 E:1253 ||| PRP
should  ||| S:1253 E:1260 ||| MD
be  ||| S:1260 E:1263 ||| VB
noted  ||| S:1263 E:1269 ||| VBN
that  ||| S:1269 E:1274 ||| IN
the  ||| S:1274 E:1286 ||| DT
placement  ||| S:1286 E:1296 ||| NN
and  ||| S:1296 E:1300 ||| CC
conformation  ||| S:1300 E:1313 ||| NN
of  ||| S:1313 E:1316 ||| IN
the  ||| S:1316 E:1320 ||| DT
RCL  ||| S:1320 E:1324 ||| NNP
in  ||| S:1324 E:1327 ||| IN
active  ||| S:1327 E:1334 ||| JJ
PAI-1  ||| S:1334 E:1340 ||| NN
is  ||| S:1340 E:1351 ||| VBZ
quite  ||| S:1351 E:1357 ||| RB
different  ||| S:1357 E:1367 ||| JJ
from  ||| S:1367 E:1372 ||| IN
that  ||| S:1372 E:1377 ||| DT
of  ||| S:1377 E:1380 ||| IN
latent  ||| S:1380 E:1387 ||| CD
PAI-1.  ||| S:1387 E:1394 ||| CD
[  ||| S:1394 E:1396 ||| -LRB-
13  ||| S:1396 E:1399 ||| CD
]  ||| S:1399 E:1401 ||| -RRB-
The  ||| S:1401 E:1413 ||| DT
movement  ||| S:1413 E:1422 ||| NN
of  ||| S:1422 E:1425 ||| IN
the  ||| S:1425 E:1429 ||| DT
distal  ||| S:1429 E:1436 ||| JJ
hinge  ||| S:1436 E:1442 ||| NN
and  ||| S:1442 E:1446 ||| CC
the  ||| S:1446 E:1450 ||| DT
insertion  ||| S:1450 E:1460 ||| NN
of  ||| S:1460 E:1463 ||| IN
the  ||| S:1463 E:1467 ||| DT
RCL  ||| S:1467 E:1479 ||| NNP
into  ||| S:1479 E:1484 ||| IN
sheet  ||| S:1484 E:1490 ||| NN
A  ||| S:1490 E:1492 ||| NN
as  ||| S:1492 E:1495 ||| IN
strand  ||| S:1495 E:1502 ||| CD
4A  ||| S:1502 E:1505 ||| CD
( ||| S:1505 E:1506 ||| -LRB-
s4A ||| S:1506 E:1509 ||| NNP
)  ||| S:1509 E:1511 ||| -RRB-
should  ||| S:1511 E:1518 ||| MD
take  ||| S:1518 E:1523 ||| VB
place  ||| S:1523 E:1529 ||| NN
during  ||| S:1529 E:1544 ||| IN
the  ||| S:1544 E:1548 ||| DT
transition  ||| S:1548 E:1559 ||| NN
from  ||| S:1559 E:1564 ||| IN
the  ||| S:1564 E:1568 ||| DT
active  ||| S:1568 E:1575 ||| JJ
into  ||| S:1575 E:1580 ||| IN
the  ||| S:1580 E:1584 ||| DT
latent  ||| S:1584 E:1591 ||| JJ
form  ||| S:1591 E:1596 ||| NN
of  ||| S:1596 E:1607 ||| IN
PAI-1 ||| S:1607 E:1612 ||| CD
.  ||| S:1612 E:1622 ||| .
The  ||| S:1622 E:1626 ||| DT
catalytic  ||| S:1626 E:1636 ||| JJ
center  ||| S:1636 E:1643 ||| NN
of  ||| S:1643 E:1646 ||| IN
tPA  ||| S:1646 E:1650 ||| JJ
interacts  ||| S:1650 E:1660 ||| NN
with  ||| S:1660 E:1665 ||| IN
the  ||| S:1665 E:1669 ||| DT
reactive  ||| S:1669 E:1686 ||| JJ
site  ||| S:1686 E:1691 ||| NN
of  ||| S:1691 E:1694 ||| IN
PAI-1  ||| S:1694 E:1700 ||| CD
with  ||| S:1700 E:1705 ||| IN
concominant  ||| S:1705 E:1717 ||| JJ
formation  ||| S:1717 E:1727 ||| NN
of  ||| S:1727 E:1730 ||| IN
1 ||| S:1730 E:1731 ||| CD
: ||| S:1731 E:1732 ||| :
1  ||| S:1732 E:1734 ||| CD
molar ||| S:1734 E:1739 ||| NN
,  ||| S:1739 E:1749 ||| ,
SDS-stable  ||| S:1749 E:1760 ||| JJ
complex ||| S:1760 E:1767 ||| NN
.  ||| S:1767 E:1769 ||| .
The  ||| S:1769 E:1773 ||| DT
P1  ||| S:1773 E:1776 ||| NNP
( ||| S:1776 E:1777 ||| -LRB-
Arg346 ||| S:1777 E:1783 ||| NNP
)  ||| S:1783 E:1785 ||| -RRB-
residue  ||| S:1785 E:1793 ||| NN
in  ||| S:1793 E:1796 ||| IN
the  ||| S:1796 E:1800 ||| DT
RCL  ||| S:1800 E:1804 ||| NNP
of  ||| S:1804 E:1815 ||| IN
PAI-1  ||| S:1815 E:1821 ||| NNP
is  ||| S:1821 E:1824 ||| VBZ
an  ||| S:1824 E:1827 ||| DT
essential  ||| S:1827 E:1837 ||| JJ
determinant  ||| S:1837 E:1849 ||| NN
for  ||| S:1849 E:1853 ||| IN
its  ||| S:1853 E:1857 ||| PRP$
target  ||| S:1857 E:1872 ||| NN
specificity  ||| S:1872 E:1884 ||| NN
and  ||| S:1884 E:1888 ||| CC
inhibitory  ||| S:1888 E:1899 ||| CD
activity.  ||| S:1899 E:1909 ||| CD
[  ||| S:1909 E:1911 ||| -LRB-
14  ||| S:1911 E:1914 ||| CD
15  ||| S:1914 E:1917 ||| CD
]  ||| S:1917 E:1919 ||| -RRB-
Since  ||| S:1919 E:1925 ||| IN
many  ||| S:1925 E:1938 ||| JJ
serpins  ||| S:1938 E:1946 ||| NN
with  ||| S:1946 E:1951 ||| IN
identical  ||| S:1951 E:1961 ||| JJ
amino  ||| S:1961 E:1967 ||| JJ
acid  ||| S:1967 E:1972 ||| NN
residue  ||| S:1972 E:1980 ||| NN
at  ||| S:1980 E:1983 ||| IN
P1  ||| S:1983 E:1986 ||| CD
position  ||| S:1986 E:2003 ||| NN
display  ||| S:2003 E:2011 ||| NN
different  ||| S:2011 E:2021 ||| JJ
specificities ||| S:2021 E:2034 ||| NN
,  ||| S:2034 E:2036 ||| ,
it  ||| S:2036 E:2039 ||| PRP
is  ||| S:2039 E:2042 ||| VBZ
unlikely  ||| S:2042 E:2051 ||| JJ
that  ||| S:2051 E:2056 ||| IN
the  ||| S:2056 E:2060 ||| DT
P1  ||| S:2060 E:2071 ||| JJ
residue  ||| S:2071 E:2079 ||| NN
is  ||| S:2079 E:2082 ||| VBZ
the  ||| S:2082 E:2086 ||| DT
sole  ||| S:2086 E:2091 ||| JJ
determinant  ||| S:2091 E:2103 ||| NN
for  ||| S:2103 E:2107 ||| IN
target  ||| S:2107 E:2114 ||| NN
protease  ||| S:2114 E:2131 ||| NN
specificity ||| S:2131 E:2142 ||| NN
,  ||| S:2142 E:2144 ||| ,
other  ||| S:2144 E:2150 ||| JJ
regions  ||| S:2150 E:2158 ||| NNS
of  ||| S:2158 E:2161 ||| IN
PAI-1  ||| S:2161 E:2167 ||| NNP
may  ||| S:2167 E:2171 ||| MD
also  ||| S:2171 E:2176 ||| RB
affect  ||| S:2176 E:2183 ||| VB
its  ||| S:2183 E:2195 ||| PRP$
specificity  ||| S:2195 E:2207 ||| NN
toward  ||| S:2207 E:2214 ||| IN
target  ||| S:2214 E:2221 ||| NN
proteases ||| S:2221 E:2230 ||| NN
.  ||| S:2230 E:2232 ||| .
The  ||| S:2232 E:2236 ||| DT
variable  ||| S:2236 E:2245 ||| JJ
region  ||| S:2245 E:2252 ||| NN
in  ||| S:2252 E:2263 ||| IN
serine  ||| S:2263 E:2270 ||| JJ
proteases  ||| S:2270 E:2280 ||| JJ
domain  ||| S:2280 E:2287 ||| NN
determines  ||| S:2287 E:2298 ||| VBZ
their  ||| S:2298 E:2304 ||| PRP$
specificity  ||| S:2304 E:2316 ||| NN
for  ||| S:2316 E:2328 ||| IN
PAI-1 ||| S:2328 E:2333 ||| CD
.  ||| S:2333 E:2335 ||| .
Alignment  ||| S:2335 E:2345 ||| NNP
of  ||| S:2345 E:2348 ||| IN
variable  ||| S:2348 E:2357 ||| JJ
region  ||| S:2357 E:2364 ||| NN
1  ||| S:2364 E:2366 ||| CD
of  ||| S:2366 E:2369 ||| IN
the  ||| S:2369 E:2373 ||| DT
serine  ||| S:2373 E:2388 ||| JJ
proteases  ||| S:2388 E:2398 ||| NN
shows  ||| S:2398 E:2404 ||| VBZ
a  ||| S:2404 E:2406 ||| DT
remarkable  ||| S:2406 E:2417 ||| JJ
correlation  ||| S:2417 E:2429 ||| NN
between  ||| S:2429 E:2437 ||| IN
the  ||| S:2437 E:2449 ||| DT
composition  ||| S:2449 E:2461 ||| NN
of  ||| S:2461 E:2464 ||| IN
this  ||| S:2464 E:2469 ||| DT
area  ||| S:2469 E:2474 ||| NN
and  ||| S:2474 E:2478 ||| CC
their  ||| S:2478 E:2484 ||| PRP$
susceptibility  ||| S:2484 E:2499 ||| NN
to  ||| S:2499 E:2510 ||| TO
inhibition  ||| S:2510 E:2521 ||| VB
by  ||| S:2521 E:2524 ||| IN
PAI-1  ||| S:2524 E:2530 ||| NNP
as  ||| S:2530 E:2533 ||| RB
shown  ||| S:2533 E:2539 ||| VBN
in  ||| S:2539 E:2542 ||| IN
Table  ||| S:2542 E:2548 ||| NNP
2.  ||| S:2548 E:2551 ||| NNP
[  ||| S:2551 E:2553 ||| -LRB-
16  ||| S:2553 E:2556 ||| CD
]  ||| S:2556 E:2558 ||| -RRB-
Both  ||| S:2558 E:2563 ||| DT
tPA  ||| S:2563 E:2575 ||| JJ
and  ||| S:2575 E:2579 ||| CC
uPA ||| S:2579 E:2582 ||| JJ
,  ||| S:2582 E:2584 ||| ,
the  ||| S:2584 E:2588 ||| DT
target  ||| S:2588 E:2595 ||| NN
proteases  ||| S:2595 E:2605 ||| NN
of  ||| S:2605 E:2608 ||| IN
PAI-1 ||| S:2608 E:2613 ||| NNP
,  ||| S:2613 E:2615 ||| ,
contain  ||| S:2615 E:2623 ||| VBP
a  ||| S:2623 E:2633 ||| DT
relatively  ||| S:2633 E:2644 ||| RB
extensive  ||| S:2644 E:2654 ||| JJ
variable  ||| S:2654 E:2663 ||| JJ
region  ||| S:2663 E:2670 ||| NN
1 ||| S:2670 E:2671 ||| CD
,  ||| S:2671 E:2673 ||| ,
consisting  ||| S:2673 E:2684 ||| VBG
of  ||| S:2684 E:2687 ||| IN
four  ||| S:2687 E:2700 ||| CD
to  ||| S:2700 E:2703 ||| TO
five  ||| S:2703 E:2708 ||| CD
positively  ||| S:2708 E:2719 ||| RB
charged  ||| S:2719 E:2727 ||| VBN
amino  ||| S:2727 E:2733 ||| JJ
acid  ||| S:2733 E:2738 ||| NN
residues  ||| S:2738 E:2747 ||| NN
present  ||| S:2747 E:2755 ||| NN
at  ||| S:2755 E:2766 ||| IN
identical  ||| S:2766 E:2776 ||| JJ
position ||| S:2776 E:2784 ||| NN
.  ||| S:2784 E:2786 ||| .
Plasmin  ||| S:2786 E:2794 ||| NNP
and  ||| S:2794 E:2798 ||| CC
thrombin  ||| S:2798 E:2807 ||| NN
with  ||| S:2807 E:2812 ||| IN
moderate  ||| S:2812 E:2829 ||| JJ
reactivity  ||| S:2829 E:2840 ||| NN
toward  ||| S:2840 E:2847 ||| IN
PAI-1  ||| S:2847 E:2853 ||| NNP
have  ||| S:2853 E:2858 ||| VBP
relatively  ||| S:2858 E:2869 ||| RB
short  ||| S:2869 E:2875 ||| JJ
variable  ||| S:2875 E:2892 ||| JJ
regions  ||| S:2892 E:2900 ||| NNS
which  ||| S:2900 E:2906 ||| WDT
contain  ||| S:2906 E:2914 ||| VBP
only  ||| S:2914 E:2919 ||| RB
two  ||| S:2919 E:2923 ||| CD
to  ||| S:2923 E:2926 ||| TO
three  ||| S:2926 E:2932 ||| CD
positively  ||| S:2932 E:2943 ||| RB
charged  ||| S:2943 E:2959 ||| VBN
residues ||| S:2959 E:2967 ||| NNS
.  ||| S:2967 E:2969 ||| .
For  ||| S:2969 E:2973 ||| IN
example ||| S:2973 E:2980 ||| NN
,  ||| S:2980 E:2982 ||| ,
positively  ||| S:2982 E:2993 ||| RB
charged  ||| S:2993 E:3001 ||| VBN
amino  ||| S:3001 E:3007 ||| JJ
acids  ||| S:3007 E:3013 ||| NNS
in  ||| S:3013 E:3024 ||| IN
the  ||| S:3024 E:3028 ||| DT
variable  ||| S:3028 E:3037 ||| JJ
region  ||| S:3037 E:3044 ||| NN
of  ||| S:3044 E:3047 ||| IN
tPA ||| S:3047 E:3050 ||| NNP
,  ||| S:3050 E:3052 ||| ,
uPA  ||| S:3052 E:3056 ||| JJ
and  ||| S:3056 E:3060 ||| CC
thrombin  ||| S:3060 E:3069 ||| NNS
play  ||| S:3069 E:3074 ||| VBP
dominant  ||| S:3074 E:3091 ||| JJ
roles  ||| S:3091 E:3097 ||| NNS
in  ||| S:3097 E:3100 ||| IN
the  ||| S:3100 E:3104 ||| DT
specific  ||| S:3104 E:3113 ||| JJ
interaction  ||| S:3113 E:3125 ||| NN
with  ||| S:3125 E:3130 ||| IN
PAI-1.  ||| S:3130 E:3137 ||| NNP
[  ||| S:3137 E:3139 ||| -LRB-
17  ||| S:3139 E:3142 ||| CD
18  ||| S:3142 E:3145 ||| CD
19  ||| S:3145 E:3148 ||| CD
]  ||| S:3148 E:3158 ||| -RRB-
Furthermore ||| S:3158 E:3169 ||| RB
,  ||| S:3169 E:3171 ||| ,
Glu350  ||| S:3171 E:3178 ||| NNP
( ||| S:3178 E:3179 ||| -LRB-
P4 ||| S:3179 E:3181 ||| NNP
' ||| S:3181 E:3182 ||| POS
)  ||| S:3182 E:3184 ||| -RRB-
of  ||| S:3184 E:3187 ||| IN
PAI-1  ||| S:3187 E:3193 ||| NNP
has  ||| S:3193 E:3197 ||| VBZ
been  ||| S:3197 E:3202 ||| VBN
shown  ||| S:3202 E:3208 ||| VBN
to  ||| S:3208 E:3219 ||| TO
mediate  ||| S:3219 E:3227 ||| VB
the  ||| S:3227 E:3231 ||| DT
interactions  ||| S:3231 E:3244 ||| NN
with  ||| S:3244 E:3249 ||| IN
tPA.  ||| S:3249 E:3254 ||| NNP
[  ||| S:3254 E:3256 ||| -LRB-
18  ||| S:3256 E:3259 ||| CD
]  ||| S:3259 E:3269 ||| -RRB-
In  ||| S:3269 E:3272 ||| IN
this  ||| S:3272 E:3277 ||| DT
study ||| S:3277 E:3282 ||| NN
,  ||| S:3282 E:3284 ||| ,
By  ||| S:3284 E:3287 ||| IN
producing  ||| S:3287 E:3297 ||| VBG
wtPAI-1  ||| S:3297 E:3305 ||| NNP
and  ||| S:3305 E:3309 ||| CC
several  ||| S:3309 E:3317 ||| JJ
single  ||| S:3317 E:3332 ||| JJ
site  ||| S:3332 E:3337 ||| NN
mutations  ||| S:3337 E:3347 ||| NNS
in  ||| S:3347 E:3350 ||| IN
the  ||| S:3350 E:3354 ||| DT
distal  ||| S:3354 E:3361 ||| JJ
hinge  ||| S:3361 E:3367 ||| NN
of  ||| S:3367 E:3370 ||| IN
PAI-1  ||| S:3370 E:3376 ||| CD
in  ||| S:3376 E:3379 ||| IN
a  ||| S:3379 E:3389 ||| DT
baculovirus  ||| S:3389 E:3401 ||| JJ
expression  ||| S:3401 E:3412 ||| NN
system ||| S:3412 E:3418 ||| NN
,  ||| S:3418 E:3420 ||| ,
we  ||| S:3420 E:3423 ||| PRP
were  ||| S:3423 E:3428 ||| VBD
able  ||| S:3428 E:3433 ||| JJ
to  ||| S:3433 E:3436 ||| TO
find  ||| S:3436 E:3441 ||| VB
out  ||| S:3441 E:3445 ||| RP
the  ||| S:3445 E:3457 ||| DT
role  ||| S:3457 E:3462 ||| NN
of  ||| S:3462 E:3465 ||| IN
the  ||| S:3465 E:3469 ||| DT
distal  ||| S:3469 E:3476 ||| JJ
hinge  ||| S:3476 E:3482 ||| NN
in  ||| S:3482 E:3485 ||| IN
conformational  ||| S:3485 E:3500 ||| JJ
transition  ||| S:3500 E:3511 ||| NN
of  ||| S:3511 E:3522 ||| IN
PAI-1  ||| S:3522 E:3528 ||| NNP
and  ||| S:3528 E:3532 ||| CC
to  ||| S:3532 E:3535 ||| TO
elucidate  ||| S:3535 E:3545 ||| VB
the  ||| S:3545 E:3549 ||| DT
role  ||| S:3549 E:3554 ||| NN
of  ||| S:3554 E:3557 ||| IN
Glu351  ||| S:3557 E:3564 ||| CD
in  ||| S:3564 E:3567 ||| IN
PAI-1  ||| S:3567 E:3573 ||| CD
for  ||| S:3573 E:3585 ||| IN
serine  ||| S:3585 E:3592 ||| JJ
protease  ||| S:3592 E:3601 ||| JJ
specificities ||| S:3601 E:3614 ||| NN
.  ||| S:3614 E:3638 ||| .
Results  ||| S:3638 E:3665 ||| NNP
Characterization  ||| S:3665 E:3682 ||| NNP
of  ||| S:3682 E:3685 ||| IN
wtPAI-1  ||| S:3685 E:3703 ||| CD
To  ||| S:3703 E:3706 ||| TO
confirm  ||| S:3706 E:3714 ||| VB
the  ||| S:3714 E:3718 ||| DT
validity  ||| S:3718 E:3727 ||| NN
of  ||| S:3727 E:3730 ||| IN
recombinant  ||| S:3730 E:3742 ||| JJ
PAI-1  ||| S:3742 E:3748 ||| NN
as  ||| S:3748 E:3751 ||| IN
a  ||| S:3751 E:3763 ||| DT
model  ||| S:3763 E:3769 ||| NN
to  ||| S:3769 E:3772 ||| TO
study  ||| S:3772 E:3778 ||| VB
the  ||| S:3778 E:3782 ||| DT
native  ||| S:3782 E:3789 ||| JJ
inhibitor  ||| S:3789 E:3799 ||| JJ
secreted  ||| S:3799 E:3808 ||| NN
from  ||| S:3808 E:3813 ||| IN
human  ||| S:3813 E:3829 ||| JJ
fibrosarcoma  ||| S:3829 E:3842 ||| JJ
cells ||| S:3842 E:3847 ||| NNS
,  ||| S:3847 E:3849 ||| ,
we  ||| S:3849 E:3852 ||| PRP
compared  ||| S:3852 E:3861 ||| VBD
the  ||| S:3861 E:3865 ||| DT
recombinant  ||| S:3865 E:3877 ||| JJ
PAI-1  ||| S:3877 E:3883 ||| NN
and  ||| S:3883 E:3897 ||| CC
the  ||| S:3897 E:3901 ||| DT
fibrosarcoma  ||| S:3901 E:3914 ||| JJ
PAI-1  ||| S:3914 E:3920 ||| CD
first  ||| S:3920 E:3926 ||| JJ
by  ||| S:3926 E:3929 ||| IN
SDS-PAGE  ||| S:3929 E:3938 ||| JJ
and  ||| S:3938 E:3942 ||| CC
immunoblot  ||| S:3942 E:3963 ||| NN
with  ||| S:3963 E:3968 ||| IN
anti-PAI-1  ||| S:3968 E:3979 ||| CD
monoclonal  ||| S:3979 E:3990 ||| CD
antibodies ||| S:3990 E:4000 ||| NNS
.  ||| S:4000 E:4002 ||| .
The  ||| S:4002 E:4006 ||| DT
molecular  ||| S:4006 E:4026 ||| JJ
weight  ||| S:4026 E:4033 ||| NN
of  ||| S:4033 E:4036 ||| IN
wtPAI-1  ||| S:4036 E:4044 ||| NNP
was  ||| S:4044 E:4048 ||| VBD
found  ||| S:4048 E:4054 ||| VBN
to  ||| S:4054 E:4057 ||| TO
be  ||| S:4057 E:4060 ||| VB
lower  ||| S:4060 E:4066 ||| JJR
than  ||| S:4066 E:4071 ||| IN
native  ||| S:4071 E:4078 ||| JJ
PAI-1  ||| S:4078 E:4094 ||| NNP
( ||| S:4094 E:4095 ||| -LRB-
~50  ||| S:4095 E:4099 ||| NNP
kDa ||| S:4099 E:4102 ||| NNP
,  ||| S:4102 E:4104 ||| ,
Fig.  ||| S:4104 E:4109 ||| CD
1B ||| S:4109 E:4111 ||| CD
) ||| S:4111 E:4112 ||| -RRB-
.  ||| S:4112 E:4114 ||| .
We  ||| S:4114 E:4117 ||| PRP
assumed  ||| S:4117 E:4125 ||| VBD
that  ||| S:4125 E:4130 ||| IN
this  ||| S:4130 E:4135 ||| DT
is  ||| S:4135 E:4138 ||| VBZ
due  ||| S:4138 E:4142 ||| JJ
to  ||| S:4142 E:4145 ||| TO
a  ||| S:4145 E:4157 ||| DT
lower  ||| S:4157 E:4163 ||| JJR
( ||| S:4163 E:4164 ||| -LRB-
probably  ||| S:4164 E:4173 ||| RB
different ||| S:4173 E:4182 ||| JJ
)  ||| S:4182 E:4184 ||| -RRB-
extent  ||| S:4184 E:4191 ||| NN
of  ||| S:4191 E:4194 ||| IN
glycosylation  ||| S:4194 E:4208 ||| NN
in  ||| S:4208 E:4211 ||| IN
the  ||| S:4211 E:4225 ||| DT
baculovirus  ||| S:4225 E:4237 ||| JJ
expression  ||| S:4237 E:4248 ||| NN
system ||| S:4248 E:4254 ||| NN
.  ||| S:4254 E:4256 ||| .
Indeed ||| S:4256 E:4262 ||| RB
,  ||| S:4262 E:4264 ||| ,
when  ||| S:4264 E:4269 ||| WRB
both  ||| S:4269 E:4274 ||| DT
proteins  ||| S:4274 E:4293 ||| NNS
were  ||| S:4293 E:4298 ||| VBD
deglycosylated  ||| S:4298 E:4313 ||| VBN
with  ||| S:4313 E:4318 ||| IN
N-glycanase  ||| S:4318 E:4330 ||| JJ
they  ||| S:4330 E:4335 ||| PRP
were  ||| S:4335 E:4340 ||| VBD
found  ||| S:4340 E:4346 ||| VBN
to  ||| S:4346 E:4359 ||| TO
have  ||| S:4359 E:4364 ||| VB
an  ||| S:4364 E:4367 ||| DT
essentially  ||| S:4367 E:4379 ||| RB
identical  ||| S:4379 E:4389 ||| JJ
M.W.  ||| S:4389 E:4394 ||| NNP
( ||| S:4394 E:4395 ||| -LRB-
~48  ||| S:4395 E:4399 ||| NNP
kDa ||| S:4399 E:4402 ||| NNP
)  ||| S:4402 E:4404 ||| -RRB-
and  ||| S:4404 E:4408 ||| CC
to  ||| S:4408 E:4421 ||| TO
cross-react  ||| S:4421 E:4433 ||| JJ
immunochemically  ||| S:4433 E:4450 ||| NNS
( ||| S:4450 E:4451 ||| -LRB-
Fig.  ||| S:4451 E:4456 ||| NNP
1B ||| S:4456 E:4458 ||| NNP
) ||| S:4458 E:4459 ||| -RRB-
.  ||| S:4459 E:4461 ||| .
Furthermore ||| S:4461 E:4472 ||| RB
,  ||| S:4472 E:4474 ||| ,
when  ||| S:4474 E:4489 ||| WRB
this  ||| S:4489 E:4494 ||| DT
wtPAI-1  ||| S:4494 E:4502 ||| NNP
was  ||| S:4502 E:4506 ||| VBD
chromatographed  ||| S:4506 E:4522 ||| VBN
on  ||| S:4522 E:4525 ||| IN
heparin-Sepharose  ||| S:4525 E:4543 ||| JJ
it  ||| S:4543 E:4556 ||| PRP
was  ||| S:4556 E:4560 ||| VBD
found  ||| S:4560 E:4566 ||| VBN
to  ||| S:4566 E:4569 ||| TO
be  ||| S:4569 E:4572 ||| VB
>  ||| S:4572 E:4574 ||| CD
98 ||| S:4574 E:4576 ||| CD
%  ||| S:4576 E:4578 ||| NN
pure  ||| S:4578 E:4583 ||| NN
by  ||| S:4583 E:4586 ||| IN
silver  ||| S:4586 E:4593 ||| JJ
staining  ||| S:4593 E:4602 ||| NN
of  ||| S:4602 E:4605 ||| IN
the  ||| S:4605 E:4619 ||| DT
gel  ||| S:4619 E:4623 ||| NN
( ||| S:4623 E:4624 ||| -LRB-
Fig.  ||| S:4624 E:4629 ||| CD
1Alane  ||| S:4629 E:4636 ||| CD
2 ||| S:4636 E:4637 ||| CD
) ||| S:4637 E:4638 ||| -RRB-
.  ||| S:4638 E:4650 ||| .
Interestingly ||| S:4650 E:4663 ||| RB
,  ||| S:4663 E:4665 ||| ,
the  ||| S:4665 E:4669 ||| DT
specific  ||| S:4669 E:4678 ||| JJ
inhibitory  ||| S:4678 E:4689 ||| JJ
activity  ||| S:4689 E:4698 ||| NN
of  ||| S:4698 E:4711 ||| IN
wtPAI  ||| S:4711 E:4717 ||| NNP
was  ||| S:4717 E:4721 ||| VBD
63  ||| S:4721 E:4724 ||| CD
±  ||| S:4724 E:4726 ||| CD
15  ||| S:4726 E:4729 ||| CD
U ||| S:4729 E:4730 ||| NNP
/ ||| S:4730 E:4731 ||| NNP
ug  ||| S:4731 E:4734 ||| VBD
just  ||| S:4734 E:4739 ||| RB
after  ||| S:4739 E:4745 ||| IN
purification ||| S:4745 E:4757 ||| NN
,  ||| S:4757 E:4759 ||| ,
and  ||| S:4759 E:4763 ||| CC
was  ||| S:4763 E:4777 ||| VBD
increased  ||| S:4777 E:4787 ||| VBN
to  ||| S:4787 E:4790 ||| TO
84  ||| S:4790 E:4793 ||| CD
±  ||| S:4793 E:4795 ||| CD
21  ||| S:4795 E:4798 ||| CD
U ||| S:4798 E:4799 ||| NNP
/ ||| S:4799 E:4800 ||| NNP
ug  ||| S:4800 E:4803 ||| NN
after  ||| S:4803 E:4809 ||| IN
denatured  ||| S:4809 E:4819 ||| NN
by  ||| S:4819 E:4822 ||| IN
6  ||| S:4822 E:4824 ||| CD
M  ||| S:4824 E:4826 ||| NNP
Gdn-HCl  ||| S:4826 E:4844 ||| NNP
and  ||| S:4844 E:4848 ||| CC
refolded  ||| S:4848 E:4857 ||| NN
in  ||| S:4857 E:4860 ||| IN
50  ||| S:4860 E:4863 ||| CD
mM  ||| S:4863 E:4866 ||| JJ
sodium  ||| S:4866 E:4873 ||| NN
acetate  ||| S:4873 E:4881 ||| NNS
( ||| S:4881 E:4882 ||| -LRB-
pH  ||| S:4882 E:4885 ||| NNP
5.6 ||| S:4885 E:4888 ||| CD
)  ||| S:4888 E:4890 ||| -RRB-
at  ||| S:4890 E:4893 ||| IN
4°C ||| S:4893 E:4896 ||| CD
.  ||| S:4896 E:4898 ||| .
In  ||| S:4898 E:4911 ||| IN
contrast ||| S:4911 E:4919 ||| NN
,  ||| S:4919 E:4921 ||| ,
the  ||| S:4921 E:4925 ||| DT
specific  ||| S:4925 E:4934 ||| JJ
activity  ||| S:4934 E:4943 ||| NN
of  ||| S:4943 E:4946 ||| IN
the  ||| S:4946 E:4950 ||| DT
fibrosarcoma  ||| S:4950 E:4963 ||| JJ
PAI-1  ||| S:4963 E:4979 ||| NN
was  ||| S:4979 E:4983 ||| VBD
only  ||| S:4983 E:4988 ||| RB
5  ||| S:4988 E:4990 ||| CD
±  ||| S:4990 E:4992 ||| CD
3  ||| S:4992 E:4994 ||| CD
U ||| S:4994 E:4995 ||| NNP
/ ||| S:4995 E:4996 ||| NNP
ug  ||| S:4996 E:4999 ||| NN
before  ||| S:4999 E:5006 ||| IN
activation ||| S:5006 E:5016 ||| NN
,  ||| S:5016 E:5018 ||| ,
and  ||| S:5018 E:5022 ||| CC
was  ||| S:5022 E:5026 ||| VBD
only  ||| S:5026 E:5041 ||| RB
increased  ||| S:5041 E:5051 ||| VBN
to  ||| S:5051 E:5054 ||| TO
45  ||| S:5054 E:5057 ||| CD
±  ||| S:5057 E:5059 ||| CD
16  ||| S:5059 E:5062 ||| CD
U ||| S:5062 E:5063 ||| NNP
/ ||| S:5063 E:5064 ||| NNP
μg  ||| S:5064 E:5067 ||| NN
after  ||| S:5067 E:5073 ||| IN
denaturing  ||| S:5073 E:5084 ||| NN
and  ||| S:5084 E:5088 ||| CC
refolding ||| S:5088 E:5097 ||| NN
.  ||| S:5097 E:5109 ||| .
The  ||| S:5109 E:5113 ||| DT
high  ||| S:5113 E:5118 ||| JJ
specific  ||| S:5118 E:5127 ||| JJ
inhibitory  ||| S:5127 E:5138 ||| JJ
activity  ||| S:5138 E:5147 ||| NN
of  ||| S:5147 E:5150 ||| IN
wt-PAI-1  ||| S:5150 E:5159 ||| NNP
could  ||| S:5159 E:5175 ||| MD
be  ||| S:5175 E:5178 ||| VB
due  ||| S:5178 E:5182 ||| JJ
to  ||| S:5182 E:5185 ||| TO
the  ||| S:5185 E:5189 ||| DT
fact  ||| S:5189 E:5194 ||| NN
that  ||| S:5194 E:5199 ||| IN
it  ||| S:5199 E:5202 ||| PRP
was  ||| S:5202 E:5206 ||| VBD
secreted  ||| S:5206 E:5215 ||| VBN
from  ||| S:5215 E:5220 ||| IN
insect  ||| S:5220 E:5237 ||| CD
High-5  ||| S:5237 E:5244 ||| CD
cells  ||| S:5244 E:5250 ||| NNS
cultured  ||| S:5250 E:5259 ||| VBN
at  ||| S:5259 E:5262 ||| IN
27°C ||| S:5262 E:5266 ||| NNP
,  ||| S:5266 E:5268 ||| ,
while  ||| S:5268 E:5274 ||| IN
the  ||| S:5274 E:5278 ||| DT
fibrosarcoma  ||| S:5278 E:5301 ||| JJ
preparation  ||| S:5301 E:5313 ||| NN
of  ||| S:5313 E:5316 ||| IN
PAI-1  ||| S:5316 E:5322 ||| NNP
was  ||| S:5322 E:5326 ||| VBD
obtained  ||| S:5326 E:5335 ||| VBN
from  ||| S:5335 E:5340 ||| IN
the  ||| S:5340 E:5344 ||| DT
medium  ||| S:5344 E:5351 ||| NN
of  ||| S:5351 E:5364 ||| IN
fibrosarcoma  ||| S:5364 E:5377 ||| JJ
cells  ||| S:5377 E:5383 ||| NNS
cultured  ||| S:5383 E:5392 ||| VBN
at  ||| S:5392 E:5395 ||| IN
37°C  ||| S:5395 E:5400 ||| NNP
[  ||| S:5400 E:5402 ||| -LRB-
20  ||| S:5402 E:5405 ||| CD
]  ||| S:5405 E:5407 ||| -RRB-
.  ||| S:5407 E:5409 ||| .
Exposure  ||| S:5409 E:5418 ||| NN
to  ||| S:5418 E:5431 ||| TO
the  ||| S:5431 E:5435 ||| DT
higher  ||| S:5435 E:5442 ||| JJR
temperature  ||| S:5442 E:5454 ||| NN
could  ||| S:5454 E:5460 ||| MD
accelerate  ||| S:5460 E:5471 ||| VB
the  ||| S:5471 E:5475 ||| DT
conversion  ||| S:5475 E:5486 ||| NN
of  ||| S:5486 E:5499 ||| IN
the  ||| S:5499 E:5503 ||| DT
inhibitor  ||| S:5503 E:5513 ||| NN
into  ||| S:5513 E:5518 ||| IN
its  ||| S:5518 E:5522 ||| PRP$
latent  ||| S:5522 E:5529 ||| JJ
form ||| S:5529 E:5533 ||| NN
.  ||| S:5533 E:5545 ||| .
The  ||| S:5545 E:5549 ||| DT
functional  ||| S:5549 E:5560 ||| JJ
stability  ||| S:5560 E:5570 ||| NN
of  ||| S:5570 E:5573 ||| IN
wtPAI-1  ||| S:5573 E:5581 ||| NNP
and  ||| S:5581 E:5585 ||| CC
the  ||| S:5585 E:5599 ||| DT
fibrosarcoma  ||| S:5599 E:5612 ||| JJ
PAI-1  ||| S:5612 E:5618 ||| NN
in  ||| S:5618 E:5621 ||| IN
the  ||| S:5621 E:5625 ||| DT
absence  ||| S:5625 E:5633 ||| NN
or  ||| S:5633 E:5636 ||| CC
in  ||| S:5636 E:5639 ||| IN
presence  ||| S:5639 E:5648 ||| NN
of  ||| S:5648 E:5661 ||| IN
vitronectin  ||| S:5661 E:5673 ||| NNS
are  ||| S:5673 E:5677 ||| VBP
illustrated  ||| S:5677 E:5689 ||| VBN
in  ||| S:5689 E:5692 ||| IN
Figure  ||| S:5692 E:5699 ||| NNP
1C.  ||| S:5699 E:5703 ||| NNP
wtPAI-1  ||| S:5703 E:5711 ||| NNP
lost  ||| S:5711 E:5726 ||| VBD
its  ||| S:5726 E:5730 ||| PRP$
inhibitory  ||| S:5730 E:5741 ||| JJ
activity  ||| S:5741 E:5750 ||| NN
at  ||| S:5750 E:5753 ||| IN
the  ||| S:5753 E:5757 ||| DT
same  ||| S:5757 E:5762 ||| JJ
pace  ||| S:5762 E:5767 ||| NN
as  ||| S:5767 E:5770 ||| IN
the  ||| S:5770 E:5784 ||| DT
fibrosarcoma  ||| S:5784 E:5797 ||| JJ
PAI-1 ||| S:5797 E:5802 ||| NN
,  ||| S:5802 E:5804 ||| ,
indicating  ||| S:5804 E:5815 ||| VBG
that  ||| S:5815 E:5820 ||| IN
its  ||| S:5820 E:5824 ||| PRP$
functional  ||| S:5824 E:5835 ||| JJ
half  ||| S:5835 E:5850 ||| NN
life  ||| S:5850 E:5855 ||| NN
as  ||| S:5855 E:5858 ||| IN
an  ||| S:5858 E:5861 ||| DT
inhibitor  ||| S:5861 E:5871 ||| NN
and  ||| S:5871 E:5875 ||| CC
its  ||| S:5875 E:5879 ||| PRP$
ability  ||| S:5879 E:5887 ||| NN
to  ||| S:5887 E:5890 ||| TO
be  ||| S:5890 E:5893 ||| VB
stabilized  ||| S:5893 E:5904 ||| VBN
by  ||| S:5904 E:5917 ||| IN
vitronectin  ||| S:5917 E:5929 ||| NNS
are  ||| S:5929 E:5933 ||| VBP
similar  ||| S:5933 E:5941 ||| JJ
to  ||| S:5941 E:5944 ||| TO
those  ||| S:5944 E:5950 ||| DT
of  ||| S:5950 E:5953 ||| IN
the  ||| S:5953 E:5957 ||| DT
fibrosarcoma  ||| S:5957 E:5980 ||| JJ
PAI-1 ||| S:5980 E:5985 ||| NN
.  ||| S:5985 E:5997 ||| .
The  ||| S:5997 E:6001 ||| DT
second-order  ||| S:6001 E:6014 ||| JJ
rate  ||| S:6014 E:6019 ||| NN
constants  ||| S:6019 E:6029 ||| NNS
( ||| S:6029 E:6030 ||| -LRB-
in  ||| S:6030 E:6033 ||| IN
M  ||| S:6033 E:6035 ||| NNP
-1s  ||| S:6035 E:6039 ||| NNP
-1units ||| S:6039 E:6046 ||| NNP
)  ||| S:6046 E:6048 ||| -RRB-
of  ||| S:6048 E:6061 ||| IN
the  ||| S:6061 E:6065 ||| DT
fibrosarcoma  ||| S:6065 E:6078 ||| JJ
PAI-1  ||| S:6078 E:6084 ||| NN
and  ||| S:6084 E:6088 ||| CC
the  ||| S:6088 E:6092 ||| DT
wtPAI-1  ||| S:6092 E:6100 ||| NN
towards  ||| S:6100 E:6108 ||| IN
t-PA  ||| S:6108 E:6113 ||| NNP
were  ||| S:6113 E:6128 ||| VBD
1.4  ||| S:6128 E:6132 ||| CD
±  ||| S:6132 E:6134 ||| CD
0.5  ||| S:6134 E:6138 ||| CD
×  ||| S:6138 E:6140 ||| CD
10  ||| S:6140 E:6143 ||| CD
7and  ||| S:6143 E:6148 ||| CD
1.7  ||| S:6148 E:6152 ||| CD
±  ||| S:6152 E:6154 ||| CD
0.6  ||| S:6154 E:6158 ||| CD
×  ||| S:6158 E:6160 ||| CD
10  ||| S:6160 E:6163 ||| CD
7 ||| S:6163 E:6164 ||| CD
,  ||| S:6164 E:6166 ||| ,
and  ||| S:6166 E:6170 ||| CC
towards  ||| S:6170 E:6178 ||| IN
uPA  ||| S:6178 E:6192 ||| NNP
were  ||| S:6192 E:6197 ||| VBD
4.1  ||| S:6197 E:6201 ||| CD
±  ||| S:6201 E:6203 ||| CD
1.4  ||| S:6203 E:6207 ||| CD
×  ||| S:6207 E:6209 ||| CD
10  ||| S:6209 E:6212 ||| CD
7and  ||| S:6212 E:6217 ||| CD
4.4  ||| S:6217 E:6221 ||| CD
±  ||| S:6221 E:6223 ||| CD
1.6  ||| S:6223 E:6227 ||| CD
×  ||| S:6227 E:6229 ||| CD
10  ||| S:6229 E:6232 ||| CD
7 ||| S:6232 E:6233 ||| CD
,  ||| S:6233 E:6235 ||| ,
respectively ||| S:6235 E:6247 ||| RB
.  ||| S:6247 E:6259 ||| .
These  ||| S:6259 E:6265 ||| DT
results  ||| S:6265 E:6273 ||| NNS
show  ||| S:6273 E:6278 ||| VBP
that  ||| S:6278 E:6283 ||| IN
the  ||| S:6283 E:6287 ||| DT
wtPAI-1  ||| S:6287 E:6295 ||| NNP
could  ||| S:6295 E:6301 ||| MD
inhibit  ||| S:6301 E:6309 ||| VB
tPA  ||| S:6309 E:6313 ||| JJ
or  ||| S:6313 E:6326 ||| CC
uPA  ||| S:6326 E:6330 ||| JJ
at  ||| S:6330 E:6333 ||| IN
the  ||| S:6333 E:6337 ||| DT
same  ||| S:6337 E:6342 ||| JJ
rate  ||| S:6342 E:6347 ||| NN
as  ||| S:6347 E:6350 ||| IN
the  ||| S:6350 E:6354 ||| DT
fibrosarcoma  ||| S:6354 E:6367 ||| JJ
PAI-1 ||| S:6367 E:6372 ||| NN
.  ||| S:6372 E:6374 ||| .
In  ||| S:6374 E:6387 ||| IN
addition ||| S:6387 E:6395 ||| NN
,  ||| S:6395 E:6397 ||| ,
it  ||| S:6397 E:6400 ||| PRP
is  ||| S:6400 E:6403 ||| VBZ
known  ||| S:6403 E:6409 ||| VBN
that  ||| S:6409 E:6414 ||| IN
PAI-1  ||| S:6414 E:6420 ||| CD
inhibits  ||| S:6420 E:6429 ||| NNS
either  ||| S:6429 E:6436 ||| CC
tPA  ||| S:6436 E:6440 ||| JJ
or  ||| S:6440 E:6453 ||| CC
uPA  ||| S:6453 E:6457 ||| JJ
by  ||| S:6457 E:6460 ||| IN
forming  ||| S:6460 E:6468 ||| VBG
a  ||| S:6468 E:6470 ||| DT
1 ||| S:6470 E:6471 ||| CD
: ||| S:6471 E:6472 ||| :
1  ||| S:6472 E:6474 ||| CD
SDS  ||| S:6474 E:6478 ||| JJ
stable  ||| S:6478 E:6485 ||| JJ
complex  ||| S:6485 E:6493 ||| NN
[  ||| S:6493 E:6495 ||| -LRB-
4  ||| S:6495 E:6497 ||| LS
]  ||| S:6497 E:6499 ||| -RRB-
,  ||| S:6499 E:6501 ||| ,
wtPAI-1  ||| S:6501 E:6519 ||| NNP
indeed  ||| S:6519 E:6526 ||| RB
could  ||| S:6526 E:6532 ||| MD
form  ||| S:6532 E:6537 ||| VB
SDS  ||| S:6537 E:6541 ||| JJ
stable  ||| S:6541 E:6548 ||| JJ
complex  ||| S:6548 E:6556 ||| NN
with  ||| S:6556 E:6561 ||| IN
tPA  ||| S:6561 E:6565 ||| JJ
or  ||| S:6565 E:6568 ||| CC
uPA  ||| S:6568 E:6582 ||| NNP
( ||| S:6582 E:6583 ||| -LRB-
Fig.  ||| S:6583 E:6588 ||| NNP
3A ||| S:6588 E:6590 ||| NNP
)  ||| S:6590 E:6592 ||| -RRB-
just  ||| S:6592 E:6597 ||| RB
as  ||| S:6597 E:6600 ||| IN
fibrosarcoma  ||| S:6600 E:6613 ||| CD
PAI-1 ||| S:6613 E:6618 ||| CD
.  ||| S:6618 E:6648 ||| .
Single  ||| S:6648 E:6655 ||| JJ
site  ||| S:6655 E:6660 ||| NN
mutations  ||| S:6660 E:6670 ||| NNS
within  ||| S:6670 E:6677 ||| IN
the  ||| S:6677 E:6681 ||| DT
distal  ||| S:6681 E:6688 ||| JJ
hinge  ||| S:6688 E:6694 ||| NN
of  ||| S:6694 E:6707 ||| IN
PAI-1  ||| S:6707 E:6723 ||| CD
Since  ||| S:6723 E:6729 ||| IN
a  ||| S:6729 E:6731 ||| DT
proline  ||| S:6731 E:6739 ||| NN
occurs  ||| S:6739 E:6746 ||| VBZ
not  ||| S:6746 E:6750 ||| RB
only  ||| S:6750 E:6755 ||| RB
in  ||| S:6755 E:6758 ||| IN
position  ||| S:6758 E:6767 ||| NN
357  ||| S:6767 E:6771 ||| CD
of  ||| S:6771 E:6784 ||| IN
PAI-1 ||| S:6784 E:6789 ||| NNP
,  ||| S:6789 E:6791 ||| ,
but  ||| S:6791 E:6795 ||| CC
also  ||| S:6795 E:6800 ||| RB
in  ||| S:6800 E:6803 ||| IN
the  ||| S:6803 E:6807 ||| DT
corresponding  ||| S:6807 E:6821 ||| JJ
position  ||| S:6821 E:6830 ||| NN
of  ||| S:6830 E:6833 ||| IN
several  ||| S:6833 E:6851 ||| JJ
other  ||| S:6851 E:6857 ||| JJ
serpins  ||| S:6857 E:6865 ||| NNS
( ||| S:6865 E:6866 ||| -LRB-
Table  ||| S:6866 E:6872 ||| NNP
1 ||| S:6872 E:6873 ||| CD
)  ||| S:6873 E:6875 ||| -RRB-
we  ||| S:6875 E:6878 ||| PRP
attempted  ||| S:6878 E:6888 ||| VBD
to  ||| S:6888 E:6891 ||| TO
find  ||| S:6891 E:6896 ||| VB
out  ||| S:6896 E:6900 ||| RP
how  ||| S:6900 E:6904 ||| WRB
does  ||| S:6904 E:6919 ||| VBZ
a  ||| S:6919 E:6921 ||| DT
mutation  ||| S:6921 E:6930 ||| NN
of  ||| S:6930 E:6933 ||| IN
P357  ||| S:6933 E:6938 ||| RB
affect  ||| S:6938 E:6945 ||| VB
the  ||| S:6945 E:6949 ||| DT
inhibitory  ||| S:6949 E:6960 ||| JJ
activity  ||| S:6960 E:6969 ||| NN
of  ||| S:6969 E:6982 ||| IN
PAI-1 ||| S:6982 E:6987 ||| CD
.  ||| S:6987 E:6989 ||| .
Mutant  ||| S:6989 E:6996 ||| NNP
of  ||| S:6996 E:6999 ||| IN
Pro357Gly  ||| S:6999 E:7009 ||| NNP
blocked  ||| S:7009 E:7017 ||| VBD
the  ||| S:7017 E:7021 ||| DT
inhibitory  ||| S:7021 E:7042 ||| JJ
activity  ||| S:7042 E:7051 ||| NN
of  ||| S:7051 E:7054 ||| IN
PAI-1  ||| S:7054 E:7060 ||| NNP
( ||| S:7060 E:7061 ||| -LRB-
Fig.  ||| S:7061 E:7066 ||| NNP
2A ||| S:7066 E:7068 ||| NNP
) ||| S:7068 E:7069 ||| -RRB-
.  ||| S:7069 E:7071 ||| .
Similarly ||| S:7071 E:7080 ||| RB
,  ||| S:7080 E:7082 ||| ,
a  ||| S:7082 E:7084 ||| DT
mutation  ||| S:7084 E:7093 ||| NN
into  ||| S:7093 E:7108 ||| IN
proline  ||| S:7108 E:7116 ||| NN
of  ||| S:7116 E:7119 ||| IN
either  ||| S:7119 E:7126 ||| DT
Asp355  ||| S:7126 E:7133 ||| NNP
or  ||| S:7133 E:7136 ||| CC
Arg356  ||| S:7136 E:7143 ||| NNP
also  ||| S:7143 E:7148 ||| RB
inactivated  ||| S:7148 E:7160 ||| VB
the  ||| S:7160 E:7174 ||| DT
inhibitor ||| S:7174 E:7183 ||| NN
.  ||| S:7183 E:7185 ||| .
It  ||| S:7185 E:7188 ||| PRP
should  ||| S:7188 E:7195 ||| MD
be  ||| S:7195 E:7198 ||| VB
noted  ||| S:7198 E:7204 ||| VBN
that  ||| S:7204 E:7209 ||| IN
all  ||| S:7209 E:7213 ||| PDT
these  ||| S:7213 E:7219 ||| DT
mutants  ||| S:7219 E:7237 ||| NN
could  ||| S:7237 E:7243 ||| MD
be  ||| S:7243 E:7246 ||| VB
activated  ||| S:7246 E:7256 ||| VBN
to  ||| S:7256 E:7259 ||| TO
a  ||| S:7259 E:7261 ||| DT
similar  ||| S:7261 E:7269 ||| JJ
extent  ||| S:7269 E:7276 ||| NN
by  ||| S:7276 E:7279 ||| IN
6  ||| S:7279 E:7281 ||| CD
M  ||| S:7281 E:7283 ||| NNP
Gnd-HCl  ||| S:7283 E:7301 ||| NNP
( ||| S:7301 E:7302 ||| -LRB-
~20 ||| S:7302 E:7305 ||| NNP
%  ||| S:7305 E:7307 ||| NN
inhibitory  ||| S:7307 E:7318 ||| NN
activity  ||| S:7318 E:7327 ||| NN
of  ||| S:7327 E:7330 ||| IN
the  ||| S:7330 E:7334 ||| DT
wtPAI-1 ||| S:7334 E:7341 ||| NNP
,  ||| S:7341 E:7343 ||| ,
activated  ||| S:7343 E:7353 ||| VBN
under  ||| S:7353 E:7369 ||| IN
the  ||| S:7369 E:7373 ||| DT
same  ||| S:7373 E:7378 ||| JJ
conditions ||| S:7378 E:7388 ||| NNS
) ||| S:7388 E:7389 ||| -RRB-
.  ||| S:7389 E:7391 ||| .
These  ||| S:7391 E:7397 ||| DT
results  ||| S:7397 E:7405 ||| NNS
suggest  ||| S:7405 E:7413 ||| VBP
that  ||| S:7413 E:7418 ||| IN
a  ||| S:7418 E:7420 ||| DT
single  ||| S:7420 E:7437 ||| JJ
site  ||| S:7437 E:7442 ||| NN
mutation  ||| S:7442 E:7451 ||| NN
at  ||| S:7451 E:7454 ||| IN
either  ||| S:7454 E:7461 ||| DT
one  ||| S:7461 E:7465 ||| NN
of  ||| S:7465 E:7468 ||| IN
the  ||| S:7468 E:7472 ||| DT
positions  ||| S:7472 E:7482 ||| NNS
355 ||| S:7482 E:7485 ||| CD
,  ||| S:7485 E:7487 ||| ,
356  ||| S:7487 E:7491 ||| CD
or  ||| S:7491 E:7504 ||| CC
357  ||| S:7504 E:7508 ||| CD
significantly  ||| S:7508 E:7522 ||| RB
inactivates  ||| S:7522 E:7534 ||| JJ
PAI-1 ||| S:7534 E:7539 ||| NN
.  ||| S:7539 E:7551 ||| .
To  ||| S:7551 E:7554 ||| TO
elucidate  ||| S:7554 E:7564 ||| VB
the  ||| S:7564 E:7568 ||| DT
mechanism  ||| S:7568 E:7578 ||| NN
through  ||| S:7578 E:7586 ||| IN
which  ||| S:7586 E:7592 ||| WDT
such  ||| S:7592 E:7607 ||| JJ
mutations  ||| S:7607 E:7617 ||| NNS
affect  ||| S:7617 E:7624 ||| VBP
the  ||| S:7624 E:7628 ||| DT
activity  ||| S:7628 E:7637 ||| NN
of  ||| S:7637 E:7640 ||| IN
PAI-1 ||| S:7640 E:7645 ||| NNP
,  ||| S:7645 E:7647 ||| ,
we  ||| S:7647 E:7650 ||| PRP
determined  ||| S:7650 E:7671 ||| VBD
their  ||| S:7671 E:7677 ||| PRP$
effect  ||| S:7677 E:7684 ||| NN
on  ||| S:7684 E:7687 ||| IN
the  ||| S:7687 E:7691 ||| DT
functional  ||| S:7691 E:7702 ||| JJ
stability  ||| S:7702 E:7712 ||| NN
of  ||| S:7712 E:7715 ||| IN
PAI-1  ||| S:7715 E:7721 ||| NNP
and  ||| S:7721 E:7725 ||| CC
on  ||| S:7725 E:7738 ||| IN
its  ||| S:7738 E:7742 ||| PRP$
ability  ||| S:7742 E:7750 ||| NN
to  ||| S:7750 E:7753 ||| TO
form  ||| S:7753 E:7758 ||| VB
an  ||| S:7758 E:7761 ||| DT
SDS  ||| S:7761 E:7765 ||| NNP
stable  ||| S:7765 E:7772 ||| JJ
complex  ||| S:7772 E:7780 ||| NN
with  ||| S:7780 E:7785 ||| IN
either  ||| S:7785 E:7792 ||| DT
tPA  ||| S:7792 E:7806 ||| JJ
or  ||| S:7806 E:7809 ||| CC
uPA ||| S:7809 E:7812 ||| JJ
.  ||| S:7812 E:7814 ||| .
As  ||| S:7814 E:7817 ||| RB
seen  ||| S:7817 E:7822 ||| VBN
in  ||| S:7822 E:7825 ||| IN
Fig.  ||| S:7825 E:7830 ||| CD
2B ||| S:7830 E:7832 ||| CD
,  ||| S:7832 E:7834 ||| ,
the  ||| S:7834 E:7838 ||| DT
rate  ||| S:7838 E:7843 ||| NN
of  ||| S:7843 E:7846 ||| IN
the  ||| S:7846 E:7850 ||| DT
spontaneous  ||| S:7850 E:7872 ||| JJ
inactivation  ||| S:7872 E:7885 ||| NN
of  ||| S:7885 E:7888 ||| IN
the  ||| S:7888 E:7892 ||| DT
inhibitor  ||| S:7892 E:7902 ||| NN
was  ||| S:7902 E:7906 ||| VBD
significantly  ||| S:7906 E:7920 ||| RB
increased  ||| S:7920 E:7940 ||| VBN
upon  ||| S:7940 E:7945 ||| IN
mutation ||| S:7945 E:7953 ||| NN
:  ||| S:7953 E:7955 ||| :
the  ||| S:7955 E:7959 ||| DT
functional  ||| S:7959 E:7970 ||| JJ
half  ||| S:7970 E:7975 ||| NN
life  ||| S:7975 E:7980 ||| NN
of  ||| S:7980 E:7983 ||| IN
the  ||| S:7983 E:7987 ||| DT
mutants  ||| S:7987 E:8005 ||| JJ
Asp355Pro ||| S:8005 E:8014 ||| NN
,  ||| S:8014 E:8016 ||| ,
Arg356Pro  ||| S:8016 E:8026 ||| NNP
and  ||| S:8026 E:8030 ||| CC
Pro357Gly  ||| S:8030 E:8040 ||| NNP
was  ||| S:8040 E:8044 ||| VBD
23.8  ||| S:8044 E:8049 ||| CD
±  ||| S:8049 E:8051 ||| CD
4.5  ||| S:8051 E:8055 ||| CD
min ||| S:8055 E:8058 ||| NN
,  ||| S:8058 E:8070 ||| ,
26.2  ||| S:8070 E:8075 ||| CD
±  ||| S:8075 E:8077 ||| CD
3.7  ||| S:8077 E:8081 ||| CD
min  ||| S:8081 E:8085 ||| NNS
and  ||| S:8085 E:8089 ||| CC
24.7  ||| S:8089 E:8094 ||| CD
±  ||| S:8094 E:8096 ||| CD
4.8  ||| S:8096 E:8100 ||| CD
min ||| S:8100 E:8103 ||| NN
,  ||| S:8103 E:8105 ||| ,
respectively ||| S:8105 E:8117 ||| RB
,  ||| S:8117 E:8119 ||| ,
while  ||| S:8119 E:8135 ||| IN
that  ||| S:8135 E:8140 ||| DT
of  ||| S:8140 E:8143 ||| IN
wtPAI-1  ||| S:8143 E:8151 ||| NNP
was  ||| S:8151 E:8155 ||| VBD
89.8  ||| S:8155 E:8160 ||| CD
±  ||| S:8160 E:8162 ||| CD
8.7  ||| S:8162 E:8166 ||| CD
min ||| S:8166 E:8169 ||| NNS
.  ||| S:8169 E:8171 ||| .
Interestingly ||| S:8171 E:8184 ||| RB
,  ||| S:8184 E:8186 ||| ,
there  ||| S:8186 E:8202 ||| EX
was  ||| S:8202 E:8206 ||| VBD
no  ||| S:8206 E:8209 ||| DT
significant  ||| S:8209 E:8221 ||| JJ
difference  ||| S:8221 E:8232 ||| NN
between  ||| S:8232 E:8240 ||| IN
the  ||| S:8240 E:8244 ||| DT
mutants  ||| S:8244 E:8252 ||| JJ
tested  ||| S:8252 E:8269 ||| NN
and  ||| S:8269 E:8273 ||| CC
the  ||| S:8273 E:8277 ||| DT
wtPAI-1  ||| S:8277 E:8285 ||| NN
in  ||| S:8285 E:8288 ||| IN
their  ||| S:8288 E:8294 ||| PRP$
ability  ||| S:8294 E:8302 ||| NN
to  ||| S:8302 E:8305 ||| TO
inactivate  ||| S:8305 E:8316 ||| VB
either  ||| S:8316 E:8323 ||| DT
tPA  ||| S:8323 E:8337 ||| JJ
or  ||| S:8337 E:8340 ||| CC
uPA  ||| S:8340 E:8344 ||| NNP
( ||| S:8344 E:8345 ||| -LRB-
Table  ||| S:8345 E:8351 ||| NNP
3 ||| S:8351 E:8352 ||| CD
) ||| S:8352 E:8353 ||| -RRB-
.  ||| S:8353 E:8355 ||| .
They  ||| S:8355 E:8360 ||| PRP
could  ||| S:8360 E:8366 ||| MD
also  ||| S:8366 E:8371 ||| RB
form  ||| S:8371 E:8376 ||| VB
SDS-stable  ||| S:8376 E:8397 ||| JJ
complexes  ||| S:8397 E:8407 ||| NNS
with  ||| S:8407 E:8412 ||| IN
tPA  ||| S:8412 E:8416 ||| JJ
or  ||| S:8416 E:8419 ||| CC
uPA  ||| S:8419 E:8423 ||| JJ
just  ||| S:8423 E:8428 ||| RB
as  ||| S:8428 E:8431 ||| RB
well  ||| S:8431 E:8436 ||| RB
as  ||| S:8436 E:8439 ||| IN
wtPAI-1  ||| S:8439 E:8447 ||| NNP
( ||| S:8447 E:8448 ||| -LRB-
Fig.  ||| S:8448 E:8463 ||| NNP
3A ||| S:8463 E:8465 ||| NNP
) ||| S:8465 E:8466 ||| -RRB-
.  ||| S:8466 E:8478 ||| .
An  ||| S:8478 E:8481 ||| DT
interesting  ||| S:8481 E:8493 ||| JJ
structural  ||| S:8493 E:8504 ||| JJ
similarity  ||| S:8504 E:8515 ||| NN
among  ||| S:8515 E:8521 ||| IN
several  ||| S:8521 E:8539 ||| JJ
serpins  ||| S:8539 E:8547 ||| NN
is  ||| S:8547 E:8550 ||| VBZ
known  ||| S:8550 E:8556 ||| VBN
to  ||| S:8556 E:8559 ||| TO
occur  ||| S:8559 E:8565 ||| VB
at  ||| S:8565 E:8568 ||| IN
the  ||| S:8568 E:8572 ||| DT
position  ||| S:8572 E:8581 ||| NN
corresponding  ||| S:8581 E:8605 ||| NN
to  ||| S:8605 E:8608 ||| TO
355  ||| S:8608 E:8612 ||| CD
in  ||| S:8612 E:8615 ||| IN
PAI-1 ||| S:8615 E:8620 ||| CD
.  ||| S:8620 E:8622 ||| .
While  ||| S:8622 E:8628 ||| IN
in  ||| S:8628 E:8631 ||| IN
PAI-1  ||| S:8631 E:8637 ||| CD
this  ||| S:8637 E:8642 ||| DT
position  ||| S:8642 E:8661 ||| NN
accommodates  ||| S:8661 E:8674 ||| VBD
a  ||| S:8674 E:8676 ||| DT
negatively  ||| S:8676 E:8687 ||| RB
charged  ||| S:8687 E:8695 ||| VBN
aspartic  ||| S:8695 E:8704 ||| JJ
acid  ||| S:8704 E:8709 ||| NN
residue ||| S:8709 E:8716 ||| NN
,  ||| S:8716 E:8728 ||| ,
in  ||| S:8728 E:8731 ||| IN
other  ||| S:8731 E:8737 ||| JJ
serpins  ||| S:8737 E:8745 ||| NN
it  ||| S:8745 E:8748 ||| PRP
sometimes  ||| S:8748 E:8758 ||| RB
accommodates  ||| S:8758 E:8771 ||| VB
its  ||| S:8771 E:8775 ||| PRP$
non  ||| S:8775 E:8789 ||| FW
charged  ||| S:8789 E:8797 ||| FW
analog  ||| S:8797 E:8804 ||| FW
asparagine  ||| S:8804 E:8815 ||| FW
( ||| S:8815 E:8816 ||| -LRB-
Table  ||| S:8816 E:8822 ||| NNP
1 ||| S:8822 E:8823 ||| CD
) ||| S:8823 E:8824 ||| -RRB-
.  ||| S:8824 E:8826 ||| .
Asp355His ||| S:8826 E:8835 ||| NNP
,  ||| S:8835 E:8847 ||| ,
Asp355Lys ||| S:8847 E:8856 ||| NNP
,  ||| S:8856 E:8858 ||| ,
Asp355Glu ||| S:8858 E:8867 ||| NNP
,  ||| S:8867 E:8869 ||| ,
Asp355Gln  ||| S:8869 E:8879 ||| NNP
and  ||| S:8879 E:8883 ||| CC
Asp355Asn  ||| S:8883 E:8893 ||| NNP
were  ||| S:8893 E:8908 ||| VBD
prepared  ||| S:8908 E:8917 ||| VBN
and  ||| S:8917 E:8921 ||| CC
used  ||| S:8921 E:8926 ||| VBN
to  ||| S:8926 E:8929 ||| TO
show  ||| S:8929 E:8934 ||| VB
that  ||| S:8934 E:8939 ||| IN
the  ||| S:8939 E:8943 ||| DT
negatively  ||| S:8943 E:8954 ||| RB
charged  ||| S:8954 E:8972 ||| VBN
aspartic  ||| S:8972 E:8981 ||| JJ
acid  ||| S:8981 E:8986 ||| NN
in  ||| S:8986 E:8989 ||| IN
PAI-1  ||| S:8989 E:8995 ||| NNP
is  ||| S:8995 E:8998 ||| VBZ
essential  ||| S:8998 E:9008 ||| JJ
( ||| S:9008 E:9009 ||| -LRB-
though  ||| S:9009 E:9016 ||| RB
not  ||| S:9016 E:9030 ||| RB
sufficient ||| S:9030 E:9040 ||| JJ
)  ||| S:9040 E:9042 ||| -RRB-
for  ||| S:9042 E:9046 ||| IN
its  ||| S:9046 E:9050 ||| PRP$
inhibitory  ||| S:9050 E:9061 ||| JJ
activity ||| S:9061 E:9069 ||| NN
.  ||| S:9069 E:9071 ||| .
Mutation  ||| S:9071 E:9080 ||| NN
of  ||| S:9080 E:9093 ||| IN
Asp355  ||| S:9093 E:9100 ||| CD
by  ||| S:9100 E:9103 ||| IN
asparagine  ||| S:9103 E:9114 ||| NNS
( ||| S:9114 E:9115 ||| -LRB-
the  ||| S:9115 E:9119 ||| DT
non  ||| S:9119 E:9123 ||| NN
charged  ||| S:9123 E:9131 ||| VBD
analog  ||| S:9131 E:9138 ||| VBN
of  ||| S:9138 E:9141 ||| IN
aspartic  ||| S:9141 E:9160 ||| JJ
acid ||| S:9160 E:9164 ||| NN
) ||| S:9164 E:9165 ||| -RRB-
,  ||| S:9165 E:9167 ||| ,
or  ||| S:9167 E:9170 ||| CC
by  ||| S:9170 E:9173 ||| IN
histidine  ||| S:9173 E:9183 ||| NN
or  ||| S:9183 E:9186 ||| CC
lysine  ||| S:9186 E:9193 ||| NNS
( ||| S:9193 E:9194 ||| -LRB-
that  ||| S:9194 E:9199 ||| WDT
have  ||| S:9199 E:9204 ||| VBP
a  ||| S:9204 E:9206 ||| DT
positively  ||| S:9206 E:9227 ||| RB
charged  ||| S:9227 E:9235 ||| VBN
side  ||| S:9235 E:9240 ||| NN
chain ||| S:9240 E:9245 ||| NN
)  ||| S:9245 E:9247 ||| -RRB-
or  ||| S:9247 E:9250 ||| CC
by  ||| S:9250 E:9253 ||| IN
alanine  ||| S:9253 E:9261 ||| NNS
( ||| S:9261 E:9262 ||| -LRB-
neutral ||| S:9262 E:9269 ||| LS
) ||| S:9269 E:9270 ||| -RRB-
,  ||| S:9270 E:9272 ||| ,
inactivated  ||| S:9272 E:9294 ||| CD
PAI-1 ||| S:9294 E:9299 ||| CD
.  ||| S:9299 E:9301 ||| .
Replacement  ||| S:9301 E:9313 ||| NN
of  ||| S:9313 E:9316 ||| IN
this  ||| S:9316 E:9321 ||| DT
aspartic  ||| S:9321 E:9330 ||| JJ
acid  ||| S:9330 E:9335 ||| NN
residue  ||| S:9335 E:9343 ||| VBZ
even  ||| S:9343 E:9348 ||| RB
by  ||| S:9348 E:9361 ||| IN
the  ||| S:9361 E:9365 ||| DT
negatively  ||| S:9365 E:9376 ||| RB
charged  ||| S:9376 E:9384 ||| VBN
glutamic  ||| S:9384 E:9393 ||| JJ
acid  ||| S:9393 E:9398 ||| NN
( ||| S:9398 E:9399 ||| -LRB-
a  ||| S:9399 E:9401 ||| DT
very  ||| S:9401 E:9406 ||| RB
close  ||| S:9406 E:9412 ||| VB
analog  ||| S:9412 E:9429 ||| VBN
of  ||| S:9429 E:9432 ||| IN
aspartic  ||| S:9432 E:9441 ||| JJ
acid ||| S:9441 E:9445 ||| NN
)  ||| S:9445 E:9447 ||| -RRB-
did  ||| S:9447 E:9451 ||| VBD
not  ||| S:9451 E:9455 ||| RB
significantly  ||| S:9455 E:9469 ||| RB
suffice  ||| S:9469 E:9477 ||| VB
to  ||| S:9477 E:9490 ||| TO
restore  ||| S:9490 E:9498 ||| VB
a  ||| S:9498 E:9500 ||| DT
full  ||| S:9500 E:9505 ||| JJ
inhibitory  ||| S:9505 E:9516 ||| JJ
activity  ||| S:9516 E:9525 ||| NN
of  ||| S:9525 E:9528 ||| IN
PAI-1  ||| S:9528 E:9534 ||| NNP
( ||| S:9534 E:9535 ||| -LRB-
Fig.  ||| S:9535 E:9540 ||| NNP
3B ||| S:9540 E:9542 ||| NNP
) ||| S:9542 E:9543 ||| -RRB-
.  ||| S:9543 E:9555 ||| .
After  ||| S:9555 E:9561 ||| IN
activation  ||| S:9561 E:9572 ||| NN
with  ||| S:9572 E:9577 ||| IN
6  ||| S:9577 E:9579 ||| CD
M  ||| S:9579 E:9581 ||| NNP
Gnd-HCl ||| S:9581 E:9588 ||| NNP
,  ||| S:9588 E:9590 ||| ,
each  ||| S:9590 E:9595 ||| DT
of  ||| S:9595 E:9598 ||| IN
the  ||| S:9598 E:9602 ||| DT
six  ||| S:9602 E:9616 ||| CD
mutants  ||| S:9616 E:9624 ||| NNS
exhibited  ||| S:9624 E:9634 ||| VBP
a  ||| S:9634 E:9636 ||| DT
relatively  ||| S:9636 E:9647 ||| RB
high  ||| S:9647 E:9652 ||| JJ
inhibitory  ||| S:9652 E:9663 ||| JJ
activity ||| S:9663 E:9671 ||| NN
,  ||| S:9671 E:9683 ||| ,
but  ||| S:9683 E:9687 ||| CC
their  ||| S:9687 E:9693 ||| PRP$
specific  ||| S:9693 E:9702 ||| JJ
activities  ||| S:9702 E:9713 ||| NNS
were  ||| S:9713 E:9718 ||| VBD
still  ||| S:9718 E:9724 ||| RB
much  ||| S:9724 E:9729 ||| RB
lower  ||| S:9729 E:9735 ||| JJR
than  ||| S:9735 E:9750 ||| IN
that  ||| S:9750 E:9755 ||| DT
of  ||| S:9755 E:9758 ||| IN
wtPAI-1  ||| S:9758 E:9766 ||| NNP
( ||| S:9766 E:9767 ||| -LRB-
Fig.  ||| S:9767 E:9772 ||| NNP
3B ||| S:9772 E:9774 ||| NNP
) ||| S:9774 E:9775 ||| -RRB-
.  ||| S:9775 E:9777 ||| .
Among  ||| S:9777 E:9783 ||| IN
them ||| S:9783 E:9787 ||| PRP
,  ||| S:9787 E:9789 ||| ,
Asp355Lys  ||| S:9789 E:9799 ||| NNP
( ||| S:9799 E:9800 ||| -LRB-
5.1  ||| S:9800 E:9804 ||| CD
±  ||| S:9804 E:9816 ||| CD
4.1  ||| S:9816 E:9820 ||| CD
U ||| S:9820 E:9821 ||| NNP
/ ||| S:9821 E:9822 ||| CD
ug ||| S:9822 E:9824 ||| CD
)  ||| S:9824 E:9826 ||| -RRB-
had  ||| S:9826 E:9830 ||| VBD
the  ||| S:9830 E:9834 ||| DT
lowest  ||| S:9834 E:9841 ||| JJS
specific  ||| S:9841 E:9850 ||| JJ
activity ||| S:9850 E:9858 ||| NN
,  ||| S:9858 E:9860 ||| ,
while  ||| S:9860 E:9866 ||| IN
the  ||| S:9866 E:9880 ||| DT
Asp355Asn  ||| S:9880 E:9890 ||| NNP
( ||| S:9890 E:9891 ||| -LRB-
20  ||| S:9891 E:9894 ||| CD
±  ||| S:9894 E:9896 ||| CD
4.2  ||| S:9896 E:9900 ||| CD
U ||| S:9900 E:9901 ||| NNP
/ ||| S:9901 E:9902 ||| CD
μg ||| S:9902 E:9904 ||| CD
)  ||| S:9904 E:9906 ||| -RRB-
had  ||| S:9906 E:9910 ||| VBD
the  ||| S:9910 E:9914 ||| DT
highest  ||| S:9914 E:9922 ||| JJS
specific  ||| S:9922 E:9941 ||| JJ
activity  ||| S:9941 E:9950 ||| NN
( ||| S:9950 E:9951 ||| -LRB-
Fig.  ||| S:9951 E:9956 ||| NNP
3B ||| S:9956 E:9958 ||| NNP
) ||| S:9958 E:9959 ||| -RRB-
.  ||| S:9959 E:9961 ||| .
Although  ||| S:9961 E:9970 ||| IN
they  ||| S:9970 E:9975 ||| PRP
had  ||| S:9975 E:9979 ||| VBD
lower  ||| S:9979 E:9985 ||| RBR
specific  ||| S:9985 E:10004 ||| JJ
activities ||| S:10004 E:10014 ||| NNS
,  ||| S:10014 E:10016 ||| ,
all  ||| S:10016 E:10020 ||| DT
of  ||| S:10020 E:10023 ||| IN
the  ||| S:10023 E:10027 ||| DT
mutants  ||| S:10027 E:10035 ||| NN
mentioned  ||| S:10035 E:10045 ||| VBD
above  ||| S:10045 E:10051 ||| RB
could  ||| S:10051 E:10067 ||| MD
still  ||| S:10067 E:10073 ||| RB
form  ||| S:10073 E:10078 ||| VB
SDS-stable  ||| S:10078 E:10089 ||| JJ
complexes  ||| S:10089 E:10099 ||| NNS
with  ||| S:10099 E:10104 ||| IN
tPA  ||| S:10104 E:10108 ||| JJ
or  ||| S:10108 E:10111 ||| CC
uPA  ||| S:10111 E:10115 ||| JJ
just  ||| S:10115 E:10120 ||| RB
as  ||| S:10120 E:10133 ||| IN
the  ||| S:10133 E:10137 ||| DT
wtPAI-1  ||| S:10137 E:10145 ||| NNP
( ||| S:10145 E:10146 ||| -LRB-
data  ||| S:10146 E:10151 ||| NNS
not  ||| S:10151 E:10155 ||| RB
shown ||| S:10155 E:10160 ||| VBN
) ||| S:10160 E:10161 ||| -RRB-
.  ||| S:10161 E:10173 ||| .
Two  ||| S:10173 E:10177 ||| CD
additional  ||| S:10177 E:10188 ||| JJ
mutations ||| S:10188 E:10197 ||| NNS
,  ||| S:10197 E:10199 ||| ,
Arg356Ala  ||| S:10199 E:10209 ||| NNP
and  ||| S:10209 E:10213 ||| CC
Arg356Glu ||| S:10213 E:10222 ||| NNP
,  ||| S:10222 E:10234 ||| ,
were  ||| S:10234 E:10239 ||| VBD
prepared  ||| S:10239 E:10248 ||| VBN
to  ||| S:10248 E:10251 ||| TO
further  ||| S:10251 E:10259 ||| VB
elucidate  ||| S:10259 E:10269 ||| VBN
the  ||| S:10269 E:10273 ||| DT
role  ||| S:10273 E:10278 ||| NN
of  ||| S:10278 E:10281 ||| IN
Arg356 ||| S:10281 E:10287 ||| CD
.  ||| S:10287 E:10299 ||| .
The  ||| S:10299 E:10303 ||| DT
specific  ||| S:10303 E:10312 ||| JJ
inhibitory  ||| S:10312 E:10323 ||| JJ
activity  ||| S:10323 E:10332 ||| NN
of  ||| S:10332 E:10335 ||| IN
Arg356Ala  ||| S:10335 E:10345 ||| NNP
was  ||| S:10345 E:10349 ||| VBD
7.2  ||| S:10349 E:10353 ||| CD
±  ||| S:10353 E:10365 ||| CD
2.5  ||| S:10365 E:10369 ||| CD
U ||| S:10369 E:10370 ||| NNP
/ ||| S:10370 E:10371 ||| NNP
μg ||| S:10371 E:10373 ||| NN
,  ||| S:10373 E:10375 ||| ,
while  ||| S:10375 E:10381 ||| IN
Arg356Glu  ||| S:10381 E:10391 ||| CD
exhibited  ||| S:10391 E:10401 ||| NNS
essentially  ||| S:10401 E:10413 ||| RB
no  ||| S:10413 E:10426 ||| DT
inhibitory  ||| S:10426 E:10437 ||| JJ
activity ||| S:10437 E:10445 ||| NN
.  ||| S:10445 E:10447 ||| .
This  ||| S:10447 E:10452 ||| DT
specific  ||| S:10452 E:10461 ||| JJ
activity  ||| S:10461 E:10470 ||| NN
was  ||| S:10470 E:10474 ||| VBD
increased  ||| S:10474 E:10494 ||| VBN
to  ||| S:10494 E:10497 ||| TO
35.4  ||| S:10497 E:10502 ||| CD
±  ||| S:10502 E:10504 ||| CD
8.7  ||| S:10504 E:10508 ||| CD
U ||| S:10508 E:10509 ||| NNP
/ ||| S:10509 E:10510 ||| NNP
ug  ||| S:10510 E:10513 ||| NN
for  ||| S:10513 E:10517 ||| IN
Arg356Ala  ||| S:10517 E:10527 ||| NNP
and  ||| S:10527 E:10531 ||| CC
6.4  ||| S:10531 E:10535 ||| CD
±  ||| S:10535 E:10537 ||| CD
2.3  ||| S:10537 E:10541 ||| CD
U ||| S:10541 E:10542 ||| NNP
/ ||| S:10542 E:10543 ||| NNP
μg  ||| S:10543 E:10546 ||| NN
for  ||| S:10546 E:10560 ||| IN
Arg356Glu  ||| S:10560 E:10570 ||| CD
after  ||| S:10570 E:10576 ||| IN
denature  ||| S:10576 E:10585 ||| NN
and  ||| S:10585 E:10589 ||| CC
refolding ||| S:10589 E:10598 ||| NN
.  ||| S:10598 E:10600 ||| .
Just  ||| S:10600 E:10605 ||| RB
like  ||| S:10605 E:10620 ||| IN
ARG356Pro ||| S:10620 E:10629 ||| NNP
,  ||| S:10629 E:10631 ||| ,
Arg356Ala  ||| S:10631 E:10641 ||| NNP
and  ||| S:10641 E:10645 ||| CC
Arg356Glu  ||| S:10645 E:10655 ||| NNP
were  ||| S:10655 E:10660 ||| VBD
much  ||| S:10660 E:10665 ||| RB
more  ||| S:10665 E:10670 ||| JJR
labile  ||| S:10670 E:10687 ||| NN
than  ||| S:10687 E:10692 ||| IN
wtPAI-1 ||| S:10692 E:10699 ||| CD
.  ||| S:10699 E:10701 ||| .
These  ||| S:10701 E:10707 ||| DT
results  ||| S:10707 E:10715 ||| NNS
suggest  ||| S:10715 E:10723 ||| VBP
that  ||| S:10723 E:10728 ||| IN
the  ||| S:10728 E:10732 ||| DT
role  ||| S:10732 E:10737 ||| NN
of  ||| S:10737 E:10740 ||| IN
the  ||| S:10740 E:10754 ||| DT
Asp355-Pro357  ||| S:10754 E:10768 ||| JJ
segment  ||| S:10768 E:10776 ||| NN
is  ||| S:10776 E:10779 ||| VBZ
to  ||| S:10779 E:10782 ||| TO
stabilize  ||| S:10782 E:10792 ||| VB
the  ||| S:10792 E:10796 ||| DT
inhibitory  ||| S:10796 E:10817 ||| JJ
conformation  ||| S:10817 E:10830 ||| NN
of  ||| S:10830 E:10833 ||| IN
PAI-1 ||| S:10833 E:10838 ||| CD
.  ||| S:10838 E:10868 ||| .
Specific  ||| S:10868 E:10877 ||| JJ
activity ||| S:10877 E:10885 ||| NN
,  ||| S:10885 E:10887 ||| ,
functional  ||| S:10887 E:10898 ||| JJ
stability  ||| S:10898 E:10908 ||| NN
and  ||| S:10908 E:10912 ||| CC
complex  ||| S:10912 E:10930 ||| JJ
formation  ||| S:10930 E:10940 ||| NN
of  ||| S:10940 E:10943 ||| IN
Glu351Ala  ||| S:10943 E:10953 ||| NNP
and  ||| S:10953 E:10957 ||| CC
Glu351Arg  ||| S:10957 E:10977 ||| CD
The  ||| S:10977 E:10981 ||| DT
specific  ||| S:10981 E:10990 ||| JJ
inhibitory  ||| S:10990 E:11001 ||| JJ
activities  ||| S:11001 E:11012 ||| NNS
of  ||| S:11012 E:11015 ||| IN
wtPAI-1 ||| S:11015 E:11022 ||| NNP
,  ||| S:11022 E:11034 ||| ,
Glu351Ala  ||| S:11034 E:11044 ||| NNP
and  ||| S:11044 E:11048 ||| CC
Glu351Arg  ||| S:11048 E:11058 ||| NNP
were  ||| S:11058 E:11063 ||| VBD
assessed  ||| S:11063 E:11072 ||| VBN
with  ||| S:11072 E:11077 ||| IN
uPA  ||| S:11077 E:11081 ||| JJ
and  ||| S:11081 E:11095 ||| CC
S-2444 ||| S:11095 E:11101 ||| NNP
.  ||| S:11101 E:11103 ||| .
As  ||| S:11103 E:11106 ||| RB
shown  ||| S:11106 E:11112 ||| VBN
in  ||| S:11112 E:11115 ||| IN
Fg.  ||| S:11115 E:11119 ||| CD
4A ||| S:11119 E:11121 ||| CD
,  ||| S:11121 E:11123 ||| ,
the  ||| S:11123 E:11127 ||| DT
specificity  ||| S:11127 E:11139 ||| NN
of  ||| S:11139 E:11142 ||| IN
wtPAI-1 ||| S:11142 E:11149 ||| NNP
,  ||| S:11149 E:11161 ||| ,
Glu351Ala  ||| S:11161 E:11171 ||| NNP
and  ||| S:11171 E:11175 ||| CC
Glu351Arg  ||| S:11175 E:11185 ||| CD
after  ||| S:11185 E:11191 ||| IN
denatured  ||| S:11191 E:11201 ||| NN
by  ||| S:11201 E:11204 ||| IN
6  ||| S:11204 E:11206 ||| CD
M  ||| S:11206 E:11208 ||| NNP
Gdn-HCl  ||| S:11208 E:11226 ||| NNP
and  ||| S:11226 E:11230 ||| CC
dialyzed  ||| S:11230 E:11239 ||| NN
against  ||| S:11239 E:11247 ||| IN
50  ||| S:11247 E:11250 ||| CD
mM  ||| S:11250 E:11253 ||| JJ
sodium  ||| S:11253 E:11260 ||| JJ
acetate ||| S:11260 E:11267 ||| NN
,  ||| S:11267 E:11269 ||| ,
pH  ||| S:11269 E:11272 ||| JJ
5.6 ||| S:11272 E:11275 ||| CD
,  ||| S:11275 E:11277 ||| ,
was  ||| S:11277 E:11281 ||| VBD
84  ||| S:11281 E:11294 ||| CD
±  ||| S:11294 E:11296 ||| CD
15 ||| S:11296 E:11298 ||| CD
,  ||| S:11298 E:11300 ||| ,
112  ||| S:11300 E:11304 ||| CD
±  ||| S:11304 E:11306 ||| CD
18  ||| S:11306 E:11309 ||| CD
and  ||| S:11309 E:11313 ||| CC
68  ||| S:11313 E:11316 ||| CD
±  ||| S:11316 E:11318 ||| CD
9  ||| S:11318 E:11320 ||| CD
U ||| S:11320 E:11321 ||| NNP
/ ||| S:11321 E:11322 ||| NNP
ug ||| S:11322 E:11324 ||| NN
,  ||| S:11324 E:11326 ||| ,
respectively ||| S:11326 E:11338 ||| RB
.  ||| S:11338 E:11340 ||| .
Glu351Ala  ||| S:11340 E:11360 ||| NNP
had  ||| S:11360 E:11364 ||| VBD
a  ||| S:11364 E:11366 ||| DT
higher ||| S:11366 E:11372 ||| JJR
,  ||| S:11372 E:11374 ||| ,
and  ||| S:11374 E:11378 ||| CC
Glu351Arg  ||| S:11378 E:11388 ||| CD
lower  ||| S:11388 E:11394 ||| JJR
specific  ||| S:11394 E:11403 ||| JJ
activity  ||| S:11403 E:11412 ||| NN
than  ||| S:11412 E:11427 ||| IN
wtPAI-1 ||| S:11427 E:11434 ||| CD
.  ||| S:11434 E:11436 ||| .
The  ||| S:11436 E:11440 ||| DT
specific  ||| S:11440 E:11449 ||| JJ
activities  ||| S:11449 E:11460 ||| NNS
of  ||| S:11460 E:11463 ||| IN
PAI-1s  ||| S:11463 E:11470 ||| NNP
determined  ||| S:11470 E:11491 ||| VBD
immediately  ||| S:11491 E:11503 ||| RB
after  ||| S:11503 E:11509 ||| IN
purification  ||| S:11509 E:11522 ||| NN
displayed  ||| S:11522 E:11532 ||| VBD
similar  ||| S:11532 E:11540 ||| JJ
pattern  ||| S:11540 E:11558 ||| NN
as  ||| S:11558 E:11561 ||| IN
that  ||| S:11561 E:11566 ||| DT
of  ||| S:11566 E:11569 ||| IN
inhibitors  ||| S:11569 E:11580 ||| JJ
reactivated ||| S:11580 E:11591 ||| NN
.  ||| S:11591 E:11593 ||| .
There  ||| S:11593 E:11599 ||| EX
was  ||| S:11599 E:11603 ||| VBD
about  ||| S:11603 E:11609 ||| IN
15-20 ||| S:11609 E:11614 ||| CD
%  ||| S:11614 E:11626 ||| NN
increase  ||| S:11626 E:11635 ||| NN
after  ||| S:11635 E:11641 ||| IN
reactivation  ||| S:11641 E:11654 ||| VBG
compared  ||| S:11654 E:11663 ||| VBN
to  ||| S:11663 E:11666 ||| TO
each  ||| S:11666 E:11671 ||| DT
untreated  ||| S:11671 E:11691 ||| JJ
protein  ||| S:11691 E:11699 ||| NN
itself ||| S:11699 E:11705 ||| PRP
.  ||| S:11705 E:11707 ||| .
As  ||| S:11707 E:11710 ||| RB
shown  ||| S:11710 E:11716 ||| VBN
in  ||| S:11716 E:11719 ||| IN
Fig.  ||| S:11719 E:11724 ||| CD
4B ||| S:11724 E:11726 ||| CD
,  ||| S:11726 E:11728 ||| ,
the  ||| S:11728 E:11732 ||| DT
two  ||| S:11732 E:11736 ||| CD
mutants  ||| S:11736 E:11744 ||| NNS
also  ||| S:11744 E:11759 ||| RB
spontaneously  ||| S:11759 E:11773 ||| RB
lost  ||| S:11773 E:11778 ||| VBD
their  ||| S:11778 E:11784 ||| PRP$
inhibitory  ||| S:11784 E:11795 ||| JJ
activity ||| S:11795 E:11803 ||| NN
( ||| S:11803 E:11804 ||| -LRB-
convert  ||| S:11804 E:11812 ||| VB
to  ||| S:11812 E:11825 ||| TO
latency ||| S:11825 E:11832 ||| CD
)  ||| S:11832 E:11834 ||| -RRB-
as  ||| S:11834 E:11837 ||| IN
wtPAI-1 ||| S:11837 E:11844 ||| NNP
,  ||| S:11844 E:11846 ||| ,
but  ||| S:11846 E:11850 ||| CC
at  ||| S:11850 E:11853 ||| IN
different  ||| S:11853 E:11863 ||| JJ
rates ||| S:11863 E:11868 ||| NNS
.  ||| S:11868 E:11870 ||| .
The  ||| S:11870 E:11884 ||| DT
functional  ||| S:11884 E:11895 ||| JJ
stability  ||| S:11895 E:11905 ||| NN
of  ||| S:11905 E:11908 ||| IN
wtPAI-1 ||| S:11908 E:11915 ||| NNP
,  ||| S:11915 E:11917 ||| ,
Glu351Ala ||| S:11917 E:11926 ||| NNP
,  ||| S:11926 E:11928 ||| ,
Glu351Arg  ||| S:11928 E:11938 ||| NNP
was  ||| S:11938 E:11952 ||| VBD
about  ||| S:11952 E:11958 ||| IN
18  ||| S:11958 E:11961 ||| CD
±  ||| S:11961 E:11963 ||| CD
5 ||| S:11963 E:11964 ||| CD
,  ||| S:11964 E:11966 ||| ,
90  ||| S:11966 E:11969 ||| CD
±  ||| S:11969 E:11971 ||| CD
8  ||| S:11971 E:11973 ||| CD
and  ||| S:11973 E:11977 ||| CC
14  ||| S:11977 E:11980 ||| CD
±  ||| S:11980 E:11982 ||| CD
3  ||| S:11982 E:11984 ||| CD
minutes ||| S:11984 E:11991 ||| NNS
,  ||| S:11991 E:11993 ||| ,
respectively ||| S:11993 E:12005 ||| RB
.  ||| S:12005 E:12007 ||| .
It  ||| S:12007 E:12020 ||| PRP
suggested  ||| S:12020 E:12030 ||| VBD
that  ||| S:12030 E:12035 ||| IN
the  ||| S:12035 E:12039 ||| DT
specific  ||| S:12039 E:12048 ||| JJ
activities  ||| S:12048 E:12059 ||| NNS
measured  ||| S:12059 E:12068 ||| VBN
above ||| S:12068 E:12073 ||| IN
,  ||| S:12073 E:12075 ||| ,
to  ||| S:12075 E:12088 ||| TO
some  ||| S:12088 E:12093 ||| DT
extent ||| S:12093 E:12099 ||| NN
,  ||| S:12099 E:12101 ||| ,
proportionally  ||| S:12101 E:12116 ||| RB
represent  ||| S:12116 E:12126 ||| VB
the  ||| S:12126 E:12130 ||| DT
functional  ||| S:12130 E:12151 ||| JJ
stability ||| S:12151 E:12160 ||| NN
.  ||| S:12160 E:12162 ||| .
More  ||| S:12162 E:12167 ||| RBR
importantly ||| S:12167 E:12178 ||| RB
,  ||| S:12178 E:12180 ||| ,
amount  ||| S:12180 E:12187 ||| NN
complexes  ||| S:12187 E:12197 ||| NNS
formed  ||| S:12197 E:12204 ||| VBN
by  ||| S:12204 E:12217 ||| IN
tPA  ||| S:12217 E:12221 ||| JJ
and  ||| S:12221 E:12225 ||| CC
PAI-1s  ||| S:12225 E:12232 ||| NNP
remained  ||| S:12232 E:12241 ||| VBD
after  ||| S:12241 E:12247 ||| IN
incubation  ||| S:12247 E:12258 ||| NN
at  ||| S:12258 E:12261 ||| IN
37°C  ||| S:12261 E:12266 ||| NNP
( ||| S:12266 E:12267 ||| -LRB-
Fig.  ||| S:12267 E:12282 ||| NNP
4C ||| S:12282 E:12284 ||| NNP
)  ||| S:12284 E:12286 ||| -RRB-
were  ||| S:12286 E:12291 ||| VBD
proportionally  ||| S:12291 E:12306 ||| JJ
concordant  ||| S:12306 E:12317 ||| NN
with  ||| S:12317 E:12322 ||| IN
the  ||| S:12322 E:12326 ||| DT
results  ||| S:12326 E:12344 ||| NNS
obtained  ||| S:12344 E:12353 ||| VBN
from  ||| S:12353 E:12358 ||| IN
enzymatic  ||| S:12358 E:12368 ||| JJ
stability  ||| S:12368 E:12378 ||| NN
assay  ||| S:12378 E:12384 ||| NNS
( ||| S:12384 E:12385 ||| -LRB-
Fig.  ||| S:12385 E:12390 ||| NNP
4B ||| S:12390 E:12392 ||| NNP
) ||| S:12392 E:12393 ||| -RRB-
.  ||| S:12393 E:12395 ||| .
This  ||| S:12395 E:12410 ||| DT
proves  ||| S:12410 E:12417 ||| NN
that  ||| S:12417 E:12422 ||| IN
results  ||| S:12422 E:12430 ||| NNS
from  ||| S:12430 E:12435 ||| IN
enzymatic  ||| S:12435 E:12445 ||| JJ
assay  ||| S:12445 E:12451 ||| NNS
are  ||| S:12451 E:12455 ||| VBP
valid ||| S:12455 E:12460 ||| JJ
.  ||| S:12460 E:12462 ||| .
The  ||| S:12462 E:12476 ||| DT
result  ||| S:12476 E:12483 ||| NN
of  ||| S:12483 E:12486 ||| IN
functional  ||| S:12486 E:12497 ||| JJ
stability  ||| S:12497 E:12507 ||| NN
suggests  ||| S:12507 E:12516 ||| VBZ
that  ||| S:12516 E:12521 ||| IN
Glu351  ||| S:12521 E:12528 ||| NNP
is  ||| S:12528 E:12541 ||| VBZ
indeed  ||| S:12541 E:12548 ||| RB
involved  ||| S:12548 E:12557 ||| VBN
in  ||| S:12557 E:12560 ||| IN
the  ||| S:12560 E:12564 ||| DT
conformational  ||| S:12564 E:12579 ||| JJ
transition  ||| S:12579 E:12590 ||| NN
of  ||| S:12590 E:12603 ||| IN
PAI-1 ||| S:12603 E:12608 ||| CD
.  ||| S:12608 E:12638 ||| .
Inhibition  ||| S:12638 E:12649 ||| NNP
of  ||| S:12649 E:12652 ||| IN
thrombin  ||| S:12652 E:12661 ||| NN
by  ||| S:12661 E:12664 ||| IN
PAI-1s  ||| S:12664 E:12671 ||| NNP
and  ||| S:12671 E:12675 ||| CC
Neutralization  ||| S:12675 E:12700 ||| NNP
of  ||| S:12700 E:12703 ||| IN
PAI-1s  ||| S:12703 E:12710 ||| CD
by  ||| S:12710 E:12713 ||| IN
Thrombin  ||| S:12713 E:12732 ||| NNP
Both  ||| S:12732 E:12737 ||| DT
mutants  ||| S:12737 E:12745 ||| JJ
inhibited  ||| S:12745 E:12755 ||| JJ
thrombin  ||| S:12755 E:12764 ||| NN
more  ||| S:12764 E:12769 ||| RBR
efficiently  ||| S:12769 E:12781 ||| RB
than  ||| S:12781 E:12796 ||| IN
wtPAI-1 ||| S:12796 E:12803 ||| NNP
,  ||| S:12803 E:12805 ||| ,
more  ||| S:12805 E:12810 ||| RBR
importantly ||| S:12810 E:12821 ||| RB
,  ||| S:12821 E:12823 ||| ,
Glu351Ala  ||| S:12823 E:12833 ||| NNP
was  ||| S:12833 E:12837 ||| VBD
better  ||| S:12837 E:12844 ||| JJR
than  ||| S:12844 E:12859 ||| IN
Glu351Arg  ||| S:12859 E:12869 ||| CD
in  ||| S:12869 E:12872 ||| IN
inhibiting  ||| S:12872 E:12883 ||| JJ
thrombin  ||| S:12883 E:12892 ||| NNS
( ||| S:12892 E:12893 ||| -LRB-
Fig.  ||| S:12893 E:12898 ||| NNP
5A ||| S:12898 E:12900 ||| NNP
) ||| S:12900 E:12901 ||| -RRB-
;  ||| S:12901 E:12903 ||| :
Inhibition  ||| S:12903 E:12914 ||| NNP
of  ||| S:12914 E:12927 ||| IN
thrombin  ||| S:12927 E:12936 ||| NN
by  ||| S:12936 E:12939 ||| IN
Glu351Arg  ||| S:12939 E:12949 ||| NNP
was  ||| S:12949 E:12953 ||| VBD
almost  ||| S:12953 E:12960 ||| RB
as  ||| S:12960 E:12963 ||| IN
same  ||| S:12963 E:12968 ||| JJ
as  ||| S:12968 E:12971 ||| IN
by  ||| S:12971 E:12974 ||| IN
Glu351Ala  ||| S:12974 E:12994 ||| CD
in  ||| S:12994 E:12997 ||| IN
presence  ||| S:12997 E:13006 ||| NN
of  ||| S:13006 E:13009 ||| IN
vitronectin  ||| S:13009 E:13021 ||| NNS
( ||| S:13021 E:13022 ||| -LRB-
Fig.  ||| S:13022 E:13027 ||| NNP
5B ||| S:13027 E:13029 ||| NNP
) ||| S:13029 E:13030 ||| -RRB-
,  ||| S:13030 E:13032 ||| ,
which  ||| S:13032 E:13038 ||| WDT
facilitated  ||| S:13038 E:13060 ||| VBZ
the  ||| S:13060 E:13064 ||| DT
thrombin  ||| S:13064 E:13073 ||| JJ
inhibition  ||| S:13073 E:13084 ||| NN
by  ||| S:13084 E:13087 ||| IN
both  ||| S:13087 E:13092 ||| DT
mutants ||| S:13092 E:13099 ||| NN
.  ||| S:13099 E:13101 ||| .
When  ||| S:13101 E:13106 ||| WRB
excess  ||| S:13106 E:13123 ||| JJ
equal  ||| S:13123 E:13129 ||| JJ
amount  ||| S:13129 E:13136 ||| NN
of  ||| S:13136 E:13139 ||| IN
thrombin  ||| S:13139 E:13148 ||| NN
was  ||| S:13148 E:13152 ||| VBD
incubated  ||| S:13152 E:13162 ||| VBN
with  ||| S:13162 E:13167 ||| IN
equal  ||| S:13167 E:13173 ||| JJ
amount  ||| S:13173 E:13190 ||| NN
of  ||| S:13190 E:13193 ||| IN
PAI-1s  ||| S:13193 E:13200 ||| CD
in  ||| S:13200 E:13203 ||| IN
term  ||| S:13203 E:13208 ||| NN
of  ||| S:13208 E:13211 ||| IN
inhibitory  ||| S:13211 E:13222 ||| JJ
activity  ||| S:13222 E:13231 ||| NN
against  ||| S:13231 E:13239 ||| IN
uPA ||| S:13239 E:13242 ||| NNP
,  ||| S:13242 E:13254 ||| ,
mutant  ||| S:13254 E:13261 ||| JJ
inhibitors  ||| S:13261 E:13272 ||| NN
were  ||| S:13272 E:13277 ||| VBD
neutralized  ||| S:13277 E:13289 ||| VBN
faster  ||| S:13289 E:13296 ||| RBR
by  ||| S:13296 E:13299 ||| IN
thrombin  ||| S:13299 E:13318 ||| NN
than  ||| S:13318 E:13323 ||| IN
wtPAI-1 ||| S:13323 E:13330 ||| NNP
,  ||| S:13330 E:13332 ||| ,
and  ||| S:13332 E:13336 ||| CC
vitronectin  ||| S:13336 E:13348 ||| VBP
also  ||| S:13348 E:13353 ||| RB
facilitated  ||| S:13353 E:13365 ||| VB
the  ||| S:13365 E:13379 ||| DT
neutralization  ||| S:13379 E:13394 ||| NN
of  ||| S:13394 E:13397 ||| IN
Glu351Ala  ||| S:13397 E:13407 ||| NNP
or  ||| S:13407 E:13410 ||| CC
Glu351Arg  ||| S:13410 E:13420 ||| CD
by  ||| S:13420 E:13423 ||| IN
thrombin ||| S:13423 E:13431 ||| NN
,  ||| S:13431 E:13443 ||| ,
just  ||| S:13443 E:13448 ||| RB
similar  ||| S:13448 E:13456 ||| JJ
to  ||| S:13456 E:13459 ||| TO
the  ||| S:13459 E:13463 ||| DT
wtPAI-1  ||| S:13463 E:13471 ||| NNP
( ||| S:13471 E:13472 ||| -LRB-
Fig.  ||| S:13472 E:13477 ||| NNP
5C ||| S:13477 E:13479 ||| NNP
) ||| S:13479 E:13480 ||| -RRB-
.  ||| S:13480 E:13510 ||| .
Inhibition  ||| S:13510 E:13521 ||| NNP
of  ||| S:13521 E:13524 ||| IN
plasmin  ||| S:13524 E:13532 ||| NN
by  ||| S:13532 E:13535 ||| IN
PAI-1s  ||| S:13535 E:13552 ||| CD
When  ||| S:13552 E:13557 ||| WRB
plasmin  ||| S:13557 E:13565 ||| NNS
was  ||| S:13565 E:13569 ||| VBD
incubated  ||| S:13569 E:13579 ||| VBN
with  ||| S:13579 E:13584 ||| IN
increased  ||| S:13584 E:13594 ||| JJ
amount  ||| S:13594 E:13601 ||| NN
of  ||| S:13601 E:13614 ||| IN
equal  ||| S:13614 E:13620 ||| JJ
active  ||| S:13620 E:13627 ||| JJ
PAI-1s  ||| S:13627 E:13634 ||| NN
in  ||| S:13634 E:13637 ||| IN
absence  ||| S:13637 E:13645 ||| NN
or  ||| S:13645 E:13648 ||| CC
in  ||| S:13648 E:13651 ||| IN
presence  ||| S:13651 E:13660 ||| NN
of  ||| S:13660 E:13673 ||| IN
vitronectin ||| S:13673 E:13684 ||| NN
,  ||| S:13684 E:13686 ||| ,
it  ||| S:13686 E:13689 ||| PRP
was  ||| S:13689 E:13693 ||| VBD
inhibited  ||| S:13693 E:13703 ||| VBN
faster  ||| S:13703 E:13710 ||| RBR
by  ||| S:13710 E:13713 ||| IN
mutants  ||| S:13713 E:13721 ||| NN
than  ||| S:13721 E:13726 ||| IN
by  ||| S:13726 E:13739 ||| IN
wtPAI-1  ||| S:13739 E:13747 ||| NNP
( ||| S:13747 E:13748 ||| -LRB-
Fig.  ||| S:13748 E:13753 ||| CD
6upper  ||| S:13753 E:13760 ||| CD
panel ||| S:13760 E:13765 ||| NN
) ||| S:13765 E:13766 ||| -RRB-
;  ||| S:13766 E:13768 ||| :
and  ||| S:13768 E:13772 ||| CC
both  ||| S:13772 E:13777 ||| DT
of  ||| S:13777 E:13780 ||| IN
mutant  ||| S:13780 E:13787 ||| VBG
also  ||| S:13787 E:13802 ||| RB
displayed  ||| S:13802 E:13812 ||| VBN
improved  ||| S:13812 E:13821 ||| JJ
inhibition  ||| S:13821 E:13832 ||| NN
toward  ||| S:13832 E:13839 ||| IN
plasmin  ||| S:13839 E:13847 ||| NN
in  ||| S:13847 E:13850 ||| IN
presence  ||| S:13850 E:13869 ||| NN
of  ||| S:13869 E:13872 ||| IN
vitronectin  ||| S:13872 E:13884 ||| NNS
( ||| S:13884 E:13885 ||| -LRB-
Fig.  ||| S:13885 E:13890 ||| CD
6lower  ||| S:13890 E:13897 ||| CD
panel ||| S:13897 E:13902 ||| NN
) ||| S:13902 E:13903 ||| -RRB-
.  ||| S:13903 E:13933 ||| .
Kinetic  ||| S:13933 E:13941 ||| JJ
analysis  ||| S:13941 E:13960 ||| NN
The  ||| S:13960 E:13964 ||| DT
rate  ||| S:13964 E:13969 ||| NN
constants  ||| S:13969 E:13979 ||| NN
of  ||| S:13979 E:13982 ||| IN
tPA  ||| S:13982 E:13986 ||| JJ
for  ||| S:13986 E:13990 ||| IN
wtPAI-1 ||| S:13990 E:13997 ||| NNP
,  ||| S:13997 E:13999 ||| ,
Glu351Ala  ||| S:13999 E:14009 ||| NNP
and  ||| S:14009 E:14023 ||| CC
Glu351Arg  ||| S:14023 E:14033 ||| NNP
were  ||| S:14033 E:14038 ||| VBD
similar  ||| S:14038 E:14046 ||| JJ
( ||| S:14046 E:14047 ||| -LRB-
Table  ||| S:14047 E:14053 ||| NNP
4 ||| S:14053 E:14054 ||| CD
) ||| S:14054 E:14055 ||| -RRB-
,  ||| S:14055 E:14057 ||| ,
however ||| S:14057 E:14064 ||| RB
,  ||| S:14064 E:14066 ||| ,
The  ||| S:14066 E:14070 ||| DT
rate  ||| S:14070 E:14085 ||| NN
constants  ||| S:14085 E:14095 ||| NN
of  ||| S:14095 E:14098 ||| IN
inhibition  ||| S:14098 E:14109 ||| NN
toward  ||| S:14109 E:14116 ||| IN
uPA  ||| S:14116 E:14120 ||| JJ
by  ||| S:14120 E:14123 ||| IN
Glu351Ala  ||| S:14123 E:14133 ||| NNP
and  ||| S:14133 E:14147 ||| CC
Glu351Arg  ||| S:14147 E:14157 ||| NNP
were  ||| S:14157 E:14162 ||| VBD
4  ||| S:14162 E:14164 ||| CD
and  ||| S:14164 E:14168 ||| CC
7-fold  ||| S:14168 E:14175 ||| CD
higher  ||| S:14175 E:14182 ||| JJR
than  ||| S:14182 E:14187 ||| IN
by  ||| S:14187 E:14190 ||| IN
wtPAI-1 ||| S:14190 E:14197 ||| NNP
,  ||| S:14197 E:14209 ||| ,
respectively ||| S:14209 E:14221 ||| RB
.  ||| S:14221 E:14223 ||| .
Moreover ||| S:14223 E:14231 ||| RB
,  ||| S:14231 E:14233 ||| ,
The  ||| S:14233 E:14237 ||| DT
rate  ||| S:14237 E:14242 ||| NN
constants  ||| S:14242 E:14252 ||| NN
of  ||| S:14252 E:14255 ||| IN
Glu351Ala  ||| S:14255 E:14275 ||| NNP
and  ||| S:14275 E:14279 ||| CC
Glu351Arg  ||| S:14279 E:14289 ||| CD
for  ||| S:14289 E:14293 ||| IN
thrombin  ||| S:14293 E:14302 ||| JJ
inhibition  ||| S:14302 E:14313 ||| NN
were  ||| S:14313 E:14318 ||| VBD
2  ||| S:14318 E:14320 ||| CD
to  ||| S:14320 E:14323 ||| TO
4  ||| S:14323 E:14325 ||| CD
folds  ||| S:14325 E:14341 ||| CD
higher  ||| S:14341 E:14348 ||| JJR
than  ||| S:14348 E:14353 ||| IN
that  ||| S:14353 E:14358 ||| DT
of  ||| S:14358 E:14361 ||| IN
wtPAI-1  ||| S:14361 E:14369 ||| NNP
and  ||| S:14369 E:14373 ||| CC
rate  ||| S:14373 E:14378 ||| NN
constants  ||| S:14378 E:14388 ||| NN
of  ||| S:14388 E:14401 ||| IN
Glu351Ala  ||| S:14401 E:14411 ||| NNP
and  ||| S:14411 E:14415 ||| CC
Glu351Arg  ||| S:14415 E:14425 ||| CD
to  ||| S:14425 E:14428 ||| TO
plasmin  ||| S:14428 E:14436 ||| NNS
were  ||| S:14436 E:14441 ||| VBD
2  ||| S:14441 E:14443 ||| CD
fold  ||| S:14443 E:14448 ||| CD
higher  ||| S:14448 E:14465 ||| JJR
than  ||| S:14465 E:14470 ||| IN
that  ||| S:14470 E:14475 ||| DT
of  ||| S:14475 E:14478 ||| IN
wtPAI-1 ||| S:14478 E:14485 ||| CD
.  ||| S:14485 E:14487 ||| .
This  ||| S:14487 E:14492 ||| DT
indicates  ||| S:14492 E:14502 ||| VBZ
that  ||| S:14502 E:14507 ||| IN
Glu351  ||| S:14507 E:14514 ||| NNP
is  ||| S:14514 E:14517 ||| VBZ
not  ||| S:14517 E:14531 ||| RB
essential  ||| S:14531 E:14541 ||| JJ
for  ||| S:14541 E:14545 ||| IN
the  ||| S:14545 E:14549 ||| DT
interaction  ||| S:14549 E:14561 ||| NN
with  ||| S:14561 E:14566 ||| IN
tPA ||| S:14566 E:14569 ||| NNP
,  ||| S:14569 E:14571 ||| ,
but  ||| S:14571 E:14575 ||| CC
it  ||| S:14575 E:14578 ||| PRP
is  ||| S:14578 E:14581 ||| VBZ
an  ||| S:14581 E:14584 ||| DT
very  ||| S:14584 E:14599 ||| RB
important  ||| S:14599 E:14609 ||| JJ
determinant  ||| S:14609 E:14621 ||| NN
for  ||| S:14621 E:14625 ||| IN
the  ||| S:14625 E:14629 ||| DT
optimal  ||| S:14629 E:14637 ||| JJ
interaction  ||| S:14637 E:14649 ||| NN
with  ||| S:14649 E:14664 ||| IN
uPA ||| S:14664 E:14667 ||| NNP
,  ||| S:14667 E:14669 ||| ,
thrombin  ||| S:14669 E:14678 ||| NN
and  ||| S:14678 E:14682 ||| CC
plasmin ||| S:14682 E:14689 ||| NN
.  ||| S:14689 E:14722 ||| .
Disscusion  ||| S:14722 E:14752 ||| FW
Cognate  ||| S:14752 E:14760 ||| FW
protease  ||| S:14760 E:14769 ||| FW
specificity  ||| S:14769 E:14791 ||| FW
Improvements  ||| S:14791 E:14804 ||| NNP
in  ||| S:14804 E:14807 ||| IN
specificity  ||| S:14807 E:14819 ||| NN
of  ||| S:14819 E:14822 ||| IN
mutants  ||| S:14822 E:14830 ||| NN
for  ||| S:14830 E:14834 ||| IN
uPA  ||| S:14834 E:14848 ||| NNP
indicates  ||| S:14848 E:14858 ||| VBZ
that  ||| S:14858 E:14863 ||| IN
Glu351  ||| S:14863 E:14870 ||| CD
involve  ||| S:14870 E:14878 ||| NN
in  ||| S:14878 E:14881 ||| IN
the  ||| S:14881 E:14885 ||| DT
interaction  ||| S:14885 E:14897 ||| NN
with  ||| S:14897 E:14912 ||| IN
uPA ||| S:14912 E:14915 ||| JJ
.  ||| S:14915 E:14917 ||| .
To  ||| S:14917 E:14920 ||| TO
the  ||| S:14920 E:14924 ||| DT
best  ||| S:14924 E:14929 ||| JJS
of  ||| S:14929 E:14932 ||| IN
our  ||| S:14932 E:14936 ||| PRP$
knowledge ||| S:14936 E:14945 ||| NN
,  ||| S:14945 E:14947 ||| ,
this  ||| S:14947 E:14952 ||| DT
is  ||| S:14952 E:14955 ||| VBZ
the  ||| S:14955 E:14959 ||| DT
first  ||| S:14959 E:14965 ||| JJ
time  ||| S:14965 E:14980 ||| NN
that  ||| S:14980 E:14985 ||| IN
the  ||| S:14985 E:14989 ||| DT
specificity  ||| S:14989 E:15001 ||| NN
of  ||| S:15001 E:15004 ||| IN
PAI-1  ||| S:15004 E:15010 ||| CD
toward  ||| S:15010 E:15017 ||| IN
uPA  ||| S:15017 E:15021 ||| NNP
is  ||| S:15021 E:15024 ||| VBZ
partially  ||| S:15024 E:15044 ||| RB
mediated  ||| S:15044 E:15053 ||| VBN
by  ||| S:15053 E:15056 ||| IN
the  ||| S:15056 E:15060 ||| DT
negatively  ||| S:15060 E:15071 ||| RB
charged  ||| S:15071 E:15079 ||| VBN
residue  ||| S:15079 E:15087 ||| RB
located  ||| S:15087 E:15095 ||| VBN
in  ||| S:15095 E:15098 ||| IN
the  ||| S:15098 E:15112 ||| DT
C-terminal  ||| S:15112 E:15123 ||| JJ
of  ||| S:15123 E:15126 ||| IN
cleavage  ||| S:15126 E:15135 ||| JJ
site  ||| S:15135 E:15140 ||| NN
in  ||| S:15140 E:15143 ||| IN
PAI-1 ||| S:15143 E:15148 ||| CD
.  ||| S:15148 E:15150 ||| .
The  ||| S:15150 E:15154 ||| DT
interaction  ||| S:15154 E:15166 ||| NN
of  ||| S:15166 E:15179 ||| IN
Glu351  ||| S:15179 E:15186 ||| CD
with  ||| S:15186 E:15191 ||| IN
uPA  ||| S:15191 E:15195 ||| NNP
is  ||| S:15195 E:15198 ||| VBZ
much  ||| S:15198 E:15203 ||| RB
more  ||| S:15203 E:15208 ||| RBR
important  ||| S:15208 E:15218 ||| JJ
than  ||| S:15218 E:15223 ||| IN
that  ||| S:15223 E:15228 ||| DT
of  ||| S:15228 E:15241 ||| IN
Glu351  ||| S:15241 E:15248 ||| CD
with  ||| S:15248 E:15253 ||| IN
tPA ||| S:15253 E:15256 ||| NNP
,  ||| S:15256 E:15258 ||| ,
which  ||| S:15258 E:15264 ||| WDT
is  ||| S:15264 E:15267 ||| VBZ
demonstrated  ||| S:15267 E:15280 ||| VBN
by  ||| S:15280 E:15283 ||| IN
improved  ||| S:15283 E:15302 ||| JJ
reactivity  ||| S:15302 E:15313 ||| NN
of  ||| S:15313 E:15316 ||| IN
Glu351  ||| S:15316 E:15323 ||| CD
mutants  ||| S:15323 E:15331 ||| NN
toward  ||| S:15331 E:15338 ||| IN
uPA ||| S:15338 E:15341 ||| NNP
,  ||| S:15341 E:15343 ||| ,
but  ||| S:15343 E:15347 ||| CC
not  ||| S:15347 E:15351 ||| RB
toward  ||| S:15351 E:15368 ||| IN
tPA ||| S:15368 E:15371 ||| NNP
,  ||| S:15371 E:15373 ||| ,
showing  ||| S:15373 E:15381 ||| VBG
that  ||| S:15381 E:15386 ||| IN
tPA  ||| S:15386 E:15390 ||| NNP
is  ||| S:15390 E:15393 ||| VBZ
not  ||| S:15393 E:15397 ||| RB
directly  ||| S:15397 E:15406 ||| RB
interact  ||| S:15406 E:15415 ||| VBN
with  ||| S:15415 E:15430 ||| IN
Glu351  ||| S:15430 E:15437 ||| CD
of  ||| S:15437 E:15440 ||| IN
PAI-1 ||| S:15440 E:15445 ||| NNP
,  ||| S:15445 E:15447 ||| ,
whereas  ||| S:15447 E:15455 ||| IN
Glu351  ||| S:15455 E:15462 ||| NNP
is  ||| S:15462 E:15465 ||| VBZ
necessary  ||| S:15465 E:15475 ||| JJ
for  ||| S:15475 E:15479 ||| IN
the  ||| S:15479 E:15493 ||| DT
optimal  ||| S:15493 E:15501 ||| JJ
interaction  ||| S:15501 E:15513 ||| NN
with  ||| S:15513 E:15518 ||| IN
uPA ||| S:15518 E:15521 ||| JJ
.  ||| S:15521 E:15523 ||| .
Our  ||| S:15523 E:15527 ||| PRP$
results  ||| S:15527 E:15535 ||| NNS
are  ||| S:15535 E:15539 ||| VBP
concordant  ||| S:15539 E:15560 ||| VBN
with  ||| S:15560 E:15565 ||| IN
previous  ||| S:15565 E:15574 ||| JJ
study ||| S:15574 E:15579 ||| NN
,  ||| S:15579 E:15581 ||| ,
[  ||| S:15581 E:15583 ||| -LRB-
25  ||| S:15583 E:15586 ||| CD
]  ||| S:15586 E:15588 ||| -RRB-
which  ||| S:15588 E:15594 ||| WDT
suggests  ||| S:15594 E:15603 ||| VBZ
that  ||| S:15603 E:15608 ||| DT
serpin  ||| S:15608 E:15625 ||| JJ
body-protease  ||| S:15625 E:15639 ||| JJ
body  ||| S:15639 E:15644 ||| NN
interactions  ||| S:15644 E:15657 ||| NNS
play  ||| S:15657 E:15662 ||| VBP
significant  ||| S:15662 E:15674 ||| JJ
roles  ||| S:15674 E:15680 ||| NNS
in  ||| S:15680 E:15693 ||| IN
determining  ||| S:15693 E:15705 ||| VBG
serpin  ||| S:15705 E:15712 ||| JJ
inhibitory  ||| S:15712 E:15723 ||| JJ
activity  ||| S:15723 E:15732 ||| NN
against  ||| S:15732 E:15740 ||| IN
target  ||| S:15740 E:15757 ||| NN
proteases ||| S:15757 E:15766 ||| NN
.  ||| S:15766 E:15796 ||| .
Non-cognate  ||| S:15796 E:15808 ||| JJ
protease  ||| S:15808 E:15827 ||| JJ
Substitution  ||| S:15827 E:15840 ||| NNS
of  ||| S:15840 E:15843 ||| IN
Glu351  ||| S:15843 E:15850 ||| NNP
also  ||| S:15850 E:15855 ||| RB
altered  ||| S:15855 E:15863 ||| VBN
the  ||| S:15863 E:15867 ||| DT
specificity  ||| S:15867 E:15889 ||| NN
toward  ||| S:15889 E:15896 ||| IN
non-cognate  ||| S:15896 E:15908 ||| JJ
proteases ||| S:15908 E:15917 ||| NN
:  ||| S:15917 E:15919 ||| :
plasmin  ||| S:15919 E:15927 ||| NNS
and  ||| S:15927 E:15931 ||| CC
thrombin ||| S:15931 E:15939 ||| NN
.  ||| S:15939 E:15941 ||| .
Glu  ||| S:15941 E:15955 ||| NNP
at  ||| S:15955 E:15958 ||| IN
351  ||| S:15958 E:15962 ||| CD
may  ||| S:15962 E:15966 ||| MD
provide  ||| S:15966 E:15974 ||| VB
steric  ||| S:15974 E:15981 ||| JJ
hindrance  ||| S:15981 E:15991 ||| NN
that  ||| S:15991 E:15996 ||| WDT
slows  ||| S:15996 E:16002 ||| VBZ
the  ||| S:16002 E:16006 ||| DT
rate  ||| S:16006 E:16021 ||| NN
of  ||| S:16021 E:16024 ||| IN
thrombin  ||| S:16024 E:16033 ||| NN
or  ||| S:16033 E:16036 ||| CC
plasmin  ||| S:16036 E:16044 ||| JJ
inhibition ||| S:16044 E:16054 ||| NN
.  ||| S:16054 E:16056 ||| .
Mutations  ||| S:16056 E:16066 ||| NNS
at  ||| S:16066 E:16069 ||| IN
Glu351  ||| S:16069 E:16086 ||| NNP
may  ||| S:16086 E:16090 ||| MD
decrease  ||| S:16090 E:16099 ||| VB
the  ||| S:16099 E:16103 ||| DT
original  ||| S:16103 E:16112 ||| JJ
repulsive  ||| S:16112 E:16122 ||| JJ
interactions  ||| S:16122 E:16135 ||| NNS
with  ||| S:16135 E:16150 ||| IN
variable  ||| S:16150 E:16159 ||| JJ
region  ||| S:16159 E:16166 ||| NN
of  ||| S:16166 E:16169 ||| IN
thrombin ||| S:16169 E:16177 ||| NN
,  ||| S:16177 E:16179 ||| ,
which  ||| S:16179 E:16185 ||| WDT
may  ||| S:16185 E:16189 ||| MD
slow  ||| S:16189 E:16194 ||| VB
the  ||| S:16194 E:16198 ||| DT
rate  ||| S:16198 E:16203 ||| NN
of  ||| S:16203 E:16216 ||| IN
thrombin  ||| S:16216 E:16225 ||| JJ
inhibition ||| S:16225 E:16235 ||| NN
,  ||| S:16235 E:16237 ||| ,
or  ||| S:16237 E:16240 ||| CC
results  ||| S:16240 E:16248 ||| NNS
in  ||| S:16248 E:16251 ||| IN
favorable  ||| S:16251 E:16261 ||| JJ
interactions  ||| S:16261 E:16284 ||| NNS
that  ||| S:16284 E:16289 ||| WDT
may  ||| S:16289 E:16293 ||| MD
not  ||| S:16293 E:16297 ||| RB
exist  ||| S:16297 E:16303 ||| VB
when  ||| S:16303 E:16308 ||| WRB
wtPAI-1  ||| S:16308 E:16316 ||| RB
react  ||| S:16316 E:16322 ||| VB
with  ||| S:16322 E:16327 ||| IN
thrombin ||| S:16327 E:16335 ||| NN
.  ||| S:16335 E:16337 ||| .
So ||| S:16337 E:16339 ||| RB
,  ||| S:16339 E:16351 ||| ,
both  ||| S:16351 E:16356 ||| DT
Glu351Arg  ||| S:16356 E:16366 ||| NNP
and  ||| S:16366 E:16370 ||| CC
Glu351Arg  ||| S:16370 E:16380 ||| NNP
are  ||| S:16380 E:16384 ||| VBP
better  ||| S:16384 E:16391 ||| RBR
thrombin  ||| S:16391 E:16410 ||| JJ
inhibitors  ||| S:16410 E:16421 ||| NN
than  ||| S:16421 E:16426 ||| IN
wtPAI-1 ||| S:16426 E:16433 ||| CD
.  ||| S:16433 E:16435 ||| .
Similar  ||| S:16435 E:16443 ||| JJ
results  ||| S:16443 E:16451 ||| NNS
were  ||| S:16451 E:16456 ||| VBD
observed  ||| S:16456 E:16475 ||| VBN
for  ||| S:16475 E:16479 ||| IN
plasmin ||| S:16479 E:16486 ||| NN
.  ||| S:16486 E:16488 ||| .
With  ||| S:16488 E:16493 ||| IN
single  ||| S:16493 E:16500 ||| JJ
mutation  ||| S:16500 E:16509 ||| NN
at  ||| S:16509 E:16512 ||| IN
position  ||| S:16512 E:16521 ||| NN
Glu351 ||| S:16521 E:16527 ||| NN
,  ||| S:16527 E:16529 ||| ,
we  ||| S:16529 E:16542 ||| PRP
improved  ||| S:16542 E:16551 ||| VBD
reactivity  ||| S:16551 E:16562 ||| VBN
of  ||| S:16562 E:16565 ||| IN
PAI-1  ||| S:16565 E:16571 ||| CD
to  ||| S:16571 E:16574 ||| TO
thrombin  ||| S:16574 E:16583 ||| VB
and  ||| S:16583 E:16587 ||| CC
plasmin  ||| S:16587 E:16605 ||| NN
without  ||| S:16605 E:16613 ||| IN
significantly  ||| S:16613 E:16627 ||| RB
affecting  ||| S:16627 E:16637 ||| VBG
its  ||| S:16637 E:16641 ||| PRP$
specificity  ||| S:16641 E:16653 ||| NN
to  ||| S:16653 E:16656 ||| TO
tPA ||| S:16656 E:16659 ||| JJ
.  ||| S:16659 E:16671 ||| .
This  ||| S:16671 E:16676 ||| DT
substantiates  ||| S:16676 E:16690 ||| JJ
previous  ||| S:16690 E:16699 ||| JJ
mutagenesis  ||| S:16699 E:16711 ||| JJ
studies ||| S:16711 E:16718 ||| NNS
,  ||| S:16718 E:16720 ||| ,
which  ||| S:16720 E:16736 ||| WDT
demonstrated  ||| S:16736 E:16749 ||| VBD
that  ||| S:16749 E:16754 ||| DT
repulsive  ||| S:16754 E:16764 ||| JJ
interactions  ||| S:16764 E:16777 ||| NNS
and ||| S:16777 E:16780 ||| CC
/ ||| S:16780 E:16781 ||| NNP
or  ||| S:16781 E:16784 ||| CC
lack  ||| S:16784 E:16789 ||| NN
of  ||| S:16789 E:16802 ||| IN
productive  ||| S:16802 E:16813 ||| JJ
electrostatic  ||| S:16813 E:16827 ||| JJ
interactions  ||| S:16827 E:16840 ||| NNS
between  ||| S:16840 E:16848 ||| IN
Glu39  ||| S:16848 E:16854 ||| NNP
and  ||| S:16854 E:16868 ||| CC
Glu192  ||| S:16868 E:16875 ||| CD
of  ||| S:16875 E:16878 ||| IN
thrombin  ||| S:16878 E:16887 ||| NN
and  ||| S:16887 E:16891 ||| CC
PAI-1  ||| S:16891 E:16897 ||| NNP
are  ||| S:16897 E:16901 ||| VBP
responsible  ||| S:16901 E:16913 ||| JJ
for  ||| S:16913 E:16917 ||| IN
the  ||| S:16917 E:16921 ||| DT
slow  ||| S:16921 E:16936 ||| JJ
reaction  ||| S:16936 E:16945 ||| NN
of  ||| S:16945 E:16948 ||| IN
thrombin  ||| S:16948 E:16957 ||| NN
with  ||| S:16957 E:16962 ||| IN
this  ||| S:16962 E:16967 ||| DT
serpin.  ||| S:16967 E:16975 ||| NNP
[  ||| S:16975 E:16977 ||| -LRB-
26  ||| S:16977 E:16980 ||| CD
]  ||| S:16980 E:16992 ||| -RRB-
Furthermore ||| S:16992 E:17003 ||| RB
,  ||| S:17003 E:17005 ||| ,
the  ||| S:17005 E:17009 ||| DT
rapid  ||| S:17009 E:17015 ||| JJ
inhibition  ||| S:17015 E:17026 ||| NN
of  ||| S:17026 E:17029 ||| IN
plasmin  ||| S:17029 E:17037 ||| NN
requires  ||| S:17037 E:17046 ||| VBZ
a  ||| S:17046 E:17058 ||| DT
non-covalent  ||| S:17058 E:17071 ||| JJ
interaction  ||| S:17071 E:17083 ||| NN
between  ||| S:17083 E:17091 ||| IN
an  ||| S:17091 E:17094 ||| DT
amino-terminal  ||| S:17094 E:17109 ||| JJ
site  ||| S:17109 E:17124 ||| NN
of  ||| S:17124 E:17127 ||| IN
plasmin  ||| S:17127 E:17135 ||| NN
and  ||| S:17135 E:17139 ||| CC
a  ||| S:17139 E:17141 ||| DT
carboxyl-terminal  ||| S:17141 E:17159 ||| JJ
on  ||| S:17159 E:17162 ||| IN
anti-plasmin ||| S:17162 E:17174 ||| NNP
,  ||| S:17174 E:17176 ||| ,
and  ||| S:17176 E:17180 ||| CC
a  ||| S:17180 E:17192 ||| DT
second  ||| S:17192 E:17199 ||| JJ
site  ||| S:17199 E:17204 ||| NN
outside  ||| S:17204 E:17212 ||| IN
the  ||| S:17212 E:17216 ||| DT
RCL  ||| S:17216 E:17220 ||| NNP
of  ||| S:17220 E:17223 ||| IN
PAI-1  ||| S:17223 E:17229 ||| NNP
contributes  ||| S:17229 E:17241 ||| VBZ
to  ||| S:17241 E:17244 ||| TO
its  ||| S:17244 E:17258 ||| PRP$
specific  ||| S:17258 E:17267 ||| JJ
interaction  ||| S:17267 E:17279 ||| NN
with  ||| S:17279 E:17284 ||| IN
proteases.  ||| S:17284 E:17295 ||| NNP
[  ||| S:17295 E:17297 ||| -LRB-
15  ||| S:17297 E:17300 ||| CD
27  ||| S:17300 E:17303 ||| CD
]  ||| S:17303 E:17305 ||| -RRB-
The  ||| S:17305 E:17319 ||| DT
specificity  ||| S:17319 E:17331 ||| NN
of  ||| S:17331 E:17334 ||| IN
the  ||| S:17334 E:17338 ||| DT
two  ||| S:17338 E:17342 ||| CD
mutants  ||| S:17342 E:17350 ||| NN
toward  ||| S:17350 E:17357 ||| IN
thrombin  ||| S:17357 E:17366 ||| NN
and  ||| S:17366 E:17380 ||| CC
plasmin  ||| S:17380 E:17388 ||| JJ
implicates  ||| S:17388 E:17399 ||| NN
that  ||| S:17399 E:17404 ||| IN
Glu351  ||| S:17404 E:17411 ||| CD
of  ||| S:17411 E:17414 ||| IN
PAI-1  ||| S:17414 E:17420 ||| NNP
is  ||| S:17420 E:17423 ||| VBZ
involved  ||| S:17423 E:17432 ||| VBN
in  ||| S:17432 E:17445 ||| IN
its  ||| S:17445 E:17449 ||| PRP$
specificity  ||| S:17449 E:17461 ||| NN
toward  ||| S:17461 E:17468 ||| IN
thrombin  ||| S:17468 E:17477 ||| NN
and  ||| S:17477 E:17481 ||| CC
plasmin ||| S:17481 E:17488 ||| NN
.  ||| S:17488 E:17521 ||| .
Conclusion  ||| S:17521 E:17540 ||| NNP
Single  ||| S:17540 E:17547 ||| NNP
site  ||| S:17547 E:17552 ||| NN
mutations  ||| S:17552 E:17562 ||| NNS
within  ||| S:17562 E:17569 ||| IN
the  ||| S:17569 E:17573 ||| DT
segment  ||| S:17573 E:17589 ||| NN
Asp355-Arg356-Pro357  ||| S:17589 E:17610 ||| NN
of  ||| S:17610 E:17613 ||| IN
PAI-1  ||| S:17613 E:17619 ||| CD
yield  ||| S:17619 E:17625 ||| NN
Gdn-HCl  ||| S:17625 E:17633 ||| JJ
activatable  ||| S:17633 E:17653 ||| JJ
inhibitors  ||| S:17653 E:17664 ||| NN
that  ||| S:17664 E:17669 ||| WDT
can  ||| S:17669 E:17673 ||| MD
still  ||| S:17673 E:17679 ||| RB
form  ||| S:17679 E:17684 ||| VB
SDS  ||| S:17684 E:17688 ||| JJ
stable  ||| S:17688 E:17695 ||| JJ
complexes  ||| S:17695 E:17705 ||| NNS
with  ||| S:17705 E:17718 ||| IN
plasminogen  ||| S:17718 E:17730 ||| JJ
activators ||| S:17730 E:17740 ||| NN
,  ||| S:17740 E:17742 ||| ,
with  ||| S:17742 E:17747 ||| IN
second  ||| S:17747 E:17754 ||| JJ
order  ||| S:17754 E:17760 ||| NN
inhibition  ||| S:17760 E:17779 ||| NN
constants  ||| S:17779 E:17789 ||| NNS
that  ||| S:17789 E:17794 ||| WDT
are  ||| S:17794 E:17798 ||| VBP
similar  ||| S:17798 E:17806 ||| JJ
to  ||| S:17806 E:17809 ||| TO
the  ||| S:17809 E:17813 ||| DT
native  ||| S:17813 E:17820 ||| JJ
inhibitor ||| S:17820 E:17829 ||| NN
.  ||| S:17829 E:17839 ||| .
Interestingly ||| S:17839 E:17852 ||| RB
,  ||| S:17852 E:17854 ||| ,
the  ||| S:17854 E:17858 ||| DT
conversion  ||| S:17858 E:17869 ||| NN
of  ||| S:17869 E:17872 ||| IN
these  ||| S:17872 E:17878 ||| DT
mutants  ||| S:17878 E:17886 ||| NN
to  ||| S:17886 E:17889 ||| TO
latent  ||| S:17889 E:17904 ||| VB
forms  ||| S:17904 E:17910 ||| NNS
was  ||| S:17910 E:17914 ||| VBD
~3-4  ||| S:17914 E:17919 ||| RB
fold  ||| S:17919 E:17924 ||| VB
faster  ||| S:17924 E:17931 ||| RBR
than  ||| S:17931 E:17936 ||| IN
wtPAI-1 ||| S:17936 E:17943 ||| NNP
,  ||| S:17943 E:17945 ||| ,
suggesting  ||| S:17945 E:17956 ||| VBG
that  ||| S:17956 E:17969 ||| IN
the  ||| S:17969 E:17973 ||| DT
Asp355-Pro357  ||| S:17973 E:17987 ||| JJ
segment  ||| S:17987 E:17995 ||| NN
is  ||| S:17995 E:17998 ||| VBZ
involved  ||| S:17998 E:18007 ||| VBN
in  ||| S:18007 E:18010 ||| IN
maintaining  ||| S:18010 E:18022 ||| VBG
the  ||| S:18022 E:18034 ||| DT
inhibitory  ||| S:18034 E:18045 ||| JJ
conformation  ||| S:18045 E:18058 ||| NN
of  ||| S:18058 E:18061 ||| IN
PAI-1 ||| S:18061 E:18066 ||| CD
.  ||| S:18066 E:18068 ||| .
Glu351  ||| S:18068 E:18075 ||| NNP
contributes  ||| S:18075 E:18087 ||| VBZ
to  ||| S:18087 E:18090 ||| TO
the  ||| S:18090 E:18102 ||| DT
optimal  ||| S:18102 E:18110 ||| JJ
functional  ||| S:18110 E:18121 ||| JJ
stability  ||| S:18121 E:18131 ||| NN
of  ||| S:18131 E:18134 ||| IN
PAI-1  ||| S:18134 E:18140 ||| NNP
and  ||| S:18140 E:18144 ||| CC
participates  ||| S:18144 E:18157 ||| VBZ
its  ||| S:18157 E:18169 ||| PRP$
conformational  ||| S:18169 E:18184 ||| JJ
stability ||| S:18184 E:18193 ||| NN
.  ||| S:18193 E:18195 ||| .
More  ||| S:18195 E:18200 ||| RBR
importantly ||| S:18200 E:18211 ||| RB
,  ||| S:18211 E:18213 ||| ,
Glu351  ||| S:18213 E:18220 ||| NNP
of  ||| S:18220 E:18223 ||| IN
PAI-1  ||| S:18223 E:18237 ||| NNP
is  ||| S:18237 E:18240 ||| VBZ
a  ||| S:18240 E:18242 ||| DT
specificity  ||| S:18242 E:18254 ||| JJ
determinant  ||| S:18254 E:18266 ||| NN
for  ||| S:18266 E:18270 ||| IN
uPA ||| S:18270 E:18273 ||| NNP
,  ||| S:18273 E:18275 ||| ,
thrombin  ||| S:18275 E:18284 ||| NN
and  ||| S:18284 E:18288 ||| CC
plasmin ||| S:18288 E:18295 ||| NN
,  ||| S:18295 E:18305 ||| ,
but  ||| S:18305 E:18309 ||| CC
not  ||| S:18309 E:18313 ||| RB
for  ||| S:18313 E:18317 ||| IN
tPA ||| S:18317 E:18320 ||| JJ
.  ||| S:18320 E:18344 ||| .
Methods  ||| S:18344 E:18371 ||| NNP
General  ||| S:18371 E:18379 ||| NNP
DNA  ||| S:18379 E:18383 ||| NNP
techniques  ||| S:18383 E:18404 ||| NNS
Plasmid  ||| S:18404 E:18412 ||| NNP
DNA  ||| S:18412 E:18416 ||| NNP
was  ||| S:18416 E:18420 ||| VBD
purified  ||| S:18420 E:18429 ||| VBN
using  ||| S:18429 E:18435 ||| VBG
either  ||| S:18435 E:18442 ||| DT
Promega  ||| S:18442 E:18450 ||| NNP
or  ||| S:18450 E:18463 ||| CC
QIAGEN  ||| S:18463 E:18470 ||| NNP
miniprep  ||| S:18470 E:18479 ||| NN
kits ||| S:18479 E:18483 ||| NNS
.  ||| S:18483 E:18485 ||| .
The  ||| S:18485 E:18489 ||| DT
DNA  ||| S:18489 E:18493 ||| NN
was  ||| S:18493 E:18497 ||| VBD
sequenced  ||| S:18497 E:18507 ||| VBN
using  ||| S:18507 E:18513 ||| VBG
the  ||| S:18513 E:18527 ||| DT
di-deoxy  ||| S:18527 E:18536 ||| JJ
chain  ||| S:18536 E:18542 ||| NN
termination  ||| S:18542 E:18554 ||| NN
reaction  ||| S:18554 E:18563 ||| NN
method  ||| S:18563 E:18570 ||| NN
using  ||| S:18570 E:18576 ||| VBG
an  ||| S:18576 E:18579 ||| DT
ABI  ||| S:18579 E:18593 ||| NNP
373  ||| S:18593 E:18597 ||| CD
DNA  ||| S:18597 E:18601 ||| NN
sequencer ||| S:18601 E:18610 ||| NN
.  ||| S:18610 E:18612 ||| .
Oligonucleotides  ||| S:18612 E:18629 ||| NNP
were  ||| S:18629 E:18634 ||| VBD
synthesized  ||| S:18634 E:18656 ||| VBN
using  ||| S:18656 E:18662 ||| VBG
a  ||| S:18662 E:18664 ||| DT
380  ||| S:18664 E:18668 ||| CD
B  ||| S:18668 E:18670 ||| NNP
DNA  ||| S:18670 E:18674 ||| NNP
synthesizer  ||| S:18674 E:18686 ||| NNS
( ||| S:18686 E:18687 ||| -LRB-
ABI  ||| S:18687 E:18691 ||| NNP
model ||| S:18691 E:18696 ||| NN
) ||| S:18696 E:18697 ||| -RRB-
.  ||| S:18697 E:18699 ||| .
DNA  ||| S:18699 E:18713 ||| NNP
manipulation  ||| S:18713 E:18726 ||| NN
techniques  ||| S:18726 E:18737 ||| NNS
were  ||| S:18737 E:18742 ||| VBD
carried  ||| S:18742 E:18750 ||| VBN
out  ||| S:18750 E:18754 ||| RP
according  ||| S:18754 E:18764 ||| VBG
to  ||| S:18764 E:18777 ||| TO
standard  ||| S:18777 E:18786 ||| JJ
procedures  ||| S:18786 E:18797 ||| NNS
[  ||| S:18797 E:18799 ||| -LRB-
29  ||| S:18799 E:18802 ||| CD
]  ||| S:18802 E:18804 ||| -RRB-
.  ||| S:18804 E:18834 ||| .
Construction  ||| S:18834 E:18847 ||| NN
of  ||| S:18847 E:18850 ||| IN
wtPAI-1  ||| S:18850 E:18858 ||| NNP
and  ||| S:18858 E:18862 ||| CC
its  ||| S:18862 E:18866 ||| PRP$
mutants  ||| S:18866 E:18884 ||| NNS
The  ||| S:18884 E:18888 ||| DT
pPAI-1-AI  ||| S:18888 E:18898 ||| NNP
was  ||| S:18898 E:18902 ||| VBD
digested  ||| S:18902 E:18911 ||| VBN
with  ||| S:18911 E:18916 ||| IN
EcoRI  ||| S:18916 E:18922 ||| JJ
and  ||| S:18922 E:18926 ||| CC
BglII  ||| S:18926 E:18932 ||| JJ
to  ||| S:18932 E:18945 ||| TO
release  ||| S:18945 E:18953 ||| VB
a  ||| S:18953 E:18955 ||| DT
1426  ||| S:18955 E:18960 ||| CD
basepair  ||| S:18960 E:18969 ||| NNS
( ||| S:18969 E:18970 ||| -LRB-
bp ||| S:18970 E:18972 ||| LS
)  ||| S:18972 E:18974 ||| -RRB-
PAI-1  ||| S:18974 E:18980 ||| FW
coding  ||| S:18980 E:18987 ||| FW
sequence ||| S:18987 E:18995 ||| FW
,  ||| S:18995 E:18997 ||| ,
which  ||| S:18997 E:19013 ||| WDT
was  ||| S:19013 E:19017 ||| VBD
isolated ||| S:19017 E:19025 ||| VBN
,  ||| S:19025 E:19027 ||| ,
purified ||| S:19027 E:19035 ||| NN
,  ||| S:19035 E:19037 ||| ,
and  ||| S:19037 E:19041 ||| CC
ligated  ||| S:19041 E:19049 ||| NN
into  ||| S:19049 E:19054 ||| IN
EcoRI  ||| S:19054 E:19060 ||| JJ
and  ||| S:19060 E:19064 ||| CC
BglII  ||| S:19064 E:19080 ||| JJ
digested  ||| S:19080 E:19089 ||| JJ
pVL1393 ||| S:19089 E:19096 ||| NN
.  ||| S:19096 E:19098 ||| .
The  ||| S:19098 E:19102 ||| DT
resultant  ||| S:19102 E:19112 ||| JJ
pVL1393-PAI-1  ||| S:19112 E:19126 ||| NN
was  ||| S:19126 E:19140 ||| VBD
analyzed  ||| S:19140 E:19149 ||| VBN
by  ||| S:19149 E:19152 ||| IN
restriction  ||| S:19152 E:19164 ||| NN
mapping  ||| S:19164 E:19172 ||| NN
and  ||| S:19172 E:19176 ||| CC
sequencing ||| S:19176 E:19186 ||| NN
.  ||| S:19186 E:19188 ||| .
The  ||| S:19188 E:19202 ||| DT
mutants  ||| S:19202 E:19210 ||| NN
at  ||| S:19210 E:19213 ||| IN
E351A ||| S:19213 E:19218 ||| NNP
,  ||| S:19218 E:19220 ||| ,
E351R ||| S:19220 E:19225 ||| NNP
,  ||| S:19225 E:19227 ||| ,
D355 ||| S:19227 E:19231 ||| NNP
,  ||| S:19231 E:19233 ||| ,
R356 ||| S:19233 E:19237 ||| NNP
,  ||| S:19237 E:19239 ||| ,
and  ||| S:19239 E:19243 ||| CC
P357  ||| S:19243 E:19248 ||| CD
of  ||| S:19248 E:19251 ||| IN
PAI-1  ||| S:19251 E:19267 ||| NNP
were  ||| S:19267 E:19272 ||| VBD
generated  ||| S:19272 E:19282 ||| VBN
by  ||| S:19282 E:19285 ||| IN
PCR ||| S:19285 E:19288 ||| NNP
.  ||| S:19288 E:19290 ||| .
The  ||| S:19290 E:19294 ||| DT
occurrence  ||| S:19294 E:19305 ||| NN
of  ||| S:19305 E:19308 ||| IN
the  ||| S:19308 E:19312 ||| DT
resulting  ||| S:19312 E:19332 ||| VBG
mutations  ||| S:19332 E:19342 ||| JJ
D355A ||| S:19342 E:19347 ||| NN
,  ||| S:19347 E:19349 ||| ,
D355E ||| S:19349 E:19354 ||| NNP
,  ||| S:19354 E:19356 ||| ,
D355H ||| S:19356 E:19361 ||| NNP
,  ||| S:19361 E:19363 ||| ,
D355K ||| S:19363 E:19368 ||| NNP
,  ||| S:19368 E:19370 ||| ,
D355N ||| S:19370 E:19375 ||| NNP
,  ||| S:19375 E:19377 ||| ,
D355P ||| S:19377 E:19382 ||| NNP
,  ||| S:19382 E:19394 ||| ,
D355Q ||| S:19394 E:19399 ||| NNP
,  ||| S:19399 E:19401 ||| ,
R356P ||| S:19401 E:19406 ||| NNP
,  ||| S:19406 E:19408 ||| ,
P357G  ||| S:19408 E:19414 ||| NNP
as  ||| S:19414 E:19417 ||| IN
well  ||| S:19417 E:19422 ||| RB
as  ||| S:19422 E:19425 ||| IN
E351A  ||| S:19425 E:19431 ||| NNP
and  ||| S:19431 E:19435 ||| CC
E351R  ||| S:19435 E:19441 ||| CD
in  ||| S:19441 E:19444 ||| IN
pRSET  ||| S:19444 E:19460 ||| NNP
was  ||| S:19460 E:19464 ||| VBD
confirmed  ||| S:19464 E:19474 ||| VBN
by  ||| S:19474 E:19477 ||| IN
sequencing ||| S:19477 E:19487 ||| NN
.  ||| S:19487 E:19489 ||| .
The  ||| S:19489 E:19493 ||| DT
PAI-1  ||| S:19493 E:19499 ||| JJ
sequence  ||| S:19499 E:19518 ||| NN
containing  ||| S:19518 E:19529 ||| VBG
the  ||| S:19529 E:19533 ||| DT
desired  ||| S:19533 E:19541 ||| JJ
mutations  ||| S:19541 E:19551 ||| NNS
was  ||| S:19551 E:19555 ||| VBD
digested  ||| S:19555 E:19564 ||| VBN
with  ||| S:19564 E:19569 ||| IN
EcoR1  ||| S:19569 E:19585 ||| NNP
and  ||| S:19585 E:19589 ||| CC
BglII ||| S:19589 E:19594 ||| JJ
,  ||| S:19594 E:19596 ||| ,
and  ||| S:19596 E:19600 ||| CC
then  ||| S:19600 E:19605 ||| RB
subcloned  ||| S:19605 E:19615 ||| VBN
into  ||| S:19615 E:19620 ||| IN
pVL1393 ||| S:19620 E:19627 ||| CD
.  ||| S:19627 E:19629 ||| .
The  ||| S:19629 E:19643 ||| DT
recombinant  ||| S:19643 E:19655 ||| JJ
baculoviruses  ||| S:19655 E:19669 ||| NNS
containing  ||| S:19669 E:19680 ||| VBG
either  ||| S:19680 E:19687 ||| DT
wtPAI-1 ||| S:19687 E:19694 ||| NNP
,  ||| S:19694 E:19696 ||| ,
or  ||| S:19696 E:19709 ||| CC
one  ||| S:19709 E:19713 ||| CD
of  ||| S:19713 E:19716 ||| IN
the  ||| S:19716 E:19720 ||| DT
above  ||| S:19720 E:19726 ||| JJ
mutants  ||| S:19726 E:19734 ||| NN
was  ||| S:19734 E:19738 ||| VBD
obtained  ||| S:19738 E:19747 ||| VBN
as  ||| S:19747 E:19750 ||| IN
deccribed  ||| S:19750 E:19760 ||| NN
by  ||| S:19760 E:19773 ||| IN
Kjoller  ||| S:19773 E:19781 ||| NNP
et  ||| S:19781 E:19784 ||| FW
al.  ||| S:19784 E:19788 ||| FW
[  ||| S:19788 E:19790 ||| -LRB-
30  ||| S:19790 E:19793 ||| CD
]  ||| S:19793 E:19823 ||| -RRB-
Expression  ||| S:19823 E:19834 ||| NNP
and  ||| S:19834 E:19838 ||| CC
purification  ||| S:19838 E:19851 ||| NN
of  ||| S:19851 E:19854 ||| IN
wtPAI-1  ||| S:19854 E:19862 ||| NNP
and  ||| S:19862 E:19866 ||| CC
its  ||| S:19866 E:19880 ||| PRP$
mutants  ||| S:19880 E:19898 ||| JJ
High  ||| S:19898 E:19903 ||| NNP
5  ||| S:19903 E:19905 ||| CD
cells ||| S:19905 E:19910 ||| NNS
,  ||| S:19910 E:19912 ||| ,
grown  ||| S:19912 E:19918 ||| VBN
at  ||| S:19918 E:19921 ||| IN
27°C  ||| S:19921 E:19926 ||| CD
in  ||| S:19926 E:19929 ||| IN
SF-900  ||| S:19929 E:19936 ||| CD
serum-free  ||| S:19936 E:19957 ||| JJ
medium ||| S:19957 E:19963 ||| NN
,  ||| S:19963 E:19965 ||| ,
were  ||| S:19965 E:19970 ||| VBD
infected  ||| S:19970 E:19979 ||| VBN
with  ||| S:19979 E:19984 ||| IN
high-titer  ||| S:19984 E:19995 ||| JJ
virus  ||| S:19995 E:20001 ||| NN
stocks  ||| S:20001 E:20008 ||| NNS
( ||| S:20008 E:20009 ||| -LRB-
1-3  ||| S:20009 E:20013 ||| CD
×  ||| S:20013 E:20025 ||| CD
10  ||| S:20025 E:20028 ||| CD
8 ||| S:20028 E:20029 ||| CD
/ ||| S:20029 E:20030 ||| CD
ml ||| S:20030 E:20032 ||| CD
) ||| S:20032 E:20033 ||| -RRB-
.  ||| S:20033 E:20035 ||| .
The  ||| S:20035 E:20039 ||| DT
medium  ||| S:20039 E:20046 ||| NN
was  ||| S:20046 E:20050 ||| VBD
collected  ||| S:20050 E:20060 ||| VBN
48  ||| S:20060 E:20063 ||| CD
hrs  ||| S:20063 E:20067 ||| NN
after  ||| S:20067 E:20073 ||| IN
the  ||| S:20073 E:20087 ||| DT
infection  ||| S:20087 E:20097 ||| NN
( ||| S:20097 E:20098 ||| -LRB-
found  ||| S:20098 E:20104 ||| VBN
to  ||| S:20104 E:20107 ||| TO
be  ||| S:20107 E:20110 ||| VB
the  ||| S:20110 E:20114 ||| DT
optimal  ||| S:20114 E:20122 ||| JJ
harvesting  ||| S:20122 E:20133 ||| JJ
time  ||| S:20133 E:20138 ||| NN
for  ||| S:20138 E:20152 ||| IN
wtPAI-1 ||| S:20152 E:20159 ||| CD
)  ||| S:20159 E:20161 ||| -RRB-
and  ||| S:20161 E:20165 ||| CC
then  ||| S:20165 E:20170 ||| RB
centrifuged  ||| S:20170 E:20182 ||| VBN
for  ||| S:20182 E:20186 ||| IN
5  ||| S:20186 E:20188 ||| CD
minutes  ||| S:20188 E:20196 ||| NNS
( ||| S:20196 E:20197 ||| -LRB-
125  ||| S:20197 E:20201 ||| CD
×  ||| S:20201 E:20203 ||| CD
g ||| S:20203 E:20204 ||| CD
) ||| S:20204 E:20205 ||| -RRB-
.  ||| S:20205 E:20217 ||| .
The  ||| S:20217 E:20221 ||| DT
supernatents  ||| S:20221 E:20234 ||| NN
( ||| S:20234 E:20235 ||| -LRB-
50  ||| S:20235 E:20238 ||| CD
ml ||| S:20238 E:20240 ||| CD
)  ||| S:20240 E:20242 ||| -RRB-
were  ||| S:20242 E:20247 ||| VBD
collected  ||| S:20247 E:20257 ||| VBN
and  ||| S:20257 E:20261 ||| CC
sodium  ||| S:20261 E:20278 ||| JJ
chloride  ||| S:20278 E:20287 ||| NN
( ||| S:20287 E:20288 ||| -LRB-
final  ||| S:20288 E:20294 ||| JJ
concentration  ||| S:20294 E:20308 ||| NN
0.25  ||| S:20308 E:20313 ||| CD
M ||| S:20313 E:20314 ||| NNP
)  ||| S:20314 E:20316 ||| -RRB-
was  ||| S:20316 E:20320 ||| VBD
added ||| S:20320 E:20325 ||| VBN
.  ||| S:20325 E:20327 ||| .
They  ||| S:20327 E:20342 ||| PRP
were  ||| S:20342 E:20347 ||| VBD
then  ||| S:20347 E:20352 ||| RB
applied  ||| S:20352 E:20360 ||| VBN
on  ||| S:20360 E:20363 ||| IN
a  ||| S:20363 E:20365 ||| DT
heparin-Sepharose  ||| S:20365 E:20383 ||| JJ
column  ||| S:20383 E:20390 ||| NN
( ||| S:20390 E:20391 ||| -LRB-
bed  ||| S:20391 E:20405 ||| NN
volume  ||| S:20405 E:20412 ||| NN
5  ||| S:20412 E:20414 ||| CD
ml ||| S:20414 E:20416 ||| CD
)  ||| S:20416 E:20418 ||| -RRB-
that  ||| S:20418 E:20423 ||| WDT
was  ||| S:20423 E:20427 ||| VBD
equilibrated  ||| S:20427 E:20440 ||| JJ
and  ||| S:20440 E:20444 ||| CC
run  ||| S:20444 E:20448 ||| VB
( ||| S:20448 E:20449 ||| -LRB-
flow  ||| S:20449 E:20454 ||| NN
rate  ||| S:20454 E:20459 ||| NN
20  ||| S:20459 E:20472 ||| CD
ml ||| S:20472 E:20474 ||| CD
/ ||| S:20474 E:20475 ||| CD
h ||| S:20475 E:20476 ||| CD
)  ||| S:20476 E:20478 ||| -RRB-
with  ||| S:20478 E:20483 ||| IN
a  ||| S:20483 E:20485 ||| DT
buffer  ||| S:20485 E:20492 ||| NN
consisted  ||| S:20492 E:20502 ||| VBD
of  ||| S:20502 E:20505 ||| IN
50  ||| S:20505 E:20508 ||| CD
mM  ||| S:20508 E:20511 ||| JJ
sodium  ||| S:20511 E:20518 ||| JJ
acetate ||| S:20518 E:20525 ||| NN
,  ||| S:20525 E:20527 ||| ,
pH  ||| S:20527 E:20540 ||| JJ
5.6 ||| S:20540 E:20543 ||| CD
,  ||| S:20543 E:20545 ||| ,
containing  ||| S:20545 E:20556 ||| VBG
0.25  ||| S:20556 E:20561 ||| CD
M  ||| S:20561 E:20563 ||| NNP
NaCl  ||| S:20563 E:20568 ||| NNP
and  ||| S:20568 E:20572 ||| CC
0.01 ||| S:20572 E:20576 ||| CD
%  ||| S:20576 E:20578 ||| NN
Tween-20 ||| S:20578 E:20586 ||| NN
.  ||| S:20586 E:20588 ||| .
The  ||| S:20588 E:20602 ||| DT
columns  ||| S:20602 E:20610 ||| NNS
were  ||| S:20610 E:20615 ||| VBD
washed  ||| S:20615 E:20622 ||| VBN
and  ||| S:20622 E:20626 ||| CC
the  ||| S:20626 E:20630 ||| DT
PAI-1s  ||| S:20630 E:20637 ||| NNP
were  ||| S:20637 E:20642 ||| VBD
eluted  ||| S:20642 E:20649 ||| VBN
with  ||| S:20649 E:20654 ||| IN
a  ||| S:20654 E:20656 ||| DT
40  ||| S:20656 E:20669 ||| CD
ml  ||| S:20669 E:20672 ||| JJ
gradient  ||| S:20672 E:20681 ||| NN
of  ||| S:20681 E:20684 ||| IN
0.25  ||| S:20684 E:20689 ||| CD
-  ||| S:20689 E:20691 ||| :
1  ||| S:20691 E:20693 ||| CD
M  ||| S:20693 E:20695 ||| NNP
NaCl  ||| S:20695 E:20700 ||| NNP
in  ||| S:20700 E:20703 ||| IN
the  ||| S:20703 E:20707 ||| DT
same  ||| S:20707 E:20712 ||| JJ
buffer ||| S:20712 E:20718 ||| NN
.  ||| S:20718 E:20748 ||| .
SDS-PAGE ||| S:20748 E:20756 ||| NNP
,  ||| S:20756 E:20758 ||| ,
immunoblotting  ||| S:20758 E:20773 ||| NN
and  ||| S:20773 E:20777 ||| CC
deglycosylation  ||| S:20777 E:20793 ||| NN
of  ||| S:20793 E:20806 ||| IN
PAI-1  ||| S:20806 E:20822 ||| CD
The  ||| S:20822 E:20826 ||| DT
medium  ||| S:20826 E:20833 ||| NN
of  ||| S:20833 E:20836 ||| IN
the  ||| S:20836 E:20840 ||| DT
infected  ||| S:20840 E:20849 ||| JJ
cells  ||| S:20849 E:20855 ||| NNS
and  ||| S:20855 E:20859 ||| CC
the  ||| S:20859 E:20863 ||| DT
elutent  ||| S:20863 E:20871 ||| NN
from  ||| S:20871 E:20886 ||| IN
heparin-Sepharose  ||| S:20886 E:20904 ||| NNP
were  ||| S:20904 E:20909 ||| VBD
separated  ||| S:20909 E:20919 ||| VBN
on  ||| S:20919 E:20922 ||| IN
10 ||| S:20922 E:20924 ||| CD
%  ||| S:20924 E:20926 ||| NN
SDS-PAGE ||| S:20926 E:20934 ||| NN
,  ||| S:20934 E:20936 ||| ,
and  ||| S:20936 E:20950 ||| CC
monitored  ||| S:20950 E:20960 ||| VBN
by  ||| S:20960 E:20963 ||| IN
silver  ||| S:20963 E:20970 ||| JJ
staining ||| S:20970 E:20978 ||| NN
.  ||| S:20978 E:20980 ||| .
Fibrosarcoma  ||| S:20980 E:20993 ||| NNP
PAI-1  ||| S:20993 E:20999 ||| NNP
and  ||| S:20999 E:21013 ||| CC
wtPAI-1  ||| S:21013 E:21021 ||| NNP
were  ||| S:21021 E:21026 ||| VBD
transferred  ||| S:21026 E:21038 ||| VBN
onto  ||| S:21038 E:21043 ||| IN
nitrocellulose  ||| S:21043 E:21058 ||| JJ
paper  ||| S:21058 E:21064 ||| NN
and  ||| S:21064 E:21078 ||| CC
the  ||| S:21078 E:21082 ||| DT
proteins  ||| S:21082 E:21091 ||| NNS
were  ||| S:21091 E:21096 ||| VBD
revealed  ||| S:21096 E:21105 ||| VBN
with  ||| S:21105 E:21110 ||| IN
anti-human  ||| S:21110 E:21121 ||| JJ
PAI-1  ||| S:21121 E:21137 ||| CD
monoclonal  ||| S:21137 E:21148 ||| CD
antibodies ||| S:21148 E:21158 ||| NNS
,  ||| S:21158 E:21160 ||| ,
followed  ||| S:21160 E:21169 ||| VBN
by  ||| S:21169 E:21172 ||| IN
horseradish  ||| S:21172 E:21184 ||| JJ
peroxidase  ||| S:21184 E:21205 ||| NNS
( ||| S:21205 E:21206 ||| -LRB-
HRP ||| S:21206 E:21209 ||| NNP
)  ||| S:21209 E:21211 ||| -RRB-
conjugated  ||| S:21211 E:21222 ||| JJ
rabbit  ||| S:21222 E:21229 ||| JJ
anti-mouse  ||| S:21229 E:21240 ||| JJ
antibody ||| S:21240 E:21248 ||| NN
,  ||| S:21248 E:21250 ||| ,
and  ||| S:21250 E:21254 ||| CC
enhanced  ||| S:21254 E:21273 ||| JJ
chemiluminescence  ||| S:21273 E:21291 ||| NNS
( ||| S:21291 E:21292 ||| -LRB-
ECL ||| S:21292 E:21295 ||| NNP
) ||| S:21295 E:21296 ||| -RRB-
.  ||| S:21296 E:21298 ||| .
5  ||| S:21298 E:21300 ||| CD
ug  ||| S:21300 E:21303 ||| NN
of  ||| S:21303 E:21306 ||| IN
Fibrosarcoma  ||| S:21306 E:21319 ||| NNP
PAI-1 ||| S:21319 E:21324 ||| NNP
,  ||| S:21324 E:21326 ||| ,
or  ||| S:21326 E:21339 ||| CC
wtPAI-1  ||| S:21339 E:21347 ||| NNP
was  ||| S:21347 E:21351 ||| VBD
denatured  ||| S:21351 E:21361 ||| VBN
by  ||| S:21361 E:21364 ||| IN
boiling  ||| S:21364 E:21372 ||| VBG
for  ||| S:21372 E:21376 ||| IN
5  ||| S:21376 E:21378 ||| CD
min  ||| S:21378 E:21382 ||| NN
in  ||| S:21382 E:21385 ||| IN
a  ||| S:21385 E:21387 ||| DT
buffer  ||| S:21387 E:21404 ||| NN
consisted  ||| S:21404 E:21414 ||| VBD
of  ||| S:21414 E:21417 ||| IN
0.5 ||| S:21417 E:21420 ||| CD
%  ||| S:21420 E:21422 ||| NN
SDS ||| S:21422 E:21425 ||| NNP
,  ||| S:21425 E:21427 ||| ,
50  ||| S:21427 E:21430 ||| CD
mM  ||| S:21430 E:21433 ||| JJ
β-mercaptoethanol  ||| S:21433 E:21451 ||| JJ
and  ||| S:21451 E:21455 ||| CC
50  ||| S:21455 E:21458 ||| CD
mM  ||| S:21458 E:21471 ||| JJ
Tris-HCl ||| S:21471 E:21479 ||| NN
,  ||| S:21479 E:21481 ||| ,
pH  ||| S:21481 E:21484 ||| JJ
7.4 ||| S:21484 E:21487 ||| CD
.  ||| S:21487 E:21489 ||| .
They  ||| S:21489 E:21494 ||| PRP
were  ||| S:21494 E:21499 ||| VBD
then  ||| S:21499 E:21504 ||| RB
digested  ||| S:21504 E:21513 ||| VBN
( ||| S:21513 E:21514 ||| -LRB-
18  ||| S:21514 E:21517 ||| CD
hr ||| S:21517 E:21519 ||| NN
,  ||| S:21519 E:21521 ||| ,
at  ||| S:21521 E:21534 ||| IN
37°C ||| S:21534 E:21538 ||| CD
)  ||| S:21538 E:21540 ||| -RRB-
with  ||| S:21540 E:21545 ||| IN
0.5  ||| S:21545 E:21549 ||| CD
units  ||| S:21549 E:21555 ||| NNS
of  ||| S:21555 E:21558 ||| IN
recombinant  ||| S:21558 E:21570 ||| JJ
N-glycanase  ||| S:21570 E:21582 ||| NN
in  ||| S:21582 E:21585 ||| IN
the  ||| S:21585 E:21599 ||| DT
presence  ||| S:21599 E:21608 ||| NN
of  ||| S:21608 E:21611 ||| IN
2.5 ||| S:21611 E:21614 ||| CD
%  ||| S:21614 E:21616 ||| NN
NP-40 ||| S:21616 E:21621 ||| NN
,  ||| S:21621 E:21623 ||| ,
and  ||| S:21623 E:21627 ||| CC
subjected  ||| S:21627 E:21637 ||| VBN
to  ||| S:21637 E:21640 ||| TO
SDS-PAGE  ||| S:21640 E:21649 ||| JJ
and  ||| S:21649 E:21663 ||| CC
silver  ||| S:21663 E:21670 ||| JJ
staining ||| S:21670 E:21678 ||| NN
.  ||| S:21678 E:21680 ||| .
Protein  ||| S:21680 E:21688 ||| NN
concentrations  ||| S:21688 E:21703 ||| NNS
were  ||| S:21703 E:21708 ||| VBD
determined  ||| S:21708 E:21729 ||| VBN
by  ||| S:21729 E:21732 ||| IN
the  ||| S:21732 E:21736 ||| DT
Bio-Rad  ||| S:21736 E:21744 ||| JJ
protein  ||| S:21744 E:21752 ||| NN
assay  ||| S:21752 E:21758 ||| NN
reagent ||| S:21758 E:21765 ||| NN
.  ||| S:21765 E:21795 ||| .
Functional  ||| S:21795 E:21806 ||| JJ
stability  ||| S:21806 E:21816 ||| NN
of  ||| S:21816 E:21819 ||| IN
fibrosarcoma  ||| S:21819 E:21832 ||| CD
PAI-1 ||| S:21832 E:21837 ||| CD
,  ||| S:21837 E:21839 ||| ,
wtPAI-1  ||| S:21839 E:21857 ||| NNP
and  ||| S:21857 E:21861 ||| CC
its  ||| S:21861 E:21865 ||| PRP$
mutants  ||| S:21865 E:21883 ||| NNS
The  ||| S:21883 E:21887 ||| DT
inhibitory  ||| S:21887 E:21898 ||| JJ
activities  ||| S:21898 E:21909 ||| NNS
of  ||| S:21909 E:21912 ||| IN
fibrosarcoma  ||| S:21912 E:21925 ||| CD
PAI-1 ||| S:21925 E:21930 ||| CD
,  ||| S:21930 E:21942 ||| ,
wtPAI-1 ||| S:21942 E:21949 ||| NNP
,  ||| S:21949 E:21951 ||| ,
and  ||| S:21951 E:21955 ||| CC
its  ||| S:21955 E:21959 ||| PRP$
mutants  ||| S:21959 E:21967 ||| NN
were  ||| S:21967 E:21972 ||| VBD
measured  ||| S:21972 E:21981 ||| VBN
by  ||| S:21981 E:21984 ||| IN
a  ||| S:21984 E:21986 ||| DT
direct  ||| S:21986 E:22003 ||| JJ
chromogenic  ||| S:22003 E:22015 ||| NNS
assay  ||| S:22015 E:22021 ||| VBP
using  ||| S:22021 E:22027 ||| VBG
uPA  ||| S:22027 E:22031 ||| JJ
( ||| S:22031 E:22032 ||| -LRB-
100  ||| S:22032 E:22036 ||| CD
U ||| S:22036 E:22037 ||| NNP
/ ||| S:22037 E:22038 ||| CD
ug ||| S:22038 E:22040 ||| CD
)  ||| S:22040 E:22042 ||| -RRB-
and  ||| S:22042 E:22046 ||| CC
its  ||| S:22046 E:22050 ||| PRP$
substrate  ||| S:22050 E:22070 ||| JJ
S-2444  ||| S:22070 E:22077 ||| NN
in  ||| S:22077 E:22080 ||| IN
a  ||| S:22080 E:22082 ||| DT
microtiter  ||| S:22082 E:22093 ||| JJ
plate  ||| S:22093 E:22099 ||| NN
as  ||| S:22099 E:22102 ||| IN
described  ||| S:22102 E:22112 ||| VBN
earlier  ||| S:22112 E:22120 ||| RBR
[  ||| S:22120 E:22122 ||| -LRB-
20  ||| S:22122 E:22125 ||| CD
]  ||| S:22125 E:22137 ||| -RRB-
.  ||| S:22137 E:22139 ||| .
Briefly ||| S:22139 E:22146 ||| RB
,  ||| S:22146 E:22148 ||| ,
fibrosarcoma  ||| S:22148 E:22161 ||| CD
PAI-1 ||| S:22161 E:22166 ||| CD
,  ||| S:22166 E:22168 ||| ,
wtPAI-1 ||| S:22168 E:22175 ||| NNP
,  ||| S:22175 E:22177 ||| ,
or  ||| S:22177 E:22180 ||| CC
its  ||| S:22180 E:22184 ||| PRP$
mutants  ||| S:22184 E:22202 ||| NN
were  ||| S:22202 E:22207 ||| VBD
diluted  ||| S:22207 E:22215 ||| VBN
1 ||| S:22215 E:22216 ||| CD
: ||| S:22216 E:22217 ||| :
10  ||| S:22217 E:22220 ||| CD
in  ||| S:22220 E:22223 ||| IN
the  ||| S:22223 E:22227 ||| DT
activity  ||| S:22227 E:22236 ||| NN
measuring  ||| S:22236 E:22246 ||| VBG
assay  ||| S:22246 E:22252 ||| JJ
buffer  ||| S:22252 E:22269 ||| NN
( ||| S:22269 E:22270 ||| -LRB-
50  ||| S:22270 E:22273 ||| CD
uM  ||| S:22273 E:22276 ||| JJ
Tris-HCl ||| S:22276 E:22284 ||| NN
,  ||| S:22284 E:22286 ||| ,
pH  ||| S:22286 E:22289 ||| JJ
7.5 ||| S:22289 E:22292 ||| CD
,  ||| S:22292 E:22294 ||| ,
containing  ||| S:22294 E:22305 ||| VBG
0.15  ||| S:22305 E:22310 ||| NNP
M  ||| S:22310 E:22312 ||| NNP
NaCl  ||| S:22312 E:22317 ||| NNP
and  ||| S:22317 E:22321 ||| CC
100  ||| S:22321 E:22335 ||| CD
ug ||| S:22335 E:22337 ||| FW
/ ||| S:22337 E:22338 ||| FW
ml  ||| S:22338 E:22341 ||| FW
BSA ||| S:22341 E:22344 ||| FW
) ||| S:22344 E:22345 ||| -RRB-
.  ||| S:22345 E:22347 ||| .
The  ||| S:22347 E:22351 ||| DT
PAI-1  ||| S:22351 E:22357 ||| CD
samples  ||| S:22357 E:22365 ||| NNS
were  ||| S:22365 E:22370 ||| VBD
incubated  ||| S:22370 E:22380 ||| VBN
in  ||| S:22380 E:22383 ||| IN
the  ||| S:22383 E:22397 ||| DT
absence  ||| S:22397 E:22405 ||| NN
or  ||| S:22405 E:22408 ||| CC
in  ||| S:22408 E:22411 ||| IN
the  ||| S:22411 E:22415 ||| DT
presence  ||| S:22415 E:22424 ||| NN
of  ||| S:22424 E:22427 ||| IN
a  ||| S:22427 E:22429 ||| DT
two  ||| S:22429 E:22433 ||| CD
molar  ||| S:22433 E:22439 ||| JJ
excess  ||| S:22439 E:22446 ||| NN
of  ||| S:22446 E:22459 ||| IN
vitronectin  ||| S:22459 E:22471 ||| NNS
( ||| S:22471 E:22472 ||| -LRB-
the  ||| S:22472 E:22476 ||| DT
fibrosarcoma  ||| S:22476 E:22489 ||| JJ
PAI-1  ||| S:22489 E:22495 ||| NN
and  ||| S:22495 E:22499 ||| CC
the  ||| S:22499 E:22503 ||| DT
wtPAI-1  ||| S:22503 E:22511 ||| NNP
were  ||| S:22511 E:22526 ||| VBD
incubated  ||| S:22526 E:22536 ||| VBN
with  ||| S:22536 E:22541 ||| IN
vitronectin ||| S:22541 E:22552 ||| CD
)  ||| S:22552 E:22554 ||| -RRB-
at  ||| S:22554 E:22557 ||| IN
37°C ||| S:22557 E:22561 ||| CD
.  ||| S:22561 E:22563 ||| .
At  ||| S:22563 E:22566 ||| IN
the  ||| S:22566 E:22570 ||| DT
times  ||| S:22570 E:22586 ||| NNS
indicated ||| S:22586 E:22595 ||| VBD
,  ||| S:22595 E:22597 ||| ,
aliquots  ||| S:22597 E:22606 ||| NN
were  ||| S:22606 E:22611 ||| VBD
removed  ||| S:22611 E:22619 ||| VBN
and  ||| S:22619 E:22623 ||| CC
analyzed  ||| S:22623 E:22632 ||| VBD
immediately  ||| S:22632 E:22654 ||| RB
for  ||| S:22654 E:22658 ||| IN
their  ||| S:22658 E:22664 ||| PRP$
inhibitory  ||| S:22664 E:22675 ||| JJ
activity ||| S:22675 E:22683 ||| NN
.  ||| S:22683 E:22685 ||| .
One  ||| S:22685 E:22689 ||| CD
unit  ||| S:22689 E:22694 ||| NN
of  ||| S:22694 E:22697 ||| IN
PAI-1  ||| S:22697 E:22703 ||| CD
activity  ||| S:22703 E:22722 ||| NN
is  ||| S:22722 E:22725 ||| VBZ
defined  ||| S:22725 E:22733 ||| VBN
as  ||| S:22733 E:22736 ||| IN
the  ||| S:22736 E:22740 ||| DT
amount  ||| S:22740 E:22747 ||| NN
that  ||| S:22747 E:22752 ||| WDT
completely  ||| S:22752 E:22763 ||| RB
neutralizes  ||| S:22763 E:22775 ||| CD
1  ||| S:22775 E:22777 ||| CD
U  ||| S:22777 E:22789 ||| NNP
of  ||| S:22789 E:22792 ||| IN
uPA ||| S:22792 E:22795 ||| JJ
.  ||| S:22795 E:22797 ||| .
The  ||| S:22797 E:22801 ||| DT
specific  ||| S:22801 E:22810 ||| JJ
activity  ||| S:22810 E:22819 ||| NN
obtained  ||| S:22819 E:22828 ||| VBN
at  ||| S:22828 E:22831 ||| IN
time  ||| S:22831 E:22836 ||| NN
zero  ||| S:22836 E:22841 ||| NN
was  ||| S:22841 E:22855 ||| VBD
assigned  ||| S:22855 E:22864 ||| VBN
a  ||| S:22864 E:22866 ||| DT
value  ||| S:22866 E:22872 ||| NN
of  ||| S:22872 E:22875 ||| IN
100 ||| S:22875 E:22878 ||| CD
% ||| S:22878 E:22879 ||| NN
.  ||| S:22879 E:22909 ||| .
Activation  ||| S:22909 E:22920 ||| NNP
of  ||| S:22920 E:22923 ||| IN
PAI-1  ||| S:22923 E:22929 ||| NNP
and  ||| S:22929 E:22933 ||| CC
kinetic  ||| S:22933 E:22941 ||| JJ
analysis  ||| S:22941 E:22960 ||| NN
Fibrosarcoma  ||| S:22960 E:22973 ||| NNP
PAI-1 ||| S:22973 E:22978 ||| NNP
,  ||| S:22978 E:22980 ||| ,
wtPAI-1  ||| S:22980 E:22988 ||| NNP
or  ||| S:22988 E:22991 ||| CC
its  ||| S:22991 E:22995 ||| PRP$
mutants  ||| S:22995 E:23003 ||| NN
were  ||| S:23003 E:23018 ||| VBD
denatured  ||| S:23018 E:23028 ||| VBN
with  ||| S:23028 E:23033 ||| IN
6  ||| S:23033 E:23035 ||| CD
M  ||| S:23035 E:23037 ||| NNP
guanidine-hydrochloride  ||| S:23037 E:23061 ||| NNP
( ||| S:23061 E:23062 ||| -LRB-
Gdn-HCl ||| S:23062 E:23069 ||| NNP
)  ||| S:23069 E:23071 ||| -RRB-
( ||| S:23071 E:23072 ||| -LRB-
45  ||| S:23072 E:23085 ||| CD
min  ||| S:23085 E:23089 ||| NN
at  ||| S:23089 E:23092 ||| IN
37°C ||| S:23092 E:23096 ||| CD
) ||| S:23096 E:23097 ||| -RRB-
,  ||| S:23097 E:23099 ||| ,
followed  ||| S:23099 E:23108 ||| VBN
by  ||| S:23108 E:23111 ||| IN
dialysis  ||| S:23111 E:23120 ||| NN
( ||| S:23120 E:23121 ||| -LRB-
4-16  ||| S:23121 E:23126 ||| CD
hours  ||| S:23126 E:23132 ||| NNS
at  ||| S:23132 E:23135 ||| IN
4°C ||| S:23135 E:23138 ||| CD
)  ||| S:23138 E:23150 ||| -RRB-
against  ||| S:23150 E:23158 ||| IN
50  ||| S:23158 E:23161 ||| CD
mM  ||| S:23161 E:23164 ||| JJ
sodium  ||| S:23164 E:23171 ||| JJ
acetate ||| S:23171 E:23178 ||| NN
,  ||| S:23178 E:23180 ||| ,
pH  ||| S:23180 E:23183 ||| JJ
5.6 ||| S:23183 E:23186 ||| CD
,  ||| S:23186 E:23188 ||| ,
containing  ||| S:23188 E:23199 ||| VBG
0.5  ||| S:23199 E:23203 ||| CD
M  ||| S:23203 E:23215 ||| NNP
NaCl  ||| S:23215 E:23220 ||| NNP
and  ||| S:23220 E:23224 ||| CC
0.01 ||| S:23224 E:23228 ||| CD
%  ||| S:23228 E:23230 ||| NN
Tween-20 ||| S:23230 E:23238 ||| NN
.  ||| S:23238 E:23240 ||| .
This  ||| S:23240 E:23245 ||| DT
process  ||| S:23245 E:23253 ||| NN
which  ||| S:23253 E:23259 ||| WDT
PAI-1  ||| S:23259 E:23275 ||| VBZ
regained  ||| S:23275 E:23284 ||| VBN
its  ||| S:23284 E:23288 ||| PRP$
activity  ||| S:23288 E:23297 ||| NN
is  ||| S:23297 E:23300 ||| VBZ
called  ||| S:23300 E:23307 ||| VBN
activation  ||| S:23307 E:23318 ||| VBN
by  ||| S:23318 E:23321 ||| IN
Gdn-HCl ||| S:23321 E:23328 ||| JJ
.  ||| S:23328 E:23340 ||| .
The  ||| S:23340 E:23344 ||| DT
inhibitory  ||| S:23344 E:23355 ||| JJ
activity  ||| S:23355 E:23364 ||| NN
of  ||| S:23364 E:23367 ||| IN
each  ||| S:23367 E:23372 ||| DT
of  ||| S:23372 E:23375 ||| IN
the  ||| S:23375 E:23379 ||| DT
PAI-1s  ||| S:23379 E:23386 ||| NNP
was  ||| S:23386 E:23390 ||| VBD
assayed  ||| S:23390 E:23408 ||| VBN
immediately ||| S:23408 E:23419 ||| RB
.  ||| S:23419 E:23421 ||| .
The  ||| S:23421 E:23425 ||| DT
second-order  ||| S:23425 E:23438 ||| JJ
rate  ||| S:23438 E:23443 ||| NN
constants  ||| S:23443 E:23453 ||| NN
for  ||| S:23453 E:23457 ||| IN
the  ||| S:23457 E:23471 ||| DT
interaction  ||| S:23471 E:23483 ||| NN
of  ||| S:23483 E:23486 ||| IN
the  ||| S:23486 E:23490 ||| DT
fibrosarcoma  ||| S:23490 E:23503 ||| JJ
PAI-1 ||| S:23503 E:23508 ||| NN
,  ||| S:23508 E:23510 ||| ,
wtPAI-1  ||| S:23510 E:23518 ||| NNP
or  ||| S:23518 E:23521 ||| CC
the  ||| S:23521 E:23535 ||| DT
indicated  ||| S:23535 E:23545 ||| JJ
mutants  ||| S:23545 E:23553 ||| NN
with  ||| S:23553 E:23558 ||| IN
single-chain  ||| S:23558 E:23571 ||| JJ
tPA  ||| S:23571 E:23575 ||| JJ
or  ||| S:23575 E:23578 ||| CC
uPA  ||| S:23578 E:23582 ||| NNP
were  ||| S:23582 E:23597 ||| VBD
determined  ||| S:23597 E:23608 ||| VBN
in  ||| S:23608 E:23611 ||| IN
a  ||| S:23611 E:23613 ||| DT
single-step  ||| S:23613 E:23625 ||| JJ
assay  ||| S:23625 E:23631 ||| NN
as  ||| S:23631 E:23634 ||| IN
previously  ||| S:23634 E:23655 ||| RB
described.  ||| S:23655 E:23666 ||| CD
[  ||| S:23666 E:23668 ||| -LRB-
20  ||| S:23668 E:23671 ||| CD
]  ||| S:23671 E:23701 ||| -RRB-
Specific  ||| S:23701 E:23710 ||| JJ
activity ||| S:23710 E:23718 ||| NN
,  ||| S:23718 E:23720 ||| ,
functional  ||| S:23720 E:23731 ||| JJ
stability  ||| S:23731 E:23741 ||| NN
and  ||| S:23741 E:23745 ||| CC
complex  ||| S:23745 E:23763 ||| JJ
formation  ||| S:23763 E:23773 ||| NN
of  ||| S:23773 E:23776 ||| IN
PAI-1s  ||| S:23776 E:23793 ||| CD
The  ||| S:23793 E:23797 ||| DT
inhibitory  ||| S:23797 E:23808 ||| JJ
activities  ||| S:23808 E:23819 ||| NNS
of  ||| S:23819 E:23822 ||| IN
wtPAI-1  ||| S:23822 E:23830 ||| NNP
and  ||| S:23830 E:23834 ||| CC
mutants  ||| S:23834 E:23842 ||| NNS
were  ||| S:23842 E:23857 ||| VBD
measured  ||| S:23857 E:23866 ||| VBN
by  ||| S:23866 E:23869 ||| IN
a  ||| S:23869 E:23871 ||| DT
direct  ||| S:23871 E:23878 ||| JJ
chromogenic  ||| S:23878 E:23890 ||| NNS
assay  ||| S:23890 E:23896 ||| VBP
using  ||| S:23896 E:23902 ||| VBG
uPA  ||| S:23902 E:23906 ||| JJ
( ||| S:23906 E:23907 ||| -LRB-
100  ||| S:23907 E:23921 ||| CD
U ||| S:23921 E:23922 ||| NNP
/ ||| S:23922 E:23923 ||| CD
μg ||| S:23923 E:23925 ||| CD
)  ||| S:23925 E:23927 ||| -RRB-
and  ||| S:23927 E:23931 ||| CC
substrate  ||| S:23931 E:23941 ||| CD
S-2444.  ||| S:23941 E:23949 ||| CD
[  ||| S:23949 E:23951 ||| -LRB-
17  ||| S:23951 E:23954 ||| CD
]  ||| S:23954 E:23956 ||| -RRB-
Briefly ||| S:23956 E:23963 ||| NNP
,  ||| S:23963 E:23965 ||| ,
serially  ||| S:23965 E:23984 ||| VBD
diluted  ||| S:23984 E:23992 ||| VBN
wtPAI-1 ||| S:23992 E:23999 ||| NNP
,  ||| S:23999 E:24001 ||| ,
or  ||| S:24001 E:24004 ||| CC
mutants  ||| S:24004 E:24012 ||| NNS
were  ||| S:24012 E:24017 ||| VBD
incubated  ||| S:24017 E:24027 ||| VBN
with  ||| S:24027 E:24032 ||| IN
equal  ||| S:24032 E:24048 ||| JJ
volume  ||| S:24048 E:24055 ||| NN
of  ||| S:24055 E:24058 ||| IN
uPA  ||| S:24058 E:24062 ||| NNP
( ||| S:24062 E:24063 ||| -LRB-
50  ||| S:24063 E:24066 ||| CD
μl ||| S:24066 E:24068 ||| NN
,  ||| S:24068 E:24070 ||| ,
50  ||| S:24070 E:24073 ||| CD
U ||| S:24073 E:24074 ||| NNP
/ ||| S:24074 E:24075 ||| CD
ml ||| S:24075 E:24077 ||| CD
)  ||| S:24077 E:24079 ||| -RRB-
for  ||| S:24079 E:24083 ||| IN
30  ||| S:24083 E:24086 ||| CD
min  ||| S:24086 E:24090 ||| NN
at  ||| S:24090 E:24093 ||| IN
37°C ||| S:24093 E:24097 ||| NNP
,  ||| S:24097 E:24109 ||| ,
followed  ||| S:24109 E:24118 ||| VBN
by  ||| S:24118 E:24121 ||| IN
addition  ||| S:24121 E:24130 ||| NN
of  ||| S:24130 E:24133 ||| IN
100  ||| S:24133 E:24137 ||| CD
μl ||| S:24137 E:24139 ||| NN
,  ||| S:24139 E:24141 ||| ,
0.5  ||| S:24141 E:24145 ||| CD
mM  ||| S:24145 E:24148 ||| JJ
S-2444 ||| S:24148 E:24154 ||| NN
.  ||| S:24154 E:24156 ||| .
Residual  ||| S:24156 E:24175 ||| JJ
uPA  ||| S:24175 E:24179 ||| JJ
activity  ||| S:24179 E:24188 ||| NN
was  ||| S:24188 E:24192 ||| VBD
quantitated  ||| S:24192 E:24204 ||| VBN
by  ||| S:24204 E:24207 ||| IN
measuring  ||| S:24207 E:24217 ||| VBG
the  ||| S:24217 E:24221 ||| DT
change  ||| S:24221 E:24228 ||| NN
in  ||| S:24228 E:24241 ||| IN
absorbance  ||| S:24241 E:24252 ||| NN
at  ||| S:24252 E:24255 ||| IN
405  ||| S:24255 E:24259 ||| CD
nm  ||| S:24259 E:24262 ||| NN
with  ||| S:24262 E:24267 ||| IN
ELISA  ||| S:24267 E:24273 ||| NNP
reader ||| S:24273 E:24279 ||| NN
.  ||| S:24279 E:24281 ||| .
The  ||| S:24281 E:24285 ||| DT
specific  ||| S:24285 E:24304 ||| JJ
activity  ||| S:24304 E:24313 ||| NN
of  ||| S:24313 E:24316 ||| IN
PAI-1  ||| S:24316 E:24322 ||| NNP
was  ||| S:24322 E:24326 ||| VBD
calculated  ||| S:24326 E:24337 ||| VBN
based  ||| S:24337 E:24343 ||| VBN
on  ||| S:24343 E:24346 ||| IN
the  ||| S:24346 E:24350 ||| DT
amount  ||| S:24350 E:24357 ||| NN
of  ||| S:24357 E:24370 ||| IN
uPA  ||| S:24370 E:24374 ||| JJ
inhibited  ||| S:24374 E:24384 ||| NN
by  ||| S:24384 E:24387 ||| IN
PAI-1 ||| S:24387 E:24392 ||| CD
.  ||| S:24392 E:24394 ||| .
The  ||| S:24394 E:24398 ||| DT
assay  ||| S:24398 E:24404 ||| NN
for  ||| S:24404 E:24408 ||| IN
PAI-1  ||| S:24408 E:24414 ||| CD
inhibitory  ||| S:24414 E:24435 ||| JJ
activity  ||| S:24435 E:24444 ||| NN
toward  ||| S:24444 E:24451 ||| IN
two-chain  ||| S:24451 E:24461 ||| JJ
tPA  ||| S:24461 E:24465 ||| NN
was  ||| S:24465 E:24469 ||| VBD
the  ||| S:24469 E:24473 ||| DT
same  ||| S:24473 E:24478 ||| JJ
for  ||| S:24478 E:24482 ||| IN
uPA  ||| S:24482 E:24486 ||| JJ
except  ||| S:24486 E:24503 ||| NN
that  ||| S:24503 E:24508 ||| IN
the  ||| S:24508 E:24512 ||| DT
samples  ||| S:24512 E:24520 ||| NNS
were  ||| S:24520 E:24525 ||| VBD
incubated  ||| S:24525 E:24535 ||| VBN
with  ||| S:24535 E:24540 ||| IN
tPA  ||| S:24540 E:24544 ||| JJ
and  ||| S:24544 E:24548 ||| CC
S-2288 ||| S:24548 E:24554 ||| NNP
.  ||| S:24554 E:24566 ||| .
PAI-1  ||| S:24566 E:24572 ||| NNP
inhibitory  ||| S:24572 E:24583 ||| JJ
activity  ||| S:24583 E:24592 ||| NN
is  ||| S:24592 E:24595 ||| VBZ
expressed  ||| S:24595 E:24605 ||| VBN
as  ||| S:24605 E:24608 ||| IN
the  ||| S:24608 E:24612 ||| DT
number  ||| S:24612 E:24619 ||| NN
of  ||| S:24619 E:24632 ||| IN
international  ||| S:24632 E:24646 ||| JJ
units  ||| S:24646 E:24652 ||| NNS
of  ||| S:24652 E:24655 ||| IN
PAs  ||| S:24655 E:24659 ||| JJ
inhibited  ||| S:24659 E:24669 ||| NN
by  ||| S:24669 E:24672 ||| IN
PAI-1 ||| S:24672 E:24677 ||| CD
.  ||| S:24677 E:24679 ||| .
Specific  ||| S:24679 E:24698 ||| JJ
activity  ||| S:24698 E:24707 ||| NN
of  ||| S:24707 E:24710 ||| IN
uPA  ||| S:24710 E:24714 ||| JJ
and  ||| S:24714 E:24718 ||| CC
two-chain  ||| S:24718 E:24728 ||| JJ
tPA  ||| S:24728 E:24732 ||| NNS
are  ||| S:24732 E:24736 ||| VBP
100  ||| S:24736 E:24740 ||| CD
U ||| S:24740 E:24741 ||| NNP
/ ||| S:24741 E:24742 ||| NNP
μg  ||| S:24742 E:24745 ||| NN
and  ||| S:24745 E:24749 ||| CC
764  ||| S:24749 E:24763 ||| CD
U ||| S:24763 E:24764 ||| NNP
/ ||| S:24764 E:24765 ||| NNP
μg ||| S:24765 E:24767 ||| NN
,  ||| S:24767 E:24769 ||| ,
respectively ||| S:24769 E:24781 ||| RB
.  ||| S:24781 E:24783 ||| .
For  ||| S:24783 E:24787 ||| IN
the  ||| S:24787 E:24791 ||| DT
functional  ||| S:24791 E:24802 ||| JJ
stability ||| S:24802 E:24811 ||| NN
,  ||| S:24811 E:24823 ||| ,
wtPAI-1 ||| S:24823 E:24830 ||| NNP
,  ||| S:24830 E:24832 ||| ,
or  ||| S:24832 E:24835 ||| CC
mutants  ||| S:24835 E:24843 ||| NNS
were  ||| S:24843 E:24848 ||| VBD
incubated  ||| S:24848 E:24858 ||| VBN
at  ||| S:24858 E:24861 ||| IN
37°C ||| S:24861 E:24865 ||| CD
.  ||| S:24865 E:24867 ||| .
Aliquots  ||| S:24867 E:24876 ||| NNP
were  ||| S:24876 E:24891 ||| VBD
taken  ||| S:24891 E:24897 ||| VBN
out  ||| S:24897 E:24901 ||| RP
at  ||| S:24901 E:24904 ||| IN
times  ||| S:24904 E:24910 ||| NNS
indicated  ||| S:24910 E:24920 ||| VBD
and  ||| S:24920 E:24924 ||| CC
analyzed  ||| S:24924 E:24933 ||| VBD
immediately  ||| S:24933 E:24945 ||| RB
as  ||| S:24945 E:24958 ||| RB
described  ||| S:24958 E:24968 ||| VBN
above ||| S:24968 E:24973 ||| IN
.  ||| S:24973 E:24975 ||| .
The  ||| S:24975 E:24979 ||| DT
specific  ||| S:24979 E:24988 ||| JJ
activity  ||| S:24988 E:24997 ||| NN
obtained  ||| S:24997 E:25006 ||| VBN
at  ||| S:25006 E:25009 ||| IN
time  ||| S:25009 E:25024 ||| NN
zero  ||| S:25024 E:25029 ||| NN
was  ||| S:25029 E:25033 ||| VBD
assigned  ||| S:25033 E:25042 ||| VBN
a  ||| S:25042 E:25044 ||| DT
value  ||| S:25044 E:25050 ||| NN
of  ||| S:25050 E:25053 ||| IN
100 ||| S:25053 E:25056 ||| CD
% ||| S:25056 E:25057 ||| NN
.  ||| S:25057 E:25059 ||| .
To  ||| S:25059 E:25062 ||| TO
provide  ||| S:25062 E:25070 ||| VB
the  ||| S:25070 E:25084 ||| DT
evidence  ||| S:25084 E:25093 ||| NN
to  ||| S:25093 E:25096 ||| TO
support  ||| S:25096 E:25104 ||| VB
the  ||| S:25104 E:25108 ||| DT
conclusion  ||| S:25108 E:25119 ||| NN
obtained  ||| S:25119 E:25128 ||| VBN
from  ||| S:25128 E:25133 ||| IN
enzyme  ||| S:25133 E:25150 ||| JJ
assay ||| S:25150 E:25155 ||| NN
,  ||| S:25155 E:25157 ||| ,
certain  ||| S:25157 E:25165 ||| JJ
amount  ||| S:25165 E:25172 ||| NN
of  ||| S:25172 E:25175 ||| IN
wtPAI-1 ||| S:25175 E:25182 ||| NNP
,  ||| S:25182 E:25184 ||| ,
E351R  ||| S:25184 E:25190 ||| NNP
and  ||| S:25190 E:25194 ||| CC
E351A  ||| S:25194 E:25200 ||| NNP
were  ||| S:25200 E:25215 ||| VBD
incubated  ||| S:25215 E:25225 ||| VBN
with  ||| S:25225 E:25230 ||| IN
equal  ||| S:25230 E:25236 ||| JJ
amount  ||| S:25236 E:25243 ||| NN
of  ||| S:25243 E:25246 ||| IN
tPA  ||| S:25246 E:25250 ||| JJ
at  ||| S:25250 E:25253 ||| IN
37°C  ||| S:25253 E:25258 ||| CD
for  ||| S:25258 E:25262 ||| IN
30  ||| S:25262 E:25265 ||| CD
minutes  ||| S:25265 E:25283 ||| NNS
before  ||| S:25283 E:25290 ||| IN
put  ||| S:25290 E:25294 ||| VBN
on  ||| S:25294 E:25297 ||| IN
ice ||| S:25297 E:25300 ||| NN
,  ||| S:25300 E:25302 ||| ,
at  ||| S:25302 E:25305 ||| IN
same  ||| S:25305 E:25310 ||| JJ
time  ||| S:25310 E:25315 ||| NN
these  ||| S:25315 E:25321 ||| DT
PAI-1s  ||| S:25321 E:25328 ||| NNP
were  ||| S:25328 E:25343 ||| VBD
incubated  ||| S:25343 E:25353 ||| VBN
in  ||| S:25353 E:25356 ||| IN
PBS  ||| S:25356 E:25360 ||| NNP
at  ||| S:25360 E:25363 ||| IN
37°C  ||| S:25363 E:25368 ||| CD
for  ||| S:25368 E:25372 ||| IN
3  ||| S:25372 E:25374 ||| CD
hours ||| S:25374 E:25379 ||| NNS
,  ||| S:25379 E:25381 ||| ,
respectively ||| S:25381 E:25393 ||| RB
,  ||| S:25393 E:25405 ||| ,
before  ||| S:25405 E:25412 ||| IN
the  ||| S:25412 E:25416 ||| DT
PAI-1s  ||| S:25416 E:25423 ||| NNP
were  ||| S:25423 E:25428 ||| VBD
incubated  ||| S:25428 E:25438 ||| VBN
with  ||| S:25438 E:25443 ||| IN
same  ||| S:25443 E:25448 ||| JJ
amount  ||| S:25448 E:25455 ||| NN
of  ||| S:25455 E:25458 ||| IN
tPA  ||| S:25458 E:25472 ||| JJ
at  ||| S:25472 E:25475 ||| IN
37°C  ||| S:25475 E:25480 ||| CD
for  ||| S:25480 E:25484 ||| IN
30  ||| S:25484 E:25487 ||| CD
minutes ||| S:25487 E:25494 ||| NNS
,  ||| S:25494 E:25496 ||| ,
then  ||| S:25496 E:25501 ||| RB
the  ||| S:25501 E:25505 ||| DT
protein  ||| S:25505 E:25513 ||| NN
samples  ||| S:25513 E:25521 ||| NNS
prepared  ||| S:25521 E:25540 ||| VBN
at  ||| S:25540 E:25543 ||| IN
two  ||| S:25543 E:25547 ||| CD
time  ||| S:25547 E:25552 ||| NN
points  ||| S:25552 E:25559 ||| NNS
were  ||| S:25559 E:25564 ||| VBD
subjected  ||| S:25564 E:25574 ||| VBN
to  ||| S:25574 E:25577 ||| TO
SDS-PAGE  ||| S:25577 E:25586 ||| JJ
and  ||| S:25586 E:25590 ||| CC
western  ||| S:25590 E:25608 ||| JJ
blot  ||| S:25608 E:25613 ||| NN
as  ||| S:25613 E:25616 ||| IN
described  ||| S:25616 E:25626 ||| VBN
before ||| S:25626 E:25632 ||| RB
.  ||| S:25632 E:25662 ||| .
Inhibition  ||| S:25662 E:25673 ||| NNP
of  ||| S:25673 E:25676 ||| IN
thrombin  ||| S:25676 E:25685 ||| NN
and  ||| S:25685 E:25689 ||| CC
plasmin  ||| S:25689 E:25697 ||| NN
by  ||| S:25697 E:25700 ||| IN
PAI-1s  ||| S:25700 E:25717 ||| NNP
Thrombin  ||| S:25717 E:25726 ||| NNP
( ||| S:25726 E:25727 ||| -LRB-
0.025  ||| S:25727 E:25733 ||| NNP
U ||| S:25733 E:25734 ||| NNP
) ||| S:25734 E:25735 ||| -RRB-
,  ||| S:25735 E:25737 ||| ,
or  ||| S:25737 E:25740 ||| CC
plasmin  ||| S:25740 E:25748 ||| NNS
( ||| S:25748 E:25749 ||| -LRB-
0.1  ||| S:25749 E:25753 ||| CD
μg ||| S:25753 E:25755 ||| CD
/ ||| S:25755 E:25756 ||| CD
ml ||| S:25756 E:25758 ||| CD
)  ||| S:25758 E:25760 ||| -RRB-
was  ||| S:25760 E:25774 ||| VBD
incubated  ||| S:25774 E:25784 ||| VBN
at  ||| S:25784 E:25787 ||| IN
37°C  ||| S:25787 E:25792 ||| CD
for  ||| S:25792 E:25796 ||| IN
30  ||| S:25796 E:25799 ||| CD
min  ||| S:25799 E:25803 ||| NN
with  ||| S:25803 E:25808 ||| IN
same  ||| S:25808 E:25813 ||| JJ
amount  ||| S:25813 E:25820 ||| NN
of  ||| S:25820 E:25823 ||| IN
wtPAI-1 ||| S:25823 E:25830 ||| NNP
,  ||| S:25830 E:25842 ||| ,
E351A  ||| S:25842 E:25848 ||| NNP
and  ||| S:25848 E:25852 ||| CC
E351R  ||| S:25852 E:25858 ||| CD
in  ||| S:25858 E:25861 ||| IN
term  ||| S:25861 E:25866 ||| NN
of  ||| S:25866 E:25869 ||| IN
inhibitory  ||| S:25869 E:25880 ||| JJ
activity  ||| S:25880 E:25889 ||| NN
toward  ||| S:25889 E:25896 ||| IN
uPA  ||| S:25896 E:25910 ||| NNP
( ||| S:25910 E:25911 ||| -LRB-
20  ||| S:25911 E:25914 ||| CD
U  ||| S:25914 E:25916 ||| NNP
in  ||| S:25916 E:25919 ||| IN
the  ||| S:25919 E:25923 ||| DT
concentration  ||| S:25923 E:25937 ||| NN
range  ||| S:25937 E:25943 ||| NN
of  ||| S:25943 E:25946 ||| IN
4-10  ||| S:25946 E:25951 ||| FW
μg ||| S:25951 E:25953 ||| FW
/ ||| S:25953 E:25954 ||| FW
ml ||| S:25954 E:25956 ||| FW
)  ||| S:25956 E:25958 ||| -RRB-
in  ||| S:25958 E:25971 ||| IN
absence  ||| S:25971 E:25979 ||| NN
or  ||| S:25979 E:25982 ||| CC
presence  ||| S:25982 E:25991 ||| NN
of  ||| S:25991 E:25994 ||| IN
vitronectin  ||| S:25994 E:26006 ||| NNS
( ||| S:26006 E:26007 ||| -LRB-
60  ||| S:26007 E:26010 ||| CD
μg ||| S:26010 E:26012 ||| CD
/ ||| S:26012 E:26013 ||| CD
ml ||| S:26013 E:26015 ||| CD
) ||| S:26015 E:26016 ||| -RRB-
.  ||| S:26016 E:26018 ||| .
Linear  ||| S:26018 E:26035 ||| NNP
increase  ||| S:26035 E:26044 ||| NN
of  ||| S:26044 E:26047 ||| IN
absorbance  ||| S:26047 E:26058 ||| NN
at  ||| S:26058 E:26061 ||| IN
405  ||| S:26061 E:26065 ||| CD
nm  ||| S:26065 E:26068 ||| NNS
were  ||| S:26068 E:26073 ||| VBD
recorded  ||| S:26073 E:26082 ||| VBN
after  ||| S:26082 E:26098 ||| IN
adding  ||| S:26098 E:26105 ||| VBG
S-2238  ||| S:26105 E:26112 ||| NNP
( ||| S:26112 E:26113 ||| -LRB-
final  ||| S:26113 E:26119 ||| JJ
concentration  ||| S:26119 E:26133 ||| NN
0.25  ||| S:26133 E:26138 ||| CD
mM ||| S:26138 E:26140 ||| NN
)  ||| S:26140 E:26142 ||| -RRB-
for  ||| S:26142 E:26146 ||| IN
thrombin ||| S:26146 E:26154 ||| NN
,  ||| S:26154 E:26166 ||| ,
or  ||| S:26166 E:26169 ||| CC
N-p-Tosyl-Gly-Pro-Lys-p-Nitroanilide  ||| S:26169 E:26206 ||| NNP
( ||| S:26206 E:26207 ||| -LRB-
final  ||| S:26207 E:26223 ||| JJ
concentration  ||| S:26223 E:26237 ||| NN
0.5  ||| S:26237 E:26241 ||| CD
mM ||| S:26241 E:26243 ||| NN
)  ||| S:26243 E:26245 ||| -RRB-
for  ||| S:26245 E:26249 ||| IN
plasmin ||| S:26249 E:26256 ||| NN
.  ||| S:26256 E:26258 ||| .
Thrombin ||| S:26258 E:26266 ||| NNP
,  ||| S:26266 E:26268 ||| ,
or  ||| S:26268 E:26271 ||| CC
plasmin  ||| S:26271 E:26289 ||| JJ
activity  ||| S:26289 E:26298 ||| NN
without  ||| S:26298 E:26306 ||| IN
PAI-1  ||| S:26306 E:26312 ||| NNP
was  ||| S:26312 E:26316 ||| VBD
taken  ||| S:26316 E:26322 ||| VBN
as  ||| S:26322 E:26325 ||| IN
100 ||| S:26325 E:26328 ||| CD
% ||| S:26328 E:26329 ||| NN
.  ||| S:26329 E:26359 ||| .
Neutralization  ||| S:26359 E:26374 ||| NN
of  ||| S:26374 E:26377 ||| IN
PAI-1s  ||| S:26377 E:26384 ||| CD
by  ||| S:26384 E:26387 ||| IN
Thrombin  ||| S:26387 E:26406 ||| NNP
wtPAI-1  ||| S:26406 E:26414 ||| NNP
and  ||| S:26414 E:26418 ||| CC
mutants  ||| S:26418 E:26426 ||| NNS
were  ||| S:26426 E:26431 ||| VBD
incubated  ||| S:26431 E:26441 ||| VBN
with  ||| S:26441 E:26446 ||| IN
four  ||| S:26446 E:26451 ||| CD
molar  ||| S:26451 E:26467 ||| JJ
excess  ||| S:26467 E:26474 ||| NN
of  ||| S:26474 E:26477 ||| IN
thrombin  ||| S:26477 E:26486 ||| NNS
( ||| S:26486 E:26487 ||| -LRB-
40  ||| S:26487 E:26490 ||| CD
nM ||| S:26490 E:26492 ||| NN
)  ||| S:26492 E:26494 ||| -RRB-
in  ||| S:26494 E:26497 ||| IN
the  ||| S:26497 E:26501 ||| DT
absence  ||| S:26501 E:26509 ||| NN
or  ||| S:26509 E:26512 ||| CC
presence  ||| S:26512 E:26521 ||| NN
of  ||| S:26521 E:26534 ||| IN
vitronectin  ||| S:26534 E:26546 ||| NNS
( ||| S:26546 E:26547 ||| -LRB-
30  ||| S:26547 E:26550 ||| CD
nM ||| S:26550 E:26552 ||| NN
) ||| S:26552 E:26553 ||| -RRB-
.  ||| S:26553 E:26555 ||| .
Control  ||| S:26555 E:26563 ||| NN
experiments  ||| S:26563 E:26575 ||| NNS
were  ||| S:26575 E:26580 ||| VBD
carried  ||| S:26580 E:26588 ||| VBN
out  ||| S:26588 E:26602 ||| RP
in  ||| S:26602 E:26605 ||| IN
the  ||| S:26605 E:26609 ||| DT
absence  ||| S:26609 E:26617 ||| NN
of  ||| S:26617 E:26620 ||| IN
thrombin ||| S:26620 E:26628 ||| NN
.  ||| S:26628 E:26630 ||| .
After  ||| S:26630 E:26636 ||| IN
20  ||| S:26636 E:26639 ||| CD
min  ||| S:26639 E:26643 ||| NN
at  ||| S:26643 E:26646 ||| IN
37°C ||| S:26646 E:26650 ||| NNP
,  ||| S:26650 E:26652 ||| ,
the  ||| S:26652 E:26666 ||| DT
activity  ||| S:26666 E:26675 ||| NN
of  ||| S:26675 E:26678 ||| IN
thrombin  ||| S:26678 E:26687 ||| NN
was  ||| S:26687 E:26691 ||| VBD
quenched  ||| S:26691 E:26700 ||| VBN
by  ||| S:26700 E:26703 ||| IN
the  ||| S:26703 E:26707 ||| DT
addition  ||| S:26707 E:26716 ||| NN
of  ||| S:26716 E:26729 ||| IN
hirudin  ||| S:26729 E:26737 ||| NNS
( ||| S:26737 E:26738 ||| -LRB-
final  ||| S:26738 E:26744 ||| JJ
concentration ||| S:26744 E:26757 ||| NN
,  ||| S:26757 E:26759 ||| ,
60  ||| S:26759 E:26762 ||| CD
units  ||| S:26762 E:26768 ||| NNS
/ ||| S:26768 E:26769 ||| CD
ml ||| S:26769 E:26771 ||| CD
) ||| S:26771 E:26772 ||| -RRB-
,  ||| S:26772 E:26774 ||| ,
resulting  ||| S:26774 E:26784 ||| VBG
in  ||| S:26784 E:26797 ||| IN
inhibition  ||| S:26797 E:26808 ||| NN
of  ||| S:26808 E:26811 ||| IN
more  ||| S:26811 E:26816 ||| JJR
than  ||| S:26816 E:26821 ||| IN
95 ||| S:26821 E:26823 ||| CD
%  ||| S:26823 E:26825 ||| NN
of  ||| S:26825 E:26828 ||| IN
the  ||| S:26828 E:26832 ||| DT
amidolytic  ||| S:26832 E:26843 ||| JJ
activity  ||| S:26843 E:26852 ||| NN
of  ||| S:26852 E:26865 ||| IN
thrombin ||| S:26865 E:26873 ||| NN
.  ||| S:26873 E:26875 ||| .
Subsequently ||| S:26875 E:26887 ||| RB
,  ||| S:26887 E:26889 ||| ,
the  ||| S:26889 E:26893 ||| DT
residual  ||| S:26893 E:26902 ||| JJ
PAI-1  ||| S:26902 E:26908 ||| CD
inhibitory  ||| S:26908 E:26929 ||| JJ
activity  ||| S:26929 E:26938 ||| NN
was  ||| S:26938 E:26942 ||| VBD
determined  ||| S:26942 E:26953 ||| VBN
by  ||| S:26953 E:26956 ||| IN
titration  ||| S:26956 E:26966 ||| NN
of  ||| S:26966 E:26969 ||| IN
aliquots  ||| S:26969 E:26978 ||| NN
on  ||| S:26978 E:26981 ||| IN
uPA ||| S:26981 E:26984 ||| NNP
,  ||| S:26984 E:26996 ||| ,
using  ||| S:26996 E:27002 ||| VBG
S2444  ||| S:27002 E:27008 ||| NN
as  ||| S:27008 E:27011 ||| IN
substrate ||| S:27011 E:27020 ||| NN
.  ||| S:27020 E:27022 ||| .
The  ||| S:27022 E:27026 ||| DT
increase  ||| S:27026 E:27035 ||| NN
of  ||| S:27035 E:27038 ||| IN
the  ||| S:27038 E:27042 ||| DT
optical  ||| S:27042 E:27060 ||| JJ
density  ||| S:27060 E:27068 ||| NN
at  ||| S:27068 E:27071 ||| IN
405  ||| S:27071 E:27075 ||| CD
nm  ||| S:27075 E:27078 ||| NN
in  ||| S:27078 E:27081 ||| IN
the  ||| S:27081 E:27085 ||| DT
samples  ||| S:27085 E:27093 ||| NNS
was  ||| S:27093 E:27097 ||| VBD
corrected  ||| S:27097 E:27107 ||| VBN
for  ||| S:27107 E:27111 ||| IN
the  ||| S:27111 E:27125 ||| DT
values  ||| S:27125 E:27132 ||| NNS
measured  ||| S:27132 E:27141 ||| VBN
with  ||| S:27141 E:27146 ||| IN
( ||| S:27146 E:27147 ||| -LRB-
hirudin-inactivated ||| S:27147 E:27166 ||| NNP
)  ||| S:27166 E:27168 ||| -RRB-
thrombin  ||| S:27168 E:27187 ||| VBZ
alone ||| S:27187 E:27192 ||| RB
,  ||| S:27192 E:27194 ||| ,
since  ||| S:27194 E:27200 ||| IN
the  ||| S:27200 E:27204 ||| DT
amidolytic  ||| S:27204 E:27215 ||| JJ
activity  ||| S:27215 E:27224 ||| NN
of  ||| S:27224 E:27227 ||| IN
thrombin  ||| S:27227 E:27236 ||| NN
on  ||| S:27236 E:27239 ||| IN
S2444  ||| S:27239 E:27255 ||| NNP
was  ||| S:27255 E:27259 ||| VBD
not  ||| S:27259 E:27263 ||| RB
completely  ||| S:27263 E:27274 ||| RB
blocked  ||| S:27274 E:27282 ||| VBN
by  ||| S:27282 E:27285 ||| IN
hirudin ||| S:27285 E:27292 ||| NN
,  ||| S:27292 E:27322 ||| ,
Complex  ||| S:27322 E:27330 ||| JJ
formation  ||| S:27330 E:27340 ||| NN
of  ||| S:27340 E:27343 ||| IN
PAI-1s  ||| S:27343 E:27350 ||| CD
with  ||| S:27350 E:27355 ||| IN
tPA  ||| S:27355 E:27359 ||| JJ
or  ||| S:27359 E:27362 ||| CC
uPA  ||| S:27362 E:27376 ||| JJ
Complex  ||| S:27376 E:27384 ||| JJ
formation  ||| S:27384 E:27394 ||| NN
of  ||| S:27394 E:27397 ||| IN
the  ||| S:27397 E:27401 ||| DT
fibrosarcoma  ||| S:27401 E:27414 ||| JJ
PAI-1 ||| S:27414 E:27419 ||| NN
,  ||| S:27419 E:27421 ||| ,
wtPAI-1  ||| S:27421 E:27439 ||| NNP
or  ||| S:27439 E:27442 ||| CC
its  ||| S:27442 E:27446 ||| PRP$
mutants  ||| S:27446 E:27454 ||| NN
with  ||| S:27454 E:27459 ||| IN
single-chain  ||| S:27459 E:27472 ||| JJ
tPA  ||| S:27472 E:27476 ||| JJ
or  ||| S:27476 E:27479 ||| CC
uPA  ||| S:27479 E:27483 ||| NNP
were  ||| S:27483 E:27498 ||| VBD
performed  ||| S:27498 E:27508 ||| VBN
as  ||| S:27508 E:27511 ||| RB
described  ||| S:27511 E:27521 ||| VBN
earlier  ||| S:27521 E:27529 ||| RBR
[  ||| S:27529 E:27531 ||| -LRB-
20  ||| S:27531 E:27534 ||| CD
]  ||| S:27534 E:27536 ||| -RRB-
.  ||| S:27536 E:27538 ||| .
Samples  ||| S:27538 E:27546 ||| NNS
of  ||| S:27546 E:27549 ||| IN
PAI-1s  ||| S:27549 E:27566 ||| NNP
( ||| S:27566 E:27567 ||| -LRB-
5  ||| S:27567 E:27569 ||| CD
U ||| S:27569 E:27570 ||| NNP
)  ||| S:27570 E:27572 ||| -RRB-
were  ||| S:27572 E:27577 ||| VBD
incubated  ||| S:27577 E:27587 ||| VBN
in  ||| S:27587 E:27590 ||| IN
the  ||| S:27590 E:27594 ||| DT
absence  ||| S:27594 E:27602 ||| NN
or  ||| S:27602 E:27605 ||| CC
in  ||| S:27605 E:27608 ||| IN
the  ||| S:27608 E:27612 ||| DT
presence  ||| S:27612 E:27621 ||| NN
of  ||| S:27621 E:27634 ||| IN
a  ||| S:27634 E:27636 ||| DT
2-fold  ||| S:27636 E:27643 ||| JJ
excess  ||| S:27643 E:27650 ||| NN
of  ||| S:27650 E:27653 ||| IN
uPA  ||| S:27653 E:27657 ||| JJ
or  ||| S:27657 E:27660 ||| CC
tPA  ||| S:27660 E:27664 ||| JJ
in  ||| S:27664 E:27667 ||| IN
the  ||| S:27667 E:27671 ||| DT
activity  ||| S:27671 E:27680 ||| NN
assay  ||| S:27680 E:27696 ||| NN
buffer ||| S:27696 E:27702 ||| NN
.  ||| S:27702 E:27704 ||| .
Following  ||| S:27704 E:27714 ||| VBG
a  ||| S:27714 E:27716 ||| DT
30  ||| S:27716 E:27719 ||| CD
min  ||| S:27719 E:27723 ||| JJ
incubation  ||| S:27723 E:27734 ||| NN
at  ||| S:27734 E:27737 ||| IN
room  ||| S:27737 E:27752 ||| NN
temperature ||| S:27752 E:27763 ||| NN
,  ||| S:27763 E:27765 ||| ,
the  ||| S:27765 E:27769 ||| DT
samples  ||| S:27769 E:27777 ||| NNS
were  ||| S:27777 E:27782 ||| VBD
subjected  ||| S:27782 E:27792 ||| VBN
to  ||| S:27792 E:27795 ||| TO
a  ||| S:27795 E:27797 ||| DT
10 ||| S:27797 E:27799 ||| CD
%  ||| S:27799 E:27801 ||| NN
SDS-PAGE  ||| S:27801 E:27820 ||| NN
and  ||| S:27820 E:27824 ||| CC
immunoblotting  ||| S:27824 E:27839 ||| VBP
as  ||| S:27839 E:27842 ||| RB
described  ||| S:27842 E:27852 ||| VBN
above ||| S:27852 E:27857 ||| IN
.  ||| S:27857 E:27890 ||| .
Abbreviations  ||| S:27890 E:27912 ||| NNP
tPA ||| S:27912 E:27915 ||| NNP
,  ||| S:27915 E:27917 ||| ,
tissue-type  ||| S:27917 E:27929 ||| JJ
plasminogen  ||| S:27929 E:27941 ||| JJ
activator ||| S:27941 E:27950 ||| NN
;  ||| S:27950 E:27952 ||| :
uPA ||| S:27952 E:27955 ||| NNP
,  ||| S:27955 E:27965 ||| ,
urokinase-type  ||| S:27965 E:27980 ||| JJ
plasminogen  ||| S:27980 E:27992 ||| JJ
activator ||| S:27992 E:28001 ||| NN
;  ||| S:28001 E:28003 ||| :
PAI-1 ||| S:28003 E:28008 ||| CD
,  ||| S:28008 E:28010 ||| ,
plasminogen  ||| S:28010 E:28030 ||| FW
activator  ||| S:28030 E:28040 ||| FW
inhibitor  ||| S:28040 E:28050 ||| FW
type  ||| S:28050 E:28055 ||| NN
1 ||| S:28055 E:28056 ||| CD
;  ||| S:28056 E:28058 ||| :
serpin ||| S:28058 E:28064 ||| CD
,  ||| S:28064 E:28066 ||| ,
serine  ||| S:28066 E:28073 ||| FW
protease  ||| S:28073 E:28090 ||| FW
inhibitor ||| S:28090 E:28099 ||| FW
;  ||| S:28099 E:28101 ||| :
RCL ||| S:28101 E:28104 ||| NNP
,  ||| S:28104 E:28106 ||| ,
reactive  ||| S:28106 E:28115 ||| JJ
center  ||| S:28115 E:28122 ||| NN
loop ||| S:28122 E:28126 ||| NNS
;  ||| S:28126 E:28128 ||| :
Vn ||| S:28128 E:28130 ||| NNP
,  ||| S:28130 E:28132 ||| ,
vitronectin ||| S:28132 E:28143 ||| NN
,  ||| S:28143 E:28145 ||| ,
SDS ||| S:28145 E:28148 ||| NNP
,  ||| S:28148 E:28158 ||| ,
sodium  ||| S:28158 E:28165 ||| JJ
dodecylsulfate ||| S:28165 E:28179 ||| NN
;  ||| S:28179 E:28181 ||| :
PAGE ||| S:28181 E:28185 ||| NNP
,  ||| S:28185 E:28187 ||| ,
polyacrylamide  ||| S:28187 E:28202 ||| FW
gel  ||| S:28202 E:28214 ||| FW
electrophoresis ||| S:28214 E:28229 ||| FW
.  ||| S:28229 E:28231 ||| .
Gdn-HCl ||| S:28231 E:28238 ||| NNP
,  ||| S:28238 E:28240 ||| ,
guanidine-hydrochloride ||| S:28240 E:28263 ||| JJ
;  ||| S:28263 E:28265 ||| :
HRP ||| S:28265 E:28268 ||| NNP
,  ||| S:28268 E:28278 ||| ,
horseradish  ||| S:28278 E:28290 ||| JJ
peroxidase ||| S:28290 E:28300 ||| NN
;  ||| S:28300 E:28302 ||| :
ECL ||| S:28302 E:28305 ||| NNP
,  ||| S:28305 E:28307 ||| ,
enhanced  ||| S:28307 E:28316 ||| JJ
chemiluminescence ||| S:28316 E:28333 ||| NN
;  ||| S:28333 E:28343 ||| :
PBS ||| S:28343 E:28346 ||| NNP
,  ||| S:28346 E:28348 ||| ,
phosphate-buffered  ||| S:28348 E:28367 ||| JJ
saline ||| S:28367 E:28373 ||| NN
;  ||| S:28373 E:28375 ||| :
BSA ||| S:28375 E:28378 ||| NNP
,  ||| S:28378 E:28380 ||| ,
bovine  ||| S:28380 E:28387 ||| FW
serum  ||| S:28387 E:28401 ||| FW
albumin ||| S:28401 E:28408 ||| FW
.  ||| S:28408 E:28432 ||| .
Authors ||| S:28432 E:28439 ||| NNP
'  ||| S:28439 E:28441 ||| POS
contribution  ||| S:28441 E:28462 ||| NN
Qingcai  ||| S:28462 E:28470 ||| NNP
Wang  ||| S:28470 E:28475 ||| NNP
carried  ||| S:28475 E:28483 ||| VBD
out  ||| S:28483 E:28487 ||| RP
the  ||| S:28487 E:28491 ||| DT
experiments  ||| S:28491 E:28503 ||| NNS
and  ||| S:28503 E:28507 ||| CC
drafted  ||| S:28507 E:28515 ||| VBD
the  ||| S:28515 E:28527 ||| DT
manuscript ||| S:28527 E:28537 ||| NN
;  ||| S:28537 E:28547 ||| :
Professor  ||| S:28547 E:28557 ||| NNP
Shmuel  ||| S:28557 E:28564 ||| NNP
Shaltiel  ||| S:28564 E:28573 ||| NNP
sponsored  ||| S:28573 E:28583 ||| NN
and  ||| S:28583 E:28587 ||| CC
supervised  ||| S:28587 E:28598 ||| VBD
the  ||| S:28598 E:28610 ||| DT
project  ||| S:28610 E:28618 ||| NN
and  ||| S:28618 E:28622 ||| CC
revised  ||| S:28622 E:28630 ||| VBN
the  ||| S:28630 E:28634 ||| DT
manuscript ||| S:28634 E:28644 ||| NN
.  ||| S:28644 E:28661 ||| .
